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1  Introduction 
The importance of vitamin A in health and disease has been recognized relatively late in 
human history, if we consider that humans have been confronted with night blindness, a 
typical disease resulting from vitamin A deficiency, for thousands of years. The curative 
role of the juice of cooked liver extracts in the treatment of night blindness was first 
recognized and practiced by the Egyptians in ancient times.1 Just at the beginning of the 
20th century, several research groups identified a lipid-soluble component in milk, 
butter and egg yolk which was therapeutic for this disease.  
In 1912, Funk suggested the term “vitamine” to describe the growth factor present in 
food which was essential for life.2 It later became clear that there was more than one 
growth factor, and McCollum divided them into two classes ”fat-soluble A” and “water-
soluble B”.3 Objecting to the chemical implications of the suffix '-ine', Drummond 
suggested deletion of the final 'e', renamed McCollum's two groups vitamin A and 
vitamin B, and proposed that further members of this series should be called vitamin C, 
vitamin D, etc.4  
In 1934, Wald isolated from animal retina a substance he called retinene.5 Morton6 
suggested that this compound was the aldehyde of vitamin A, and called it 
retinaldehyde (rather than retinal).7 The correct structure of vitamin A was deduced in 
1931 by Karrer8 who proposed the name axerophthol9 (Axerophtol in German), based 
on its action in preventing the eye disease xerophthalmia. A second vitamin A, isolated 
by Morton and others, was called vitamin A2.
10 
Although the first recommendations for the nomenclature of the vitamins were 
published by IUPAC in 1960,11 including names for the three parent compounds - 
retinol, retinal and retinoic acid - as well as for their 3-dehydro analogues, just in 1982 
the IUPAC defined the retinoids as “a class of compounds consisting of four isoprenoid 
units joined in a head-to-tail manner. All retinoids may be formally derived from a 
monocyclic parent compound containing five carbon-carbon double bonds and a 
functional group at the terminus of the acyclic portion”.12 Due to newly synthesized 
non-polyisoprenoid compounds, more active than retinol in typical assays for retinoid 
activity, and due to better understanding on the functions of some retinoids not always 
mediated through retinoid receptors, a new definition considered retinoids as substances 
that are either structurally related to vitamin A alcohol (retinol) or display vitamin A 
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activity. According to this definition, non-active compounds are considered retinoids 
only if they are structurally related to retinol. 
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The three retinoids all-trans-retinol (1), retinal (2) and retinoic acid (tretinoin, 3) are the 
most characteristic examples of naturally occurring retinoids. Their structure is 
generally divided into three segments: a hydrophobic β-ionone ring, a conjugated 
tetraene side chain and a polar terminal group. Replacement of the β-ionone ring by a 
substituted benzene ring leads to aromatic compounds, some with higher therapeutic 
activity than naturally occurring retinoids, like etretinate (4). A further class of retinoids 
was obtained by restriction on the flexibility of the conjugated side chain by 
incorporating of aromatic ring systems in different positions. By incorporation of amide, 
sulfonamide or other groups, highly active retinoids were obtained (Figure 1). 
MeO
COOEt
 
COOH
 
4, etretinate 5, TTNPB 
N
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S
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6, Am-580 7, AGN191701 
Figure 1. Structure of modified retinoids. 
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Rich sources of vitamin A can be found in food (milk, cheese, butter, eggs, internal 
organs, fish). Mammals cannot synthesize vitamin A active compounds, therefore the 
necessary quantities are obtained by ingestion of vitamin A (retinol and retinyl ester) or 
by consumption of appropriate provitamin A compounds, such as β-carotene (8). 
Carotenoids, red or yellow fat-soluble pigments, are produced exclusively by plants and 
photosynthetic bacteria.1 Their basic structure consists of eight isoprenoid units, which 
is cleaved in the organisms by carotenoid dioxygenase mostly at the central C15-C15' 
double bond to retinal. Cleavage of other double bonds give β-apo-carotenals, which 
can be further oxidized to retinal and reduced by retinal reductase to retinol. Although 
more then 400 natural carotenoids are known, only 50-60 of them have provitamin A 
activity, which means that they can be converted to vitamin A, β-carotene being the 
most active. Other carotenoids, like lycopene (9), have no vitamin A activity but they 
are particularly efficient antioxidants.13 Oxidation of carotenoids to biologically inactive 
xanthophylls represents an important degradation pathway for these compounds.  
15
15'
 
 8, trans-β-carotene 
 
 9, trans-lycopene 
Figure 2. A selection of provitamin A compounds. 
1.1 Biological Importance of Vitamin A Derivatives 
The biological potency of vitamin A has been known since the second decade of the 20th 
century. Initial studies had focused on retinol deficiency and its major consequences: 
night blindness and xerophthalmia. More recently, it became evident that retinoids, 
natural and synthetic analogues, are essential for both normal embryonic development 
and maintenance of differentiation in the adult organism,14 accounting for intense 
interest in these compounds in biology and medicine.  
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All-trans-retinol (ROH, 1) is the most abundant retinoid in blood (approximately 95 to 
99 % of all retinoids in the circulation), however the retinyl ester is the most abundant 
storage form.15 In the body 1 is metabolized into hormonally active metabolites. The 
major established pathway of retinol activation involves metabolization of retinyl ester, 
the reversible oxidation of the released retinol to retinal (RAL, 2) by alcohol 
dehydrogenase and irreversible conversion of RAL into retinoic acid (RA, 3) by retinal 
dehydrogenase (RALDH, Figure 3). 
CRABP
RAR
RXR
RXRE
RARE
CRBP
ROH, 1
all-trans-RA
all-trans-3
Cell
Cytoplasm
inactive
metabolites
Nucleus
ROH, 1
all-trans-RA
all-trans-3
RE
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9-cis-RA
9-cis-3
ADH
ALDH
(storage in liver)
 
Figure 3. The retinoid signal transduction pathway.12a 
Metabolites of all-trans-RA generated in vivo include 13-cis-RA, 9-cis-RA, retinoyl β-
glucuronide, 5,6-epoxy-RA, 4-hydroxy-RA, 4-oxo-RA, 18-hydroxy-RA, 14-hydroxy-
4,14-retro-retinol and 3,4-didehydro-RA.12b Some of these metabolites are active in 
mediating RA functions, whereas others are probably catabolic products. 
Unlike the water soluble peptide hormones and growth factors, which bind to cell-
surface receptors, the retinoids are fat soluble hormones that can pass through the lipid 
bilayer of the cell membrane, after which they are free to interact with intracellular 
proteins. This hormone-receptor complex is able to initiate the cellular response. There 
are several proteins found to bind in vivo retinol and retinoic acid. Extracellular retinol 
is transported from retinoid stores in the liver to target tissues by binding the 
extracellular retinol binding protein (RBP). The first intracellular protein was 
discovered by Ong and Chytil in 1978 as cellular retinoic acid binding protein 
(CRABP), but its absence in the nucleus showed that other receptors are mediating the 
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retinoid signaling pathway (Figure 3).12a Two families of nuclear retinoid receptors have 
been discovered: the retinoid acid receptor (RAR) and retinoid X receptor (RXR), each 
consisting of three types α, β and γ. They are members of a superfamily consisting of 
the nuclear receptors of steroid hormones, thyroid hormone, vitamin D and retinoids, as 
well as receptors of yet unidentified ligands called orphan receptors. Once all-trans-RA 
and 9-cis-RA have been metabolically produced in the cytoplasm, they are transported 
to the nucleus by a yet unknown mechanism and bind to the corresponding receptor. 
While RARs have almost equal affinity to all-trans-RA and 9-cis-RA, RXRs 
preferentially bind 9-cis-RA. Therefore, to understand the function and activation 
pathway of different isomers of vitamin A metabolites, it is essential to understand their 
role in the body.  
The mechanism of retinoid action can be mediated by interaction with the retinoid 
receptors, as shown before, or by other mechanisms in which retinoid receptors are not 
directly involved, like the visual process. In the retinal pigment epithelium an 
unidentified enzyme carries out the isomerization of all-trans-ROH to 11-cis-ROH, 
which can be oxidized to 11-cis-RAL, the active metabolite of ROH. Visual pigment 
generation involves the interaction of 11-cis-RAL (or derivatives) with opsin, a protein 
tailor made to shift the absorption spectrum of the retinoid into the visible range, 
increase its quantum efficiency of photoisomerization and activate further biochemical 
response.12c The absolute requirement of vitamin A for vision is well known and proven 
by half a million of new cases of childhood blindness occurring annually, from which 
approximately 70 % are the result of severe vitamin A deficiency.12c  
Vitamin A is an essential nutrient for humans. An equilibrated intake of vitamin A is 
vital in embryo genesis, growth and development, cell proliferation and differentiation, 
the visual process, immunity, and reproduction. Also its pharmacological use in bone 
diseases, dermatology, cancer and leukemia prevention and therapy is today of essential 
importance.  
When ingested in large doses, vitamin A can be toxic. The three categories of toxicity 
are acute, chronic and teratogenic toxicity. Vitamin A is non-toxic until there is no more 
retinol binding protein (RBP) available to bind it, and ROH circulates freely in the 
plasma. When unbound retinol is presented to cells and membranes, vitamin A toxicity 
tends to appear, because ROH is metabolized to RA, which is the toxic species.12d  
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1.2 Aim of this Work 
Following investigations on vitamin A metabolism, Shirley reported in 1996 that 
9-cis-RA can be metabolized in rats by oxidation to 4-hydroxy- and 4-oxo-9-cis-RA, as 
well as by reduction to a new vitamin A metabolite, 9-cis-13,14-dihydro-RA (10).16 
After administration of an equimolar mixture of labeled and non-labeled 9-cis-RA to 
rats, he observed the formation of a labeled 9-cis-13,14-dihydro metabolite, which 
means that the precursor of the new metabolite was the 9-cis-isomer of RA or ROH and 
not the all-trans-isomer. The potential for the new metabolite to retain biological 
activity was assessed by binding and transactivation studies indicating an activity less 
than 1 % of the corresponding 9-cis-RA. Thus, the minor structural change brought 
about by reduction may represent an important mechanism for inactivating 9-cis-RA in 
vivo by rats.16 
COOH  
O
COOH  
9-cis-10 9-cis-11 
In a study on the influence of polychlorodibenzodioxin on the homeostasis of retinoids, 
Nau and Schmidt reported the discovery and isolation of a second 13,14-dihydro 
vitamin A metabolite.17 The new metabolite was detected in liver, kidney and serum of 
mice and rats, and in one human liver. Spectroscopic analysis (1H NMR, MS and UV) 
indicated the 9-cis-4-oxo-13,14-dihydro-RA (11) structure, but insufficient amounts of 
the isolated substance made a complete characterization and further investigations 
impossible. Higher dietary levels of vitamin A palmitate in mice result in higher level of 
the new metabolite accompanied by higher total ROH and lower all-trans-RA contents. 
A reason for this finding may be the acute saturation of the metabolic capacity of the 
organism in case of higher dosing regimes, in which retinoids may be metabolized via 
additional pathways. Due to the relatively high hepatic levels, one can assume that 11 is 
biosynthesized in the liver. There are two possible pathways by which the formation of 
this metabolite may proceed: it may originate from all-trans-RA following 
isomerization, reduction and oxidation, or it is also possible that the precursor is 9-cis- 
or 9,13-di-cis-ROH.18 Further studies were necessary to clarify whether this new 
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metabolite has any biological activity or if it is just one inactivated derivative in the 
catabolism of vitamin A. To confirm the assigned structure of this metabolite, for a 
better under-standing of its function and formation pathway, and for biological tests, 
synthetic material was needed.  
Subsequently during the course of this work, Palczewski19a reported investigations on 
reduced metabolites of vitamin A and described a novel enzyme (RetSat) that carries 
out the saturation of the C-13/C-14 bond of all-trans-ROH to generate all-trans-13,14-
dihydro-ROH (all-trans-12), which was oxidized to all-trans-13,14-dihydro-RA (all-
trans-10). Trying to find out more about the 13,14-dihydro-RA metabolites, he 
performed the synthesis of 11, respectively 10 in 13 steps, without taking the chirality at 
C-13 into consideration.19b After feeding rats with synthetic 12 the only isolated 
metabolites were all-trans-10 and all-trans-11. The 9-cis-isomer of this 13,14-dihydro-
RA derivatives is evidently not formed. No information about the absolute 
configuration of the isolated 13,14-dihydro-retinoids is given, and the biological tests 
were performed with racemic compounds.19b Contrary to the previous report of Shirley, 
the enzyme RetSat could not convert all-trans-RA into all-trans-13,14-dihydro-RA, 
which implies that the previously observed 13,14-dihydro metabolites should be 
downstream products of the oxidation of all-trans-13,14-dihydro-ROH. This 
supposition holds when all three 13,14-dihydro metabolites are products of the same 
metabolization pathway. It is also known that 9-cis-RA can participte in additional 
metabolization pathways, independent of that for all-trans-ROH.15  
OH
 
all-trans-12 
As shown before, the major established pathway of ROH activation, involves reversible 
oxidation to retinal (RAL), and irreversible conversion of the latter into retinoic acid 
(RA), which can undergo oxidative metabolism to yield 4-hydroxy-RA or 4-oxo-RA. If 
this observation concerning a possible metabolic pathway is true for 9-cis-11, it still 
remains unclear at what stage the C-9/C-10 bond isomerization occurs and the 
C-13/C-14 double bond is reduced. Information about the biological activity of all new 
derivatives and their role in the metabolism are vital for a better understanding of the 
general vitamin A metabolism.  
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Another important aspect not mentioned in the previous papers is the chirality of these 
vitamin A analogues. Within the body, the metabolites exist in a chiral environment 
where their release, absorption, transport, action and degradation involve interactions 
with enzymes, cell surface and so on. This means that two enantiomeric molecules 
should be acted on differently by the body and the new chiral vitamin A enantiomers 
should be investigated separately. 
With this in mind, the synthesis of 11 was the first target, to confirm the structure that 
Nau and co-workers had assigned for their isolated vitamin A metabolite. All geometric 
isomers should be obtained and investigated. The racemic synthesis offers the 
advantage that both enantiomers can be compared with the isolated compound, while an 
enantioselective synthesis can confirm the assigned configuration. Separation of the 
racemate by chiral high pressure liquid chromatography (HPLC) would make further 
analysis in biological assays with both enantiomers possible. The developed method for 
chiral separation should give the possibility for analysis of all diastereomers of the new 
reported RA metabolites.  
After synthesis of 4-oxo-13,14-dihydro-RA (11) and complete characterization of the 
new metabolite, its possible precursor in the metabolization process, 13,14-dihydro-RA 
(10) should also be synthesized and analyzed. Several methods were followed here for 
the preparation of these new retinoids. Wittig reactions were preferentially used to 
obtain all geometrical isomers. By controlling the synthesis of the phosphonium salts, 
an enantioselective or racemic synthesis can be achieved. Using new substitution 
patterns on the phosphonium salts or on the β-ionone skeleton further modification of 
the retinoid chain can be performed. Most reactions started from an ionone derivate.  
R
2
R
3
R
1
R
4
1
2
3
4
5
6
7
8
9
10
11
12
13 14
15
16 17
18
 
13 
Figure 4. Modifications undertaken on the retinoid skeleton. 
Modifications on the retinoid skeleton were undertaken at C-4, C-9 and C-13. 
Mechanism of formation and action, as well as further degradation pathways for the 
13,14-dihydro metabolites can be studied with labeled retinoids. For some of the known 
active retinoids, like ROH and RA synthesis of labeled material has been reported in the 
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literature.12e Because these methods could not be applied here, a similar approach was 
developed for the 13,14-dihydro-RAs. Deuterium labeling offers the advantage of 
inexpensive starting materials, stable labeled products and a simple analysis by mass 
spectrometry. It is known that oxidative decarboxylation and β-oxidative chain 
shortening are other metabolic processes of all-trans-RA.16 When rats were treated with 
[14-14C]-ROH or [15-14C]-all-trans-RA, radiolabelled 14CO2 was lost through 
respiration. For this reason, the 13,14-dihydro retinoids were labeled at C-9 (R2), a 
position that would enable their monitoring by mass spectrometry over several chain 
degradation steps in the metabolization path.  
For further theoretical and practical biological investigations, modification of the 
retinoid skeleton, at C-13 (R3) was performed. This position was chosen because 
retinoid activity can be modified when bulky groups at C-13, near the retinoic acid 
active center, substitute the native methyl group. The trans-isomers are the most active 
isomers in retinoid metabolism. Which role the 9-cis-13,14-dihydro retinoid metabolites 
are playing is not clear presently. By inserting a sterically demanding substituent at C-
13, the 9-cis-isomers can be investigated in the retinoid receptor pocket and their 
interactions with the amino acids could be analyzed. One can try to get additional 
information about the binding affinity of the different isomers, especially when steric 
interactions in the retinoid receptor pocket are playing an additional role. This 
information can help to understand the role and the biological activity of the newly 
discovered 13,14-dihydro retinoids.  
Theoretical calculations of the newly synthesized retinoids can be obtained ahead of the 
experimental biological tests. Spectroscopic analysis helps to understand the 
conformation and other possible interaction of different isomers.  
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Figure 5. Steric hindrance due to larger substituents at C-13. 
In summary, the structure of a new chiral vitamin A metabolite (11) has to be confirmed 
and its absolute configuration to be assigned. The developed synthetic methods should 
provide other possible isomers of the found metabolite as well, and the biological 
function of each isomer should be investigated. If the isolated compound is produced as 
one enantiomer, an enantioselective synthesis should be developed. Furthermore, a 
chiral separation method should be developed for the analysis and comparison of 
synthetic samples with biological material.  
Differently substituted retinoids have to be synthesized and their properties to be 
compared. The synthetic approach for the new chiral retinoids, the development of 
analytical separation by chiral and non-chiral chromatography, the spectroscopic 
characterization, and theoretical calculations should give information on their biological 
activity. Further investigations with all newly synthesized retinoids are necessary to 
understand their biological function and to complete our assumptions on a new 
endogenous metabolic pathway of vitamin A.  
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2 Retrosynthesis  
A general classification of synthetic routes to the retinoid polyene skeleton distinguishes 
two processes, double and single bond formation, and labels the building blocks 
according to the number of carbon atoms contributing to the final diterpene skeleton. 
Wittig- and Horner-Wadsworth-Emmons (HWE) condensations are among the most 
often used double bond formation reactions in vitamin A synthesis. Julia olefination is 
also often used as an alternative.20 The synthesis of polyenes involving C-C single bond 
formation usually features metal-catalyzed cross-coupling reactions between alkenyl 
organometallic reagents and alkenyl electrophiles. This second methodology has been 
established mostly for constructing biaryl substituted retinoids. Variation of coupling 
reactions has permitted the synthesis of ring systems bearing functional groups such as 
ester, amide and nitro groups. This metallorganic chemistry will not be discussed here. 
Double bond formation through Wittig and HWE reactions of carbonyl compounds with 
triphenylphosphonium halides, respectively dialkylphosphonates, will be presented and 
discussed here for the synthesis of the novel retinoids. 
In his Nobel lecture “Von Diylen über Ylide zu meinem Idyll”,21 Wittig mentioned the 
importance of the Wittig reaction in vitamin A synthesis that made its industrial 
production possible. Today there are several technical processes for the synthesis of 
vitamin A, most of them still using the Wittig reaction.  
R
C18 + C2
C15 + C5
C10 + C10
C13 + C7
 
Figure 6. Possible building blocks for retinoids. 
The methodology for synthesizing many retinoid analogs is based on established 
methods because the goals are drug discovery based on structure-activity investigations 
and the use of previously reported preparative methods rather then development of new 
synthons. In this study several methods for the synthesis of chiral 13,14-dihydro-
retinoic acid derivatives have been developed to enable preparation of a particular 
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diastereomer selectively or without any selectivity for a one pot synthesis of all 
diastereomers. The best method was optimized to produce the desired product 
enantioselectively in a few steps. Retrosynthetically the new metabolites could be 
synthesized using one of the following pathways: 
a) The C13+C7 pathway using the Horner-Wadsworth-Emmons (HWE) reaction of 
β-ionone derivative 14 with phosphonate 15 offers a trans-selective synthetic 
method for the retinoid derivatives. By controlling the configuration at the chiral 
center of the phosphonate, an enantioselective synthesis of the retinoids should 
be possible.  
b) Wittig reaction between the C15 phosphonium salt 16 and the C5 aldehyde 17 can 
be used for obtaining retinoic acid derivatives as well as retinol derivatives, 
mostly in trans-configuration.  
c) Stepwise construction of the conjugated double bonds by Wittig reactions offers 
the possibility of a better control of the cis-/trans-isomer formation. 
Enantioselective synthesis of phosphonium salt 19 allows the enantioselective 
synthesis of the vitamin A derivatives. New substituents can be incorporated in 
the retinoid backbone when phosphonium salt 19 is chemically modified at the 
desired positions. Using just one of the isomers of aldehyde 18, a cis-, 
respectively trans-selective synthesis can be performed. 
c1) Several modifications on the retinoid skeleton can be planned when starting 
from commercially available ionone. The chain length can be increased with 
additional double bonds by Wittig reactions. The C-4 position can be 
oxidized to give 4-oxo and 4-hydroxy derivatives. The methyl group at C-9 
can be substituted with deuterium to give labeled retinoic acid derivatives.  
c2) The synthesis of aldehyde 18 was designed to be cis-selective by using a 
metal catalyzed addition to alkyne 21. 
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Figure 7. Retrosynthesis of 13,14-dihydro retinoid derivatives 13.  
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3 Syntheses 
3.1 β-Ionone (22) and 4-Oxo-β-ionone (23) as Starting Materials 
Ionone derivatives are one of the most important building blocks in vitamin A and 
carotenoid synthesis. β-Ionone and α-ionone are commercially available, other 
derivatives can be easily obtained. 4-Oxo-β-ionone (23) can be extracted from 
Osmanthus Absolue
22 or the juice of the yellow Passion Fruit23, and it has been found in 
the black tea aroma24 and in tobacco fractions.25 Synthesis of 23 can start from β- or α-
ionone, to 4-hydroxy-β-ionone which can be oxidized to the 4-oxo derivative.26,27 Better 
yields are obtained in a one step reaction, by which 22 reacts with 
pyridiniumchlorochromate (PCC), in DMSO at 100 °C to give 53 % of 23 as yellow 
crystals.27 This second approach was used in this work for the synthesis of 23.  
O
 
PCC
DMSO  
O
O  
22  23 (53 %) 
Scheme 1. Oxidation of β-ionone (22). 
To investigate all potential metabolites of RA, the newly discovered 4-oxo-dehydro-RA 
metabolite17 but also possible precursors, all new retinoids synthesized in this thesis 
were based on the β-ionone and the 4-oxo-β-ionone skeleton, respectively.  
3.2 Synthetic Approach to 13,14-Dihydro-retinoids by Horner-Wadsworth-
Emmons Reaction. Retrosynthetic Path a 
Following route a, phosphonate 27 was chosen as one of the starting materials for the 
HWE reaction with 22 to the 13,14-dihydro retinoids. One important advantage of this 
phosphonate is the possibility to synthesize it in enantiomerically pure form as S-27 and 
R-27, which will enable enantioselective syntheses of 13,14-dihydro retinoids. This 
approach seems to be ideal for a trans-enantioselective synthesis of 11. 
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1,2-Addition of crotonaldehyde (25) to the phosphonate 24 gave allyl alcohol 26 as 
racemic mixture. By using the Sharpless methodology of kinetic resolution of racemic 
allylic alcohols, it should be possible to separate this hydroxy phosphonate racemate 
into its enantiomers.28 The next reaction step with racemic or enantiomerically pure 26 
is a Claisen rearrangement, which proceeds stereospecifically, so no racemisation will 
affect the enantiomeric purity of 27.28 Racemic synthesis was first undertaken. The 
Claisen rearrangement29 (Scheme 3) of 26 with triethyl orthoacetate and a catalytic 
amount of propionic acid, gave the appropriate trans-ester phosphonate 27 in 53 % 
yield (Scheme 2). 
(iPrO)
2
P
OHO
H
O
(iPrO)
2
P
O
Me
a+
 
24 25 26 
(iPrO)
2
P COOEt
O
b
 
 27  
a) nBuLi, THF, -78 °C (58 %); b) MeC(OEt)3, EtCOOH, 140 °C (53 %) 
Scheme 2. Synthesis of C7 phosphonate. 
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P(OiPr)
2
O
CH3C(OEt)3 +
 
28 26   
P(OiPr)
2OEtO
EtO
O
P(OiPr)
2
OEtO
O
P(OiPr)
2
OEtO
O
 
29 30 27 
Scheme 3. Mechanism of Claisen rearrangement to 27. 
Under several deprotonation conditions (base: NaH, LDA, NaHMDS, nBuLi, KOtBu) 
22 was reacted with phosphonate 27, but the reaction failed to give the desired product. 
 16
22  + (iPrO)
2
P COOEt
O
base, THF
1 5   
 27  
COOEt
 
 31  
Scheme 4. Attempted Horner-Wadsworth-Emmons reaction of 22 with phosphonate 27. 
To understand the reason for this failure, investigations on the acidity of the protons of 
27 were conducted by deprotonation with different bases and quenching the resulting 
anion with D2O. When NaH was used, no deprotonation took place. With LDA and 
NaHMDS deprotonation took place at C-1 and C-5. KOtBu and nBuLi gave possible 
deprotonation of C-1 but several other decomposition products. NaH followed by nBuLi 
gave complete decomposition of the phosphonate. Computational calculation of the 
proton affinity of the acidic protons at C-1, C-4 and C-5 were performed for a deeper 
understanding on the reactivity of this phosphonate. These results will be discussed in 
Chapter 8.  
To overcome the competition between the deprotonation reactions of the acidic protons 
near the ester and the phosphonate group, the carboxylic function was protected as a 
cyclic ortho ester 34 (Scheme 5). Saponification of the phosphonate ester 27 gave the 
corresponding acid 32, which was reesterificated to the oxetane 33 with 3-methyl-3-
hydroxymethyloxetane, DMAP and DCC in Et2O at 25 °C. The oxetane rearranged 
under acidic conditions to give the new cyclic ortho ester 34.  
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(iPrO)
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P
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34  
a) KOH, EtOH, H2O (93 %); b) (3-hydroxymethyl)-3-
methyloxetane, DMAP, DCC, Et2O, 25 °C (87 %);  
c) [i] BF3-Et2O, CH2Cl2, -4 °C; [ii] NEt3 (74 %) 
Scheme 5. Synthesis of ortho ester phosphonate 34. 
The phosphonate 34, with a protected carboxylic function, was treated again with 
several bases and quenched with D2O to gain a first impression of its reactivity in the 
HWE reaction. The new phosphonate was not stable enough and decomposition took 
place easily. Due to these results, further investigations on this pathway to the 13,14-
dihydro retinoids were not continued.  
3.3 Synthesis of Retinoic Acid Derivatives by Wittig Reaction with C15+C5 
Backbones. Retrosynthetic Path b 
The retrosynthetic route b, was developed as described by Rosenberger and his group 
using the Wittig reaction.30 The same methodology has been used previously by Isler 
for the vitamin A and A2 synthesis
31 and by researchers at Hoffmann-La Roche for the 
synthesis of carotenoids.32,27 This method uses the C15 + C5 path for building the 
retinoid skeleton with C15 phosphonium salt and C5 aldehyde. Retinol can also be 
obtained by this procedure. Instead of phosphonium salt 37, the analogous C15 
sulfonium salt has been used by Rosenberger to obtain RA derivatives.30b Building the 
retinoid backbone by Wittig reactions, as shown in Scheme 4, is one of the methods that 
found its application in the industrial synthesis of retinoids and carotenoids by the 
BASF company.33 
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This methodology based on the Wittig reaction can be used successfully for the 
synthesis of the all-trans-isomers. All other isomers are obtained as by-products in very 
small quantities and can be isomerized to the all-trans-product. By this protocol, RA 
and 4-oxo-RA were obtained as analytical standards and synthetic material for 
biological investigations.  
Grignard reaction of β-ionone (22) with vinylmagnesium chloride followed by 
treatment of formed vinyl-β-ionol 35 with Ph3P·HBr in MeOH gave phosphonium salt 
37. The crude phosphonium salt was used directly in the Wittig reaction, further 
purification by recrystallisation showed decomposition of the salt and consequently a 
decrease of the yield. In the same way, the 4-oxo phosphonium salt 38 was synthesized 
by Grignard reaction of 23 with vinyl magnesium chloride to provide 4-oxo-vinyl-β-
ionol (36) followed by reaction with Ph3P·HBr (Scheme 6). 
O
R  
a  
OH
R  
b
 
R  
H,H 22 
O 23 
 
 R  % 
H,H 35 80 
O 36 35 
 
 
PPh
3
R
Br
+ -
 
   
R  % 
H,H 37 100 
O 38 100 
 
   
a) CH2=CHMgCl, THF, -78°C; b) PPh3HBr, CH2Cl2  
Scheme 6. Synthesis of C15 phosphonium salts. 
Wittig reaction of 37 with aldehyde 39 gave the esters of all-trans- and 11-cis-RA, 
which were saponificated with KOH in EtOH/H2O to the corresponding acids 3 and 42 
(Scheme 7). The ratio of the two isomers, all-trans-/11-cis- = 2:1, was determined by 1H 
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NMR spectroscopy and confirmed by HPLC on Puropsher RP-18 endcapped column, 5 
µm material, with CH3CN/H2O 60:40, isocratic flow of 0.7 mL/min.  
37 
or 
38 
+ O COOEt
 
a
 
COOR
R
1
 
  39  R1 R  % 
H,H Et 40 72 
H,H H 3 98 
O Et 41 73 
O H 42 99 
 
a) [i] NaOEt, EtOH, -30 °C to room temp., 2 h; [ii] KOH, EtOH/H2O, 3h reflux 
Scheme 7. C15+C5 Wittig reaction. 
The 13,14-dihydro retinoids can be obtained by this pathway when the aldehyde 43 is 
used in the last Wittig steps. Heterogeneous reduction of 39 on Pd/C and 10 bar H2 
pressure at 30 °C gave 43 in 62 % yield (Scheme 8) 
O COOEtO COOEt
a
 
39 43  
a) H2, Pd/C, ethylacetate, 10 bar, 30 °C (62 %) 
Scheme 8. Hydrogenation of 39. 
Enantioselective reduction of the C-C double bond should be possible when using a 
chiral reduction catalyst. Investigations on the proper catalyst for a good 
enantioselective reduction were not undertaken here, because the Wittig reaction of the 
synthesized aldehyde 43 and 38 yielded mostly the all-trans-isomer and not the desired 
9-cis-isomer of 11 (all-trans-, 9-cis-, 11-cis-, 9,11-di-cis-ratio = 8.1:1.6:2.0:1.0).  
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37 + 43 
 
 11 
a) KOtBu, THF, room temp.; b) KOH, EtOH/H2O (23 %) 
Scheme 9. C15+C5 Wittig reaction. 
Thus, route b is a good alternative for the synthesis all-trans-RA and all-trans-13,14-
dihydro-RA derivatives.  
3.4 Consecutive Double Bond Formation of the Retinoid Skeleton. 
Retrosynthetic Path c 
3.4.1 Synthesis of β-Ionylidene-acetaldehyde (47) and 4-Oxo-β-ionylidene-
acetaldehyde (53) 
The consecutive double bond formation pathway was chosen for a better control of the 
cis-/trans-selectivity in the synthesis of the finally required retinoids. Keeping in mind 
that the supposed configuration of the new metabolite isolated by Nau18 is cis at C-9/C-
10 and trans at C-11/C-12, the first double bond formation reaction from β-ionone 
backbone should be cis- and the second trans-selective.  
Although the stereoselectivity of the conversion of aldehydes into olefins can be more 
than 95 %, that of ketones to olefins is often disappointingly low.34 This synthetic 
problem was tried to be solved here, by an alternate carbometallation reaction of the 
ketones 22 and 23. 
Recently, an aromatic retinoid derivative has been synthesized cis selectively by 1,4-
addition of dimethyllithiumcuprate (Me2CuLi) to a propargyl ester derivative to produce 
tri-substituted alkenes.35 Bennani reported previously the same cis selective 1,4-addition 
of Me2CuLi to the acetylenic nitrile analogue of 46.
36 For our purpose, the alkyne 
aldehyde 46 seems ideal as the starting material for the reaction with the cuprate, 
because no further reduction steps of the terminal group would be necessary. For this 
reason, the Negishi method for conversion of methyl ketones into teminal acetylenes 
was used.34 Deprotonation of 22 with LDA, followed by reaction of the enol with 
COOH
a,b
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diethyl chlorophosphate gave the enol phosphonate 44. This was reacted further in an 
one pot reaction with 2 equivalents of LDA to give in a β-elimination the terminal 
alkyne 45 (i.e. its metal salt) followed by quenching of the reaction mixture with DMF 
to yield the aldehyde-alkyne 46. This compound was subsequently reacted with 
Me2CuLi to provide 47 (Scheme 10). 
O
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P(OEt)
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22  44  45 
c
 
 
d
 
 
 
 46  47  
a) LDA, ClPO(OEt)2, THF; b) LDA (2 eq.); c) DMF (68 %);  
d) Me2CuLi, -78 °C, THF (48 %) 
Scheme 10. Synthesis of 47 by cuprate addition. 
The product obtained in acceptable yield was a cis-/trans-mixture of 47 in 1:1 ratio. 
Although, as mentioned before, the 1,4-addition of organometallic copper compounds 
R2CuLi (Gilman’s cuprate) to conjugated alkyne-acid ester gives mostly the kinetically 
controlled product of the syn addition,35 this was not observed for the α,β-unsaturated 
aldehyde 46. In this case keto-enol tautomerism of the final products 51/47 was the 
reason for a unselective stereochemistry. The mechanism of this reaction is shown in 
Scheme 11. The Gilman cuprate dimer formed from methyllithium and a mixture of 
CuBr · DMS reacts with the unsaturated system to the Li-enolate 48 in which the Cu 
forms a pi-complex with the alkyne group. After reductive elimination, a new C-C bond 
is formed between one methyl group from Cu and the β-carbon to give monomeric 
Me2CuLi, which by dimerisation will generate the starting reactive Gilman cuprate 
again, and the Li-enolate 49, associated with CuMe. In the presence of an electrophile, 
like aqueous NH4
+, the formed enolate yields the cis-/trans-mixture of aldehyde 46 by 
tautomerisation.  
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Scheme 11. Mechanism of 1,4-addition of Gilman’s cuprate to the α,β-unsaturated aldehyde 46.  
Because this metallation pathway was not cis selective, the aldehydes 47 and 53 were 
synthesized in a one step Wittig reaction starting from 22 and 23 (Scheme 12). 
O
O
Ph
3
PBr
- +
O
R R
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R  
H,H 22 
O 23 
 
52 R  % 
H,H 47 83 
O 53 80  
 
a) KOtBu, THF, room temp. 
Scheme 12 C-9/C-10 double bound extension by Wittig reaction.  
β-Ionone (22) was reacted with [(1,3-dioxan-2-yl)-methyl]-triphenylphosphonium 
bromide (52) in the presence of KOtBu as base, followed by dioxolane ring cleavage 
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with oxalic acid to give the desired 47 in 71 % yield as a mixture of cis-/trans-isomers 
in 1:2 ratio. When 4-oxo-β-ionone (23) was used, aldehyde 53 was obtained in 80 % 
yield and 1.0:1.5 cis-/trans-isomer ratio. The Wittig salt 52 is commercially available 
but can be easily prepared by reacting one equivalent of 2-(bromomethyl)-1,3-dioxolane 
with one equivalent of triphenylphosphine for 84 h at 70 °C, and precipitating the 
product from acetone. The Wittig reaction with 52 offers a one step alternative to the 
often used method for preparing 47 and analogues by HWE reaction with (diethoxy-
phosphoryl) acetic acid ethyl ester or cyanomethylphosphonate followed by reduction 
of the ester, respectively cyano derivative, to the aldehydes.37,38,39 The HWE reaction 
gives preferentially the trans-isomer, which was not desired here, on the way to the 
target vitamin A metabolite. This one step method has the advantage to give the cis-
isomer in considerable amounts compared to other methods. Variation of the reaction 
conditions (base: KOtBu, LiHMDS, NaHMDS) did not show any improvement of the 
cis-selectivity of the formed product.  
This can be explained by the mechanism of Wittig reaction shown in Scheme 13. The 
cis/trans-ratio can be influenced by several parameters: temperature, solvent, 
concentration and choice of the aldehyde, type of the ylide and the presence or absence 
of lithium salts.  
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Scheme 13. Mechanism of the Wittig reaction.40a 
The first step in the Wittig reaction is a [2+2]cycloaddition of the ylid 55 to the 
aldehyde 54 to form the oxaphosphetanes 56 and 58.40a This heterocyclic intermediate 
then decomposes further into triphenylphosphine oxide 60 and the alkenes 61 and 62. 
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cis-Disubstituted oxaphosphetane 56 decomposes stereospecifically to the cis-alkene 61 
whereas trans-disubstituted 58 decomposes to the trans-alkene 62. Which of the two 
oxaphosphetanes is formed depends on the ylid used in the reaction. The non-stabilized 
ylids give the cis-oxaphosphetane 56 very rapidly (kcis is the rate constant for the 
formation of the cis-oxaphosphetane) and reversibly. On the other hand, from the same 
ylid the trans-oxaphosphetane 58 is formed very slowly (ktrans is the rate constant) but 
irreversibly. The cis-oxaphosphetane can isomerize to the trans-diastereomer before 
decomposing to the alkene, giving rise to a mixture of olefinic isomers. To prevent this 
isomerization, the Wittig reaction is performed in the absence of Li salts, using bases 
like NaNH2, NaHMDS, KOtBu. This type of Wittig reaction of non-stabilized ylids 
under “Li free conditions” is known to give cis-olefins stereoselectively. When Li salts 
are present, the faster formed oxaphosphetane 56 cannot react further to the cis-
aldehyde 61, because the cycle is opened to form the zwitterionic intermediate betaine 
57. In this reversible process, isomerization can occur and the trans-oxaphosphetane 58 
is thermodynamically favored. The reaction of non-stabilized ylids in the presence of 
Li-salts is called the Schlosser variant of the Wittig reaction.  
P-ylids react faster with C=O groups on increasing the electrophilicitiy of this bond. For 
this reason ketones react more slowly than aldehydes, enabling isomerization processes 
and yielding product mixtures of the two isomers without selectivity.  
This was observed in the case of β-ionone (22), and 4-oxo-β-ionone (23), respectively, 
in reaction with phosphonium salt 52. TLC and GC monitoring after 2 days of reaction 
saw complete transformation of the starting materials. The two isomers were formed in 
almost equal amounts.  
Separation of the cis-/trans-isomers of aldehyde 47 and 53 is possible by column 
chromatography, although several runs are necessary for complete separation of the 
reaction products. Independently, the separated two isomers have been used further in a 
second Wittig reaction. As an alternative, the isomeric mixture cam also be used and 
subsequently all isomers of the final products can then be separated by HPLC.  
3.4.2 Racemic and Enantioselective Synthesis of Phosphonium Salt 66 and its 
Derivatives 
For the second Wittig reaction used to build the retinoid backbone, phosphonium salt 66 
was synthesized. The synthesis was developed for the racemic phosphonium salt so that 
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eventually both enantiomers of 11 would be available for comparison with the natural 
product.  
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a) Ac2O, reflux, 16 h (63 %); b) MeOH, reflux, 1h (86 %); c) I2, Pb(AcO)4, CCl4 (60 %); 
d) PPh3, benzene (61 %) 
Scheme 14. Synthesis of rac-66. 
Starting from commercially available 3-methyl-glutaric acid (63) the corresponding 
anhydride was obtained after 16 h reflux in acetic acid anhydride, followed by 
hydrolysis in methanol to the half acid ester 64. This was reacted in a Hunsdiecker 
iodination with I2 and Pb(OAc)4 in CCl4 to the iodo derivative 65. Reaction with 
triphenylphosphine in benzene gave the desired phosphonium salt 66 as a racemic 
mixture. The iodo derivative proved to be quite instable so immediate reaction with 
triphenylphosphine was necessary, first without heating and after 10 h by heating the 
yellow solution slowly to 70 °C for 2 d. After the solvent had been evaporated the 
resulting viscous oil was stirred vigorously with diethyl ether to precipitate the white 
phosphonium salt 66.  
This was reacted with aldehyde 53, as shown below, and the hydrolyzed product 11 was 
compared with the isolated vitamin A metabolite. Spectroscopic analysis and molecular 
modeling calculations indicated the S configuration of the natural product. To confirm 
this assumption an enantioselective synthesis of S-66 was developed, using sections of 
the synthetic method already presented for rac-66.  
3-Methyl-glutaric acid (63) was first esterified with methanol to the diester 67, which in 
an enzymatically catalyzed desymmetrization reaction introduced the chiral center on 
the glutarate molecule enantioselectively. 
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a) NaOH (1 eq.), PLE (92 %); b) I2, Pb(AcO)4, CCl4 (65 %);  
c) PPh3, toluene (55 %) 
Scheme 15. Synthesis of S-66. 
The asymmetric enzymatic synthesis of glutarates using pig liver esterase (PLE) has 
often been used in recent times. PLE is one of the hydrolytic enzymes with considerable 
asymmetric synthetic potential whose value for the production of useful chiral synthons, 
like 3-substituted glutarate monoesters has been demonstrated.28 PLE-catalyzed 
hydrolysis of 67 was performed at pH 7 by addition of 1M aqueous sodium hydroxide. 
The reaction was worked up after addition of 1 equivalent of base. The diester 67 gave 
the R-half acid 64 in 70-80 % ee, depending on the reaction temperature and other 
solvent additives.28 Mechanistically it has been proposed that the ester group to be 
hydrolyzed must be located adjacent to the nucleophilic serine function, the catalytic 
site of PLE.28 The substituent at C-3 has a significant influence on the rate and 
stereoselectivity of the hydrolysis. For small substituents the hydrolysis is fastest but it 
falls progressively as the substituents become larger. Also, the stereoselectivity 
decreases for the 3-substitueted diester glutarate from methyl to propyl substituents and 
for larger groups inversion of the configuration was observed.28 
Following the route given for rac-64, Hunsdiecker iodination of R-64 gave S-65, which 
was reacted with triphenylphosphine to S-66.  
The monoester R-64 is commercially available, but for a significant price. Taking into 
account that the PLE needed for the synthesis of 64 is also quite expensive, and the 
product ee is lower than for the commercial compound, it is recommendable to start the 
synthesis of chiral phosphonium salt 66, from commercially available R-64. In this case, 
94 % ee of S-11 was determined by chiral HPLC. The ee of 64, 65, and 66 is difficult to 
determine experimentally without further derivatization, and for this reason the ee of the 
enantioselective reaction was measured on the final chiral retinoids, by HPLC. The half 
ester R-64, has a very small reported [α]D value of 0.4° in neat form, which makes 
calculation of the ee difficult. Because of the very low absorption spectra, these 
compounds were not detectable with the HPLC UV detector. The iodo derivate S-65 
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(measured at room temp. [α]D = -0.53 °, c = 1.7055 g/100 mL in CHCl3) and the 
phosphonium salt S-66 (measured at room temp [α]D = +0.98 °, c = 1.4285 g/100 mL in 
CHCl3) have not been reported in the literature, so the [α]D could not be compared to 
published values.  
The racemic pathway to phosphonium salt 66 was applied for the synthesis of other new 
derivatives e.g. 72, 73, which were used, as described below, for the synthesis of C-13 
modified retinoids.  
O
NC COOEt
HO
2
C CO
2
H
a
+
 
  68 69          70 
a) [i] piperidine, benzene, reflux 1.5 h; [ii] diethylmalonate, Na, 
MeOH, reflux 4 h (64 %) 
Scheme 16. Synthesis of 3-substituted glutaric acid derivative 70. 
3-Isopropyl-glutaric acid 70 was obtained as described in Scheme 16 by refluxing sec-
butyraldehyde 68, ethylcyanoacetate 69 and piperidine in benzene under Dean-Stark 
conditions until dehydration was complete.41 The formed 2-cyano-4-methyl-2-
penteneoic acid ethyl ester was refluxed with sodium dimethylmalonate in a Michael 
addition followed by acid catalyzed hydrolysis of the cyano and ester groups and 
decarboxylation to the diacid 70. Following the same methodology described for the 
synthesis of rac-66, 70 was reacted to the corresponding phosphonium salt 72 (Scheme 
17). 
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a) Ac2O, reflux, 16 h (iPr: 88 %, Ph: 62 %); b) MeOH, reflux, 1 h (iPr: 
62%, Ph: 98 %); c) I2, Pb(AcO)4, CCl4 (iPr: 64 %, Ph: 87 %); d) PPh3, 
benzene (iPr:10 %, Ph: 74 %) 
Scheme 17. Synthesis of substituted phosphonium salts. 
Commercially available 3-phenyl-glutaric acid was used for the synthesis of 73, via the 
anhydride and iodo derivatives.  
These modified phosphonium salts 72 and 73 were prepared as racemic mixtures, an 
enantioselective synthesis was not needed before first biological tests with the C-13 
substituted retinoids would show any interesting properties.  
3.4.3 Synthesis of 13,14-Dihydro-retinoic Acid (10) and 4-Oxo-13,14-dihydro-
retinoic Acid (11) 
Using the aldehydes 47, and 53, respectively, two methods were developed for the 
synthesis of the target vitamin A derivatives. Wittig and HWE reactions were used to 
construct the terminal part of the retinoid chain. For this purpose, the new phosphonium 
salt 66 and the analog phosphonate 105 were employed. Each of these reactions 
presented advantages and disadvantages, as will be discussed below.  
The Wittig reaction was performed between aldehyde 47 or 53 and the nonstabilized 
phosphonium salt 66, which, because of the reasons discussed above, will form the cis 
double bond stereoselectively. But in the target compound 11, the C-11/C-12 double 
bond should be trans and for this reason, the stereochemical preference was shifted to 
this isomer by the presence of Li containing bases. Li ions induce the heterolytic 
cleavage of the O-P bond of the oxaphosphetane, forming the lithiobetaine 57 and 59 
(Scheme 13), which influence the stereochemical course of the Wittig reaction because 
the faster reaction path to the alkene 61 is hindered. Further details of this process 
remain to be established until today.40a 
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The Wittig reaction between aldehyde 47 and phosphonium salt 66 was carried out in 
the presence of lithium hexamethyldisilazide (LiHMDS) as a base. When the trans-
aldehyde 47 was used, all-trans- and 11-cis-13,14-dh-RA methyl ester (74) were 
obtained in 1.0:1.5 ratio. The cis-aldehyde 47 gave 9-cis- and 9,11-di-cis-74 in 1:1 ratio. 
If 47 was used without previous separation of the isomers, all possible four isomers (all-
trans-, 9-cis-, 11-cis-, 9,11-di-cis-47) were obtained in 1.7:1.0:3.0:1.0 ratio.  
Most isomer ratios presented in this work were assigned by 1H NMR analysis of the 
isomer mixtures directly after the reaction. HPLC chromatograms are not always giving 
reproducible results because isomerization occurs within time or because long retention 
times needed for a good separation increased the peaks area and gave incorrect 
integrals.  
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R
R
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H,H 47 
O 53 
 
R  % 
H,H 74 78 
O 75 62 
 
R  % 
H,H 10 98 
O 11 91 
 
a) 66, LiHMDS, THF, -78 °C - room temp., 3 h; b) KOH, EtOH/H2O, reflux, 3 h 
Scheme 18. Synthesis of dh-RA derivatives 10 and 11. 
Using the same Wittig reaction conditions, aldehyde 53 gave the four possible isomers 
all-trans-, 9-cis, 11-cis- and 9,11-di-cis-75 in 2.0:1.0:3.4:1.0 ratio. When the separated 
isomers of 53 were employed, all-trans- and 11-cis-75 were obtained in 1.2:1.0, and 9-
cis- and 9,11-di-cis-75 were obtained in 1.0:1.2 ratio, respectively. Hydrolysis to the 
corresponding acids 11 and 10 was performed with KOH in EtOH/H2O as shown in 
Scheme 18. All isomer ratios are summarized in Table 1.  
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Table 1. Isomer ratios for 13,14-dihydro-retinoids determined by 1H NMR spectroscopy. 
 all-trans 9-cis 11-cis 
9,11-di-
cis 
13,14-dh-RA-methyl ester (74) 1.7 1.0 3.0 1.0 
 1.0 - 1.5 - 
 - 1.0 - 1.0 
13,14-dh-RA (10) 1.6 1.0 3.0 1.2 
 1.0 - 1.7 - 
 - 1.0 - 1.1 
4-oxo-13,14-dh-RA-methyl ester (75) 2.0 1.0 3.4 1.0 
 1.0 - 1.5 - 
 - 1.0 - 1.3 
4-oxo-13,14-dh-RA (11) 2.2 1.0 3.1 1.2 
 1.2 - 1.0 - 
  1.0  1.2 
 
The esters, and the acids of the RA derivatives, respectively, synthesized here were 
analyzed by reversed phase and normal phase HPLC. Analytical separation methods 
were developed for some of the new derivatives and complete characterization was 
performed by the usual spectroscopic techniques (NMR, MS, IR, UV) and CD for the 
diastereomers separated by chiral HPLC. 
3.4.4 Synthesis of Modified 13,14-Dehydro-retinoids 
New retinoids incorporating a bulky substituent at the chiral center C-13 were 
synthesized as described before for the methyl derivative.  
When phosphonium salt 73 was reacted with 47 in the presence of LiHMDS as base, 
13-phenyl-13,14-dh-RA methyl ester (78) was obtained in 85 % yield. Saponification 
with KOH in EtOH/H2O gave the corresponding acid 82 in 92 % yield. Wittig reaction 
of the 4-oxo-aldehyde 53 with 73 and LiHMDS furnished the ester 79 in 82 % yield, 
which was hydrolyzed to the corresponding acid 83 almost quantitatively. Under the 
same conditions, the isopropyl substituted phosphonium salt 72 was reacted with 
aldehyde 47, and 53 to give the 13-isopropyl substituted retinoid esters 76, and 77 
respectively. During hydrolysis these esters underwent additional reactions, which were 
not further clarified after the first experiments. Due to insufficient quantity of available 
starting material 72 the reaction was not repeated.  
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R
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COOMe  
    R1 R2  % 
H,H iPr 76 3 
O iPr 77 3 
H,H Ph 78 85 
O Ph 79 82 
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R
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1
COOH  
 R1 R2  % 
H,H iPr 80 0 
O iPr 81 0 
H,H Ph 82 92 
O Ph 83 97 
 
a) LiHMDS, THF; b) KOH, EtOH/H2O 
Scheme 19. Synthesis of C-13 substituted 13,14-dh-RA derivatives. 
These new C-13 substituted retinoids can be tested for their biological properties using 
the racemic products. If pure enantiomers are needed, good chiral HPLC separation 
methods have to be developed. This was achieved for the 4-oxo-13-ph-dh- and 13-ph-
dh-retinoids. Alternatively, a new enantioselective synthesis has to be developed. 
Further details are given in Chapter 4.  
3.4.5 Synthesis of Labeled 13,14-Dihydro-retinoic Acids  
The developed pathway for the synthesis of 13,14-dh-RA derivatives, offers not only a 
short and fast synthetic method to the desired new retinoids, but also the possibility to 
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design new derivatives. Substitution of hydrogen atoms by deuterium can be performed 
and the labeled retinoids can be used for a deeper understanding of the metabolism of 
RA. Investigations on the mechanism of retinoid interaction with receptor proteins have 
been carried out already with labeled vitamin A derivatives.12e The methods include 
labeling with 2H, 3H, 14C, 125I at different positions of the retinoid skeleton.  
In this study the most convenient method was to use deuterium labeling, because 
deuterated retinoids are particularly useful in investigations in which mass 
spectrometric analysis of HPLC peaks can be used to detect the retinoid metabolites. 
The deuteration position was chosen in such a way, that, if further metabolization 
occurs on the chain or on the cyclohexen ring, the retinoid backbone could be traced 
through all steps. Oxidations, reductions and other degradation processes are known to 
take place at the terminal functional group of the chain and/or on the cyclohexene ring, 
and for this reason the C-9 position seems ideal for labeling.  
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H,H 85 
O 86 
 
R1 R  
H,H Me 87 
H,H H 88 
O Me 89 
O H 90 
 
a) NaOD, D2O, pyridine, 1 h, room temp. (100 %); b) for obtaining 86: PCC, 
DMSO, 5 h, 105 °C (43 %); c) 52, KOtBu, THF, C2H2O4/H2O (75 %, 73 %); 
d) [i] 66, LiHMDS, THF; [ii] KOH, EtOH/H2O (66 %, 74 %) 
Scheme 20. Synthesis of D-labeled 13,14-dh-RA derivatives. 
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β-Ionone (22) was first labeled with deuterium, using a procedure developed by Liaaen-
Jensen for carotenoids.42  
Deuterium was introduced by base-catalyzed deuterium exchange of enolizable 
hydrogen. Reaction of 22 with NaOD, in D2O/pyridine gave after 1 hour in quantitative 
chemical yield 80 % CD3 incorporation, 18 % CD2H incorporation and 2 % 
monodeuterated 84. 
Oxidation of 84 at C-4 with PCC gave deuterated 4-oxo-β-ionone (91). During acidic 
work-up of this reaction some of the deuterium was exchanged by hydrogen. The 
retinoids were further synthesized as described for the unlabeled compounds. In the first 
Wittig reaction, although some of the deuterium was exchanged again by hydrogen in 
the acid deprotection steps of the dioxolan ring, the samples were still over 60 % 
deuterated. In the next steps, no further loss of deuterium was observed, the isotopic 
pattern in the mass spectra remaining constant.  
The deuterium ratio was determined from the MS spectra, and is summarized in Table 
2. 
Table 2. Deuterium incorporation (%) determined by mass spectrometry. 
 CH3 CH2D CHD2 CD3 
84 0.3 2.2 17.9 78.7 
91 21.0 40.7 29.1 8.9 
85 12.2 40.2 28.8 15.9 
86 38.4 39.9 18.4 3.9 
87 16.6 34.9 31.1 14.4 
88 16.2 35.1 31.4 14.7 
89 43.6 38.0 13.7 4.0 
90 45.7 36.6 13.2 3.7 
 
The characteristic pattern of the molecular ion peaks in the mass spectra of the 
deuterated samples allows using these samples in biological matrices, which after 
treatment with the labeled retinoids can be extracted and analyzed for the different 
metabolites by HPLC/MS. For these investigations, very small amounts of sample are 
needed and the gained information can be vital in understanding unknown steps in 
retinoid metabolism. 
3.4.6 Synthesis of 4-Hydroxy-retinoids 
As mentioned above, consecutive built-up of the retinoids by Wittig reactions has 
several advantages for the preparation of other new derivatives. Starting materials α- 
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and β-ionone offer several possibilities for chemical modification of the cyclohexene 
ring, near 4-oxo-dh-RAs shown above, the synthesis of 4-hydroxy-13,14-dh-RA (98) 
was designed. 
A first approach to synthesize this derivative started from the 4-oxo ester 75. Reduction 
with NaBH4 gave a complex mixture of inseparable compounds and proved to be 
unsuccessful. 
The second approach was to obtain 4-hydroxy-β-ionone (94), protect the hydroxy 
group, perform the Wittig reactions to the target retinoid esters, and in one step 
deprotect the hydroxy function and hydrolyze the ester to the free acid. For this 
sequence α-ionone (92) was chosen as starting material. The non-conjugated double 
bond was oxidized with metachloroperbenzoic acid (MCPB) to the epoxide 93 in 96 % 
yield. By treatment of 93 with NaOCH3 the epoxide ring opens to the free alcohol 94. 
Because racemic α-ionone was used in this synthesis, 94 was obtained as a mixture of 
the two enantiomers. The same reaction sequence could be enantioselectively performed 
when starting from enantiomerically pure α-ionone, because epoxidation of 92 is cis-
stereoselective.26 In this way enantiocontrol at C4 could be achieved, which could be 
advantageous for the final chiral separation of 97, 98 respectively.  
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O
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c
OAc
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 95 96  
a) MCPB, CH2Cl2, room temp., 3 h (96 %); b) NaOMe, MeOH (86 %); c) Ac2O, 
pyridine, CH2Cl2 (42 %); d) 52, KOtBu, THF, C2H2O4/H2O (41 %) 
Scheme 21. Synthesis of aldehyde 96. 
Allyl alcohol 94 was protected with triethylsilyl chroride (TESCl) to the corresponding 
silyl ether, which, similar to β-ionone, was reacted in a first Wittig reaction with 
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phosphonium salt 52 to the appropriate chain elongated aldehyde. The obtained product 
was not the expected 4-OTES protected aldehyde but the 4-hydroxy aldehyde. 
Hydrolysis of the dioxolan ring deprotected also the silyl ether, even when aqueous 
acetic acid in THF (4:1:1 CH3COOH/H2O/THF), rather than oxalic acid was used. To 
avoid this deprotection, the acetyl function was used as protecting group and aldehyde 
96 was obtained. Following the same synthetic route as described for 74, by means of a 
second Wittig reactions, the ester 97 was obtained as a mixture of four isomers (all-
trans/9-cis/11-cis/9,11-di-cis) in 1.7:1.0:2.6:1.1 ratio.  
96 
COOMe
OAc OH
COOH
a
b
 
 97 98 
a) 66, LiHMDS, THF (32 %); b) KOH, EtOH/H2O 
Scheme 22. Wittig reaction and saponification to derivative 98. 
Hydrolysis of the two ester groups was performed using KOH in EtOH/H2O. After 2 h 
at 70 °C, under Ar, the reaction mixture was extracted with ether. The basic aqueous 
phase was acidified to pH 5-5.5 with diluted acetic acid, so that the free acid group can 
be protonated and hydroxy-acid 98 can be extracted from water into the organic phase. 
It seems that during this step, the deprotected hydroxyl function was also protonated in 
the acidic milieu and undesired reactions took place, which destroyed the product. The 
4-OH-13,14-dh-RA 98 could not be isolated.  
The instability of this molecule could be also one reason why this metabolite was not 
detectable so far in retinoid polar fractions of analyzed biological samples.  
3.4.7 Horner-Wadsworth-Emmons Approach 
The synthesis of the target molecule 11 was achieved as shown above, by two 
consecutive Wittig reactions. The cis-/trans-selectivity of these reactions can be 
controlled only poorly so that almost equal amounts of all four isomers were obtained. 
This enables biological investigations on all isomers after their separation. However, the 
most active derivatives should be the all-trans- and the 9-cis-isomers.  
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The HWE reaction is known to have a higher trans-selectivity than the Wittig reaction. 
For this reason an alternative HWE two reaction sequence was developed for the all-
trans-11 and all-trans-10 retinoids.  
Alternatively, after construction of the C-9/C-10 double bond by Wittig reaction (as 
described above for 47 and 53) and separation by column chromatography of the 
formed isomers, each of them can be used separately in a HWE reaction to build the 
C-11/C-12 double bond trans-selectively. In this way, using a combination of Wittig- 
and HWE-reactions, a stereoselective synthesis of all-trans- and 9-cis-11 and -10 would 
become available.  
In carotenoid and retinoid synthesis there are several examples in which the HWE 
reaction was used to form the linear polyene chain. Eugster and coworkers used this 
reaction for the synthesis of various new substituted carotenoids.38 Using the same 
procedure, the aldehyde 47 was obtained.  
Deprotonation of diethoxyphosphoryl acetic acid ethyl ester (99) with NaH and reaction 
of the formed anion with 22 gave the ester 100 as a trans-/cis-isomer mixture in 8:1 
ratio. This ester was reduced with DIBAL to the corresponding alcohol 101, which was 
reoxidized with MnO2 to the aldehyde 47. The trans-selectivity of the C-9/C-10 bond is 
obviously improved by this pathway. However, this route cannot be used for the 4-oxo 
derivative 53, without an additional protection step of the 4-oxo ketone group, because 
reduction of the ester function with DIBAL or other reducing reagents will also reduce 
this function.  
O
(EtO)
2
P COOEt
O COOEt
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22 99  100 
OOHb c
 
101  47 
a) NaH, THF (31 %); b) DIBAL, Et2O (100 %); c) MnO2, ethyl acetate (72 %) 
Scheme 23. Synthesis of aldehyde 47 by HWE reaction followed by oxidation. 
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For constructing the next double bond, C-11/C-12 of the final retinoids, the 
phosphonate corresponding to the phosphonium salt 66 was synthesized.  
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107 (R = Et)  
Scheme 24. Michael addition to the phosphonates 105 and 106. 
Michael addition of ethyl crotonate 102 to the phosphoric acid derivative 104 gave the 
1,4-addition product 105 as well as di-addition product 107 in approximately 1:5 ratio 
(obtained by GC analysis). To avoid this undesired product, t-butyl crotonate 103 was 
used. In this case only the 1,4-addition product 106 was observed.  
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Scheme 25. Attempted synthesis of 10 by HWE reaction. 
HWE reaction of 106 and aldehyde 47 was performed using NaH as base. Since GC 
control showed that no reaction took place, a stronger base was employed for 
deprotonation. Using nBuLi, a complex mixture of products was observed by GC 
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analysis. Since nBuLi is not only a strong base but also a good nucleophile, side 
reactions can take place on the carbonyl or on the phosphonate groups.  
Deprotonation experiments with one equivalent of nBuLi followed by quenching the 
anion with D2O showed deuterium incorporation at C-2. By using 2 equiv. of nBuLi and 
quenching again with D2O, the same methylene group was deuterated and the ester 
function was attacked by the n-butyl rest.  
The acidity difference between the methylenic groups C-2 and C-4 of phosphonate 105 
was calculated by computational methods. These calculations measure thermodynamic 
acidity. The energy of the starting phosphonate was compared with the energy of the 
deprotonated species and ∆G was calculated. Under equilibrium conditions, the 
thermodynamically most stable product will be the predominant or even exclusive 
product.40b Calculations of the kinetic acidity (which reaction path has the lower 
activation barrier and which product is formed faster) were not undertaken here.  
The energy difference between deprotonation of the two methylene groups C-2 (∆G1), 
and C-4 (∆G2) is relatively small (∆G1-∆G2 = 4.8 kcal/mol). Comparable energy 
differences in the proton affinity of the CH2 groups in the vicinity of an ester and of a 
phosphonate function were also noted in case of phosphonate 27 (see Chapter 3.2 and 
Chapter 8). For phosphonium salt 66 this energy difference is much higher (∆∆G = 26.2 
kcal/mol), enabling selective deprotonation. Details about these theoretical proton 
affinity calculations will be discussed in Chapter 8.  
These facts made the stereoselective synthesis of all-trans-, respectively 9-cis-retinoids 
unattainable at present.  
Thus, the best method for the synthesis of 13,14-dihydro-retinoids is the consecutive 
Wittig reaction protocol, followed by HPLC-purification (see next chapter). Even if 
selective reactions would have been available, small amounts of the undesired isomers 
are always formed, which for biological investigations should be removed.  
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4 Analysis of Retinoids by High Performance Liquid 
Chromatography 
4.1 Separation of Retinoids by Reversed Phase HPLC 
High performance liquid chromatography (HPLC) is the method of choice for 
separating and quantifying naturally occurring and synthetic retinoids. Most retinoids 
analyses are performed under reversed phase conditions, using a hydrophobic stationary 
phase (typically RP C2, C8, C18) and a more polar mobile phase (methanol, acetonitrile 
with small amounts of water).43 The polar components interact less with the unpolar 
alkyl chains bound to silica and are eluted faster than the nonpolar samples. Partition 
chromatography (reversed phase) has the advantage to give a better separation for 
different classes of retinoids, which is the case in biological samples where ROH, RAL, 
RA and retinyl esters have to be first separated from each other. Adsorption 
chromatography (normal-phase) sometimes gives better results in separating the isomers 
of retinoids. In adsorption chromatography the sample is adsorbed onto the polar 
stationary phase and is displaced from its adsorption sites by the mobile phase, typically 
hexane. In this mode, less polar samples are eluted before the more polar. Normal phase 
columns were used especially in early carotenoid analysis as open-columns, later on 
HPLC.44 There are no standard methods for separation of retinoids, most researchers 
develop their own methods with different eluents and additives of the mobile phase. 
For the analysis and separation of the synthetic retinoids reported here, both types of 
HPLC columns were used and compared. Adsorption chromatography was performed 
on chiral columns also as will be discussed later.  
Reversed phase chromatography combined with gradient or isocratic HPLC was used to 
separate 11 and 10. Several columns, respectively stationary phase materials were used 
and compared: Hibar RT 250-10 filled with Lichrosorb RP-18 (7 µm) material, 
LiChroCART 250-4 filled with Purospher RP-18 endcapped (5 µm) material, and 
Nucleosil 250-10, C18 (7 µm) material. The retinoids were detected by measuring the 
absorbance of ultraviolet light with a diode array detector (DAD) or UV detector. 
Octadecylsilane (ODS, C18) stationary phase was used by Nau and co-workers for 
analysis of liver extracts and for comparison of isolated metabolites with synthetic 
products.  
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The characteristics of different packings are determined by the mode of preparation of 
the silica particles, the mode of covalent attachment of the hydrocarbon chains to the 
silica, the density of hydrocarbon coverage (carbon load) of the column, and the 
presence or absence of unreacted silanol groups. Unreacted silanol groups on the silica 
particles can interact by hydrogen bonding with some functional groups of the analytes. 
Some commercial column packing are endcapped (those silanol groups remaining after 
covalent addition of the octadecyl chains are subsequently reacted with trimethylsilyl 
groups) to reduce these silanol-sample interactions.44  
Unfortunately, only a small number of isocratic separation methods have been 
developed, mostly because the isomers are not baseline separated and long retention 
times are required for a good separation. Of course, an isocratic method would be easier 
to use and also more economical than the gradient method because no stabilization of 
the column is necessary after each run.  
Purospher RP-18 material, which consists of tightly packed 5 µm spherical silica 
particles was expected to show high efficiency in the separation of the isomers. Smaller 
particles packed into columns with higher density allow less diffusion of the sample 
between particles causing narrower, sharper peaks. On this material, shorter analysis 
times are noted, and an isocratic method could become suitable.  
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Figure 8. HPLC separation of 75 on Purospher RP-18, 5 µm, CH3CN/H2O 60:40, 1 mL/min. 
Fraction 1: 9-cis- and 9,11-di-cis-75; fraction 2: 11-cis-75; fraction 3: all-trans-75. 
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Figure 9. HPLC separation of 41 on Purospher RP-18, 5 µm, CH3CN/H2O 60:40, 1 mL/min (all-trans- 
and 11-cis-isomers eluted together). 
The synthesized 13,14-dihydro retinoids 11, 75, 10, 74 were analyzed on a Purospher 
endcapped column and compared with the known retinoids RA ester and 4-oxo-RA 
ester. On this column, different isocratic methods methanol/water and acetonitrile/water 
in several proportions were tried.  
The isomers of the 4-oxo-13,14-dh-RA ester (75) were not completely resolved on this 
column. The retention time of all-trans-41 is shorter than that of all-trans-75 and almost 
identical with that of the 9-cis- and 9,11-di-cis-isomers of 75, which were eluted 
together.  
The acids 11 and 10 are eluting too fast on this column. The reason could be their high 
polarity and the lack of any additional interactions of the acid group with free hydroxyl 
groups on the endcapped material of the column. 
When the all-trans- and 11-cis-74 products of the selective synthesis were injected, the 
two isomers were separated (Figure 11), while 9-cis- and 9,11-di-cis-74 eluted together 
(Figure 10), as the 4-oxo ester 75. All-trans-40 eluted later than the same isomer of the 
13,14-dihydro compound.  
 42
-0.1
0.1
0.3
0.5
0.7
0 5 10 15 20 25
time [min]
a
b
s
 [
m
A
u
]
1+2
COOMe
 
Figure 10. HPLC analysis of 9-cis- and 9,11,-di-cis-74 on Purospher RP-18-endcapped, 5 µm, 
CH3CN/H2O 60:40, 1mL/min. 
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Figure 11. HPLC separation of 74 on Purospher RP-18-endcapped, 5 µm, CH3CN/H2O 60:40, 1mL/min. 
Fraction 1: all-trans-74; fraction 2: 11-cis-74. 
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Figure 12. HPLC separation of 40 on Purospher RP-18-endcapped, 5 µm, CH3CN/H2O 60:40, 1mL/min. 
Fraction 1: 11-cis-; fraction 2: all-trans-40. 
On a Lichrosorb RP-18 column, particle size 7 µm, an isocratic method for separating 
the isomers of 11 also proved unsuccessful. Although under the same isocratic 
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conditions, the retention time was longer than on the Purospher column, complete 
separation of all isomers was not achieved.  
For retinoid analysis, an isocratic program that can separate the isomers in a short time 
and with no buffer eluents was desirable. Because this was not achieved on the 
Purospher and Lichrosorb columns, other columns and gradient methods were tested.  
On Nucleosil C18, particle size 7 µm, separation of all four isomers was possible only 
with a very long gradient program. The solvents used were A: water, B: methanol, C: 
acetonitrile at a constant flow of 2 mL/min in the following program:  
time (min) B (%) C (%) 
0 10 10 
60 10 10 
61 20 10 
64 20 10 
65 30 10 
80 30 10 
90 30 20 
100 10 10 
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Figure 13. HPLC analysis of 11 on Nucleosil C18, 7 µm with a gradient program. Fraction 1: 9,11-di-cis-; 
fraction 2: all-trans-; fraction 3: 9-cis-; fraction 4: 11-cis-11. 
Because of the long retention time, the peaks became broad so the solvent polarity had 
to be increased. The chromatogram with the new method is shown in Figure 14. The 
program was run with the same solvents and flow and the new gradient was: 
time (min) B (%) C (%) 
0 10 10 
40 10 10 
42 20 10 
60 20 10 
80 30 10 
85 30 20 
100 10 10 
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Using this method, 9-cis-11 is not separated anymore from the 11-cis-isomer. Several 
modifications on the solvent mixture and the gradient program did not improve the 
separation.  
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Figure 14. HPLC analysis of 11 on Nucleosil C18, 7 µm, gradient program and buffer additive. 
Fraction 1: 9,11-di-cis-; fraction 2:all-trans-; fraction 3: 9-cis- and 11-cis-11. 
An improvement was achieved by using a buffer in the mobile phase. 
A binary gradient of solvent A: 1:1 methanol/water with ammonium acetate, 60 mM, 
and B: methanol was used. The gradient composition was: 1) 0 min 1 % B, 2) 20 min 1 
% B, 3) 22 min 10 % B, 4) 45 min 10 % B, 5) 49 min 1 % B, 6) 60 min 1 % B, at a 
constant flow rate of 3 mL/min (Figure 15). The method was adapted after the analytic 
separation method developed by C. Schmidt for the analysis of polar retinoids in 
biological samples.17 
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Figure 15. HPLC separation of 11 on Nucleosil C18, 7µm, 250 x 10 mm with a gradient program.  
Fraction 1: 9,11-di-cis-; fraction 2: all-trans-; fraction 3: 9-cis-; fraction 4: 11-cis-11. 
In conclusion, the differently modified RAs are easily separated by using isocratic 
methods on RP-18 HPLC columns, as shown on a Purospher 5 µm column, but to find a 
proper method for the complete separation of all geometric isomers of the 13,14-
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dihydro retinoids proved to be time consuming. For this reason normal phase HPLC 
was tested.  
4.2 Enantioselective Separation 
Resolution of racemates is one of the most important methods to obtain optically active 
compounds. Since Pasteur succeeded in the first resolution of a racemic compound,45 
sodium ammonium salt of (±)-tartaric acid in 1848, numerous methods of resolution 
have been developed. The first method was crystallization (ex: manual sorting of 
conglomerates, preferential crystallization, resolution as diastereomer, inclusion in a 
optically active host compound). Other methods include kinetic resolution by enzymes 
or chromatographic separations.  
Chiral separation by HPLC using a chiral stationary phase (CSP) is today one of the 
most efficient methods to separate enantiomers, not only on the analytical but also on 
the preparative scale.  
There are basically two types of CSPs: one consist of a chiral selector, like a chiral 
small molecule that is usually bound to an achiral support, such a silica gel; the second 
is based on a chiral polymer which can be used as a porous gel or can be bound on 
silica. The first stationary phase belonging to the first group, prepared by Pirkle,46,47 was 
based on dinitrobenzoyl derivatives of amino acids, particularly phenylglycine and 
leucine, coated onto silica materials. These ionic phases showed excellent efficiency but 
were limited to low-polarity solvents, which initiated the development of covalently 
bound phases46 like β-naphthoyl derivatives of alanine. The second group of chiral 
phases includes polyacryamides, one-handed helical polymethacrylates, polyamides, 
proteins and polysaccharide derivatives. Polysaccharides such as cellulose, amylose and 
chitin are the most accessible optically active polymers on earth. These polysaccharides 
themselves show rather low chiral recognition, but their derivatives, such as triacetate, 
tribenzoate, and triphenylcarbamates, exhibit high chiral recognition ability and can 
resolve a broad range of racemates. The first CSP derived from cellulose was prepared 
by Hesse and Hagel in 1973.48,49  
These results provided a breakthrough in the area of chiral stationary phases based on 
derivatized polysaccharides. Among the cellulose esters, cellulose carbamates and 
amylose carbamates show characteristic high resolving abilities as CSP when coated on 
silica gel.50 Chiral recognition greatly depends on the substituents on the aromatic ring, 
but also on the coating conditions, particularly the additives added to the solvent used 
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for coating.51 Another important step in improving the properties of the chiral phase was 
achieved by Okamoto52 with the development of chiral immobilized phases by radical 
copolymerization with styrene or 2,3-dimethylbutadiene. The immobilization of 
polysaccharides on a matrix has been considered as an evolutionary approach to 
implement universal solvent compatibility on the CSPs. Table 3 lists some of the 
polysaccharide derivatives that have already been commercialized as CSPs for HPLC. 
From them, Chiracel OJ, OD, AD, AS and Chiralpak IA, IB were tested for the 
separation of 11, 75, 10, 74, 79, 83, 78, 82. The best efficiency was achieved on 
Chiracel OD and OJ columns (analytical column 0.46 x 25 cm, and preparative column 
2 x 25 cm), using normal or reversed phase conditions. Althrough several eluents were 
tested and their composition was varied, Chiracel AD, AS, IA, IB columns were tested 
without satisfactory results. Some explanations and conclusions for the success of a 
specific separation will be discussed.  
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Table 3. Structure of polysaccharides derivatives with a high chiral resolving power.53 
Polysaccharide derivatives R Commercial names 
O O
O
O
O
R
O
R
O
O
R  
Cellulose ester 
Chiracel CTA (micro-crystalline), 
-CH3 
Chiracel OA (coated type) 
 
Chiracel OB 
CH
3
 
Chiracel OJ 
 
O O
O
O
O
NH
O
N
H
O
O
NH
R
R
R
Cellulose carbamates 
 
Chiracel OC 
CH
3
CH
3  
Chiracel OD 
Chiralpak IB (immobilized type) 
 
O
O
O
O
NH
O
N
H
O
O
NH
R
R
R
O
Amylose carbamates 
CH
3
CH
3  
Chiracel AD 
Chiralpak IA (immobilized type) 
 
The known metabolites of vitamin A are usually achiral, so most separations of the cis-
/trans-isomers, were performed on non-chiral columns. There are just very few 
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examples of isolated chiral retinoids and even less methods for their enantioseparation. 
Lately a chiral retinal dimer formed in the visual process was characterized by chiral 
HPLC on a Chiracel OD column.54 The chirality of the 13,14-dihydro retinoid 
metabolites reported to date, the 9-cis-4-oxo-13,14-dh-RA (by Nau), 9-cis-13,14-dh-RA 
(by Shirley), all-trans-13,14-dh-ROH and all-trans-13,14-dh-RA (by Palczewski) was 
not investigated by the original authors. 
4.3 Chiral Separation of 4-Oxo-13,14-dihydro-retinoic acid (11) and its Ester 
Using an isocratic method with hex/iPrOH/TFA 95:5:0.1 and a flow rate of 0.5 mL/min 
from 0 to 40 min then 1 mL/min to the end, all diastereomers of 11 were separated on a 
Chiracel OJ column, 0.46 x 25 cm, 10 µm particle size.  
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Figure 16. Chiral separation of racemic 4-oxo-13,14-dh-RA (11) on Chiracel OJ, hex/iPrOH/TFA 
95:5:0.1. (Fraction 1: R-11-cis-; fraction 2: S-9,11-di-cis-; fraction 3: S-all-trans-; fraction 4: S-9-cis-; 
fraction 5: R-9-cis-; fraction 6: S-11-cis-; fraction 7: R-all-trans-; fraction 8: R-9,11-di-cis-11). 
When a Chiracel OJ-H, 5 µm particle size column was used, the resolution became 
better because the separation surface of the column material increased. This time the 
flow rate was 0.9 mL/min from start 0 min to 30 min, increased to 1.2 mL/min till 35 
min, and kept constant until the end of the separation. These additional improvements 
resulted in a reduction of the retention time and sharper peaks.  
A very good separation of all diastereomers of 11 was important because these will be 
used further for biological investigations. If the esters are first separated and 
subsequently saponificated there is a high possibility of isomerization during workup, 
and purification has to be repeated again. This supposition was verified by preparing the 
ester 75 from the separated isomers of aldehyde 53 followed by saponification to 11. In 
this case just four diastereomers were obtained (Figure 17). HPLC peak ratios and 1H 
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NMR spectra show that no isomerization occurred during the saponification and the 
workup of 75 to 11. However, isomerization of the acid takes place in time. 11-cis-11 
isomerizes to all-trans-11 and the 9,11-di-cis-derivative to the 9-cis-isomer quite rapidly 
(hours to days), while 9-cis-11 isomerizes to all-trans-11 only slowly (days to weeks). 
The possibility of isomerization during HPLC separation due to the use of TFA additive 
in the eluent mixture was also investigated. Immediately after the fractions were 
separately collected and the solvent removed, their purity was established by HPLC. All 
chromatograms showed just one peak. This crucial observation is important also for the 
analysis of the isolated vitamin A metabolite on the Chiracel OJ column with the same 
separation method.  
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Figure 17. Chiral separation of 11 on Chiracel OJ-H, 5 µm, hex/iPrOH/TFA 95:5:0.1 (curve a: racemix 
mixture, fraction 1: R-11-cis-; fraction 2: S-9,11-di-cis-; fraction 3: S-all-trans-; fraction 4: S-9-cis-; 
fraction 5: R-9-cis-; fraction 6: S-11-cis-; fraction 7: R-all-trans-; fraction 8: R-9,11-di-cis-11,  
curve b: 11-cis- and all-trans-11, curve c: 9,11-di-cis- and 9-cis-11). 
Because the spectroscopic data were not sufficient for a clear identification of chirality 
for each separated fraction, an enantioselective synthesis of 11 was carried out (see 
previous chapter). The chiral analysis of rac-11 compared with the isolated metabolite, 
CD spectroscopy, and molecular modeling studies supported a target enantioselective 
synthesis for the S enantiomer. Comparison of the two chromatograms of rac-11 and 
S-11 allowed the assignment of all synthetic enantiomers (Figure 18) and of the absolute 
configuration of the natural vitamin A metabolite as S (see Chapter 9). 
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Figure 18. Chiral HPLC of 11 on Chiracel OJ-H, hex/iPrOH/TFA 95:5:0.1 (curve a: product of racemic 
synthesis, curve b: product of enantioselective synthesis). Fraction 1: R-11-cis-; fraction 2: S-9,11-di-cis-; 
fraction 3: S-all-trans-; fraction 4: S-9-cis-; fraction 5: R-9-cis-; fraction 6: S-11-cis-; fraction 7: R-all-
trans-; fraction 8: R-9,11-di-cis-11. 
The developed separation method allows a good preparative chiral separation on a 
Chiracel OJ 10 µm, 2 x 25 cm column, with a flow rate of 10 mL/min. All 
diastereomers were characterized by CD and by the usual spectroscopic techniques 
(NMR, MS, IR and UV analysis). This separation method was also used for purification 
and analysis of the samples used for the biological tests. 
The ester 75 was separated on a Chiracel OJ column with hex/iPrOH 93:7 and 0.5 
mL/min flow rate. A perfect resolution of all diastereomers was not achieved, but was 
also not the goal as long as the acids had been completely resolved. The fractions were 
paired by CD spectroscopy to the corresponding enantiomer pairs. From the NMR 
spectra of the reaction mixture, the ratio between the isomers was known and 
comparing the elution order on the same chiral material between the diastereomers of 
the acid 11 and its ester 75, each fraction was assigned to the corresponding 
diastereomer. Also from the peak ratio, fraction 1 and 4 were postulated to be the 
enantiomers of 9-cis- or 9,11-di-cis-isomer. However, a definite assignment was not 
possible without preparative separation and investigation of each fraction by NMR 
analysis. For fraction 2 and 3 the 11-cis-configuration was assigned, while fraction 5 
and 6 are the enantiomers of all-trans-75. This isomer assignment was confirmed by 
molecular modeling calculations of the CD spectra in comparison with the experimental 
results as will be shown in detail in Chapter 6. 
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Figure 19. Chiral separation of 75 on Chiracel OJ, hex/iPrOH 97:3, 0.5 mL/min. 
Fraction 1, fraction 4: 9,11-di-cis-, 9-cis-; fraction 2: R-11-cis-; fraction 3: S-11-cis-; fraction 5: S-all-
trans-; fraction 6: R-all-trans-75. 
4.4 Chiral Separation of 13,14-Dihydro-retinoic acid (10) and its Ester 
Several columns were tested for the chiral resolution of 10 and the ester 74. Chiracel 
OD, OJ, AD, AS and Chiralpak IA and IB columns under a variety of normal phase 
solvent conditions could not resolve these retinoids. The solvents used for the Chiracel 
columns were hexane and iPrOH in different proportions, for the acid derivative 
additional TFA was used. Chiral separation on the Chiralpak columns was tried with 
different mixtures of hexane and chloroform. All these columns show no adsorption of 
the 13,14-dihydro retinoids on the chiral stationary phase. Retention time was always 
between 5 and 10 min. Reversed phase conditions were tested on a Chiracel OD 
column, again with unsatisfactory results. The absence of the 4-oxo group in the 
molecule changes the adsorption affinity on the CSP, so that 10 and 74 were eluted 
without any adsorption on the CSP. The mechanism of the chiral separation will be 
discussed later and possible solutions for the resolution of the 13,14-dihydro retinoids 
are proposed based on this mechanism.  
4.5 Chiral Separation of 4-Oxo-13,14-dihydro-13-phenyl-retinoic acid (83) and 
its Ester 
The 4-oxo-moiety in 83 and 79 proved again to play a decisive role in the separation. 
These derivatives have been successfully separated by isocratic methods on an 
analytical Chiracel OD column, 10 µm. The acid 83 was separated with hex/iPrOH/TFA 
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96:4:0.1 and a constant flow rate of 0.5 mL/min while the corresponding esters 79 show 
the best resolution with hex/iPrOH 90:10 at the same flow rate.  
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Figure 20. Chiral separation of 79 on Chiracel OD, 10 µm, hex/iPrOH 90:10.  
Fraction 1: S-9,11-di-cis-; fraction 2: S-9-cis-; fraction 3: S-11-cis-; fraction 4: S-all-trans-; 
fraction 5: R-all-trans-; fraction 6: R-9,11-di-cis-; fraction 7: R-11-cis-79. 
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Figure 21. Chiral separation of 83 on Chiracel OD, 10 µm, hex/iPrOH/TFA 96:4:0.1. 
Fraction 1: S-9,11-di-cis-; fraction 2: S-9-cis-; fraction 3: S-11-cis-; fraction 4: S-all-trans-; 
fraction 5: R-all-trans-; fraction 6: R-9,11-di-cis-; fraction 7: R-11-cis-83. 
The enantiomers were paired by their CD spectra and the isomers were assigned by 1H 
NMR spectroscopy and comparison of the NMR and HPLC isomer ratio of the reaction 
product. The HPLC separation of 79 is shown in Figure 20, where the peaks 1 and 6 are 
assigned to the S and R enantiomers of the 9,11-di-cis-isomer, peak 2 is the S-9-cis-
isomer, the 3rd and the 7th peaks belong to the S- and R-11-cis-isomer, and the peaks 4 
and 5 are the two S and R enantiomers of the all-trans-isomer, respectively. The second 
enantiomer of the 9-cis-isomer is co-eluting with another diastereomer. The 
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corresponding acids 83 show a similar resolution on the chiral stationary phase, all 
diastereomers display the same elution order. The assignment of the absolute 
configuration for each isomer of 79 and 83 was performed by CD spectroscopy and 
molecular modeling calculations and will be discussed in detail in Chapter 6.  
4.6 Chiral Separation of 13,14-dihydro-13-phenyl-retinoic acid (82) and its Ester 
As expected, the separation of the 13-phenyl substituted retinoids without the keto 
functionality at C-4 was not trivial. The Chiracel OD, OJ, AD, AS and Chiralpak IA and 
IB were again tested under normal phase conditions. Several methods were developed; 
none of them gave a satisfactory separation. When reversed phase conditions were tried 
on a Chiracel OD column, the esters 78 show an improvement of the retention time, 
indicating adsorption on the CSP. After method optimization, with the eluent mixture 
MeOH/H2O 90:10 and a constant flow rate 0.5 mL/min., a partial separation was finally 
possible (Figure 22).  
The isomer ratio known from 1H NMR analysis was used for configuration assignment: 
peaks 1, 3, 6 should belong to 9-cis- and 9,11-di-cis-78, while peaks 2, 4, 5 should 
belong to all-trans- and 11-cis-78. Two diastereomers are eluted under these peaks as 
well. From their CD spectra, peaks 1 and 3, 2 and 4 were paired. Again, experimental 
CD spectra were compared with the calculated spectra for enantiomer assignment. All 
this information leads to the following assignment: peak 1: S-9,11-di-cis-, peak 2: S-all-
trans-, peak 3: R-9,11-di-cis-, peak 4: R-all-trans-78. The other diastereomers were not 
assigned. 
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Figure 22. Chiral separation of 78 on Chiracel OD, MeOH/H2O 90:10, 0.5mL/min. 
Fraction 1: S-9,11-di-cis-; fraction 2: S-all-trans-; fraction 3: R-9,11-di-cis-; fraction 4: R-all-trans-78; 
fraction 5 and fraction 6 not assigned. 
When comparing the two esters 78 and 74 the only difference between these molecules 
is the substituent at C-13, the phenyl ring, and the methyl group, respectively. This 
means that the phenyl ring interacts with the CSP so that adsorption becomes possible 
on the column, which is evidently not the case for 74.  
The different adsorption mechanism of the four molecules, 11, 10, 83 and 82, tested 
here for separation on the different CSP was analyzed and is discussed further.  
4.7 Chiral Separation Mechanism 
To understand the retention mechanism is of essential importance when a stationary 
phase is chosen for separation. To elucidate the chiral recognition mechanism, 
experiments using chromatography, NMR spectroscopy, X-ray crystallography and 
computational methods have been used.55 These results show that chiral polymers have 
a number of different binding sites with different affinities for enantiomers. The 
cellulose polymer chains are held together by intramolecular and intermolecular 
hydrogen bonds that result in the formation of sheets. Chiral cavities are created 
between sheets, further imparting chiral character. The chiral recognition mechanism 
for derivatized cellulose involves attractive interactions followed by the steric fit of the 
molecules into the chiral surface. 
This means that the analyte-CSP complexes are first formed by attractive interactions 
and chiral discrimination takes place due to the steric fit of the analyte into the chiral 
cavity. The attractive interactions make use of hydrogen bonding, dipole-dipole, and pi-
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pi interactions. Different mechanistic aspects were found to play a stronger role in the 
cellulose esters compared to the celullose carbamates CSP.55  
On Chiracel OD, with phenylcarbamate derivatized cellulose as CSP, the chiral 
recognition mechanism most likely involves the formation of diastereomeric analyte-
CSP complexes by hydrogen bonding and interactions between the polar carbamate 
moieties, NH and C=O groups with the functional groups of the analyte. Stabilization of 
these complexes is due to insertion of the aromatic ring of the analyte, 79, 83, 78, into 
the chiral cavities of the CSP, and by dipole-dipole interactions between the analyte and 
CSP. The phenyl carbamate ring on the CSP is 3,5-disubstituted with electron donating 
groups and methyl groups, which increase the electron density at the carbonyl oxygen 
atom of the carbamates and therefore enhanced hydrogen bonding is induced. 
O
O
O N
H R
pi−pi interactions
H-bonding
O R
O
H
OR
O
R
H-bonding
dipol-dipol 
interactions
 
Figure 23. Chiral separation mechanism on carbamate CSP (Chiracel OD). 
The chiral recognition mechanism on a Chiracel OJ column, with cellulose ester as 
CSP, takes place by an inclusion of the enantiomers in the chiral cavities.55  
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Figure 24. Chiral resolution on the cellulose ester CSP (Chiracel OJ). 
The main chiral adsorption sites of the cellulose tribenzoate phase are considered to be 
the polar carbonyl group of esters, which can interact with the racemate of 11 or 75 by 
way of hydrogen bonds and dipol-dipol interactions. The inclusion of the molecules in 
the cavity is due to attractive interactions through functional groups rather than the 
shape of the analyte. This agrees with the observations previously presented here where 
the 4-oxo-13,14-dh-RAs were resolved best on the cellulose tribenzoate ester. Here a 
strong interaction can take place between the 4-oxo group and the ester function on the 
CSP. The 13,14-dh-RAs on the other hand do not possess have enough interaction sites 
for absorption on the CSP.  
On the cellulose ester CSP, consisting of cellulose triacetate (CTA), the chiral 
resolution was postulated to function in an opposite way as for the cellulose tribenzoate 
(CTB).55 The inclusion of the molecules in the cavity is not governed by attractive 
interactions between functional groups but mainly by the shape of the molecules. On 
such a column it should be possible to resolve the RA derivatives 10 and 74. In this 
project, a cellulose triacetate column was not available for testing. 
In conclusion, the 4-oxo-13,14-dh-retinoids can be resolved on Chiracel OD or Chiracel 
OJ columns, while the 13,14-dh-retinoids are not suited for separation on these 
columns, as long as additional functional groups capable to interact with the CSP are 
present in the retinoid backbone. 
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5 Spectroscopic Analysis 
5.1 Infrared Spectroscopy 
Infrared spectroscopy (IR) was used for the characterization of the new retinoids, 
especially for the identification of the functional groups, which give a characteristic IR 
absorption signal and indicate intra- and/or intermolecular hydrogen bonds of the acid 
and other polar functions.  
The absorption due to the C-H stretch of methyl and methylene groups is for all 
retinoids in the range 2965-2820 cm-1. The H-C-H bending mode can be observed at 
1456-1437 cm-1 for the asymmetric and 1380-1350 cm-1 for the symmetric vibrations. 
The H-C=C-H stretching of the different isomers can be assigned from the lower 
wavelength range of the IR spectra. trans-Isomers give a band of medium intensity 
around 970-960 cm-1 and the cis-isomers between 760-700 cm-1. The C=C stretching 
vibration produces a medium to weak band around 1605-1580 cm-1. For the RA 
derivatives a broad band at 3400 cm-1 due to the acidic OH group is observed. A 
characteristic differentiation between the different RA derivatives based on this group 
was not possible because of the width of the signal. This indicates that no 
intramolecular hydrogen bonds are formed, which would cause sharper signals; but 
intermolecular H-bonds are present because the absorption band is extending to almost 
2600 cm-1. Strong sharp bands between 1720 and 1600 cm-1 are attributed to the 
stretching mode of the carbonyl groups. For 11 and 75 (Figure 25), two bands are 
observed, one for the carbonyl of the acid function at 1781-1690 cm-1 and the second 
one for the 4-oxo carbonyl function almost at constant wavelength 1660-1658 cm-1. For 
10 and 74 (Figure 26) only the first band can be observed. The carbonyl absorption 
band of the ester function is visible at higher wavelengths (1781-1712 cm-1) compared 
to the same group in the acid functions (1736-1690 cm-1). Retinoids incorporating the 
phenyl ring at C-13 (Figure 27) show weak signals for this group at 3070-3000 cm-1. 
The IR spectra of the labeled compounds do not differ very much from those of their 
unlabeled analogs; the stretching vibrations are very slightly shifted to smaller 
frequencies as expected. The exact values for all newly synthesized RA derivatives are 
summarized in Table 4. Because there is almost no literature on the IR spectra of 
retinoids, some of the spectra of the newly synthesized RA derivatives are shown here.  
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Figure 25. IR spectrum of 11 and 75. 
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Figure 26. IR spectra of 10 and 74. 
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Figure 27. IR spectra of phenyl substituted derivatives 83 and 82. 
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Although from the IR spectra it is often difficult to assign a structure unambiguously, 
there is a lot of information that can be derived from these spectra, like the existence of 
hydrogen bonding, if the retinoid is a RA, RAL or ROH derivative, containment of 
further carboxyl or carbonyl functions etc. Furthermore, one can determine the absolute 
configuration of chiral retinoids by using vibration circular dichroism (VCD). Chirality 
can be studied using the vibration optical activity (VOA) of a molecule, and the IR form 
of VOA is the VCD.56 This technique can be very useful for the analysis of biological 
samples, because the nature of the retinoid metabolites and, if existent their chirality, 
can be analyzed directly by an IR or VCD detector coupled to a HPLC instrument 
without further separation and purification steps. Another important aspect concerns the 
possibility to calculate, by molecular modeling, the IR and the VCD spectrum of a 
molecule and compare them with the experimental spectra. For this reason, IR 
spectroscopy is a powerful method in retinoid and biological sample analysis. 
5.2 UV/Vis-Spectroscopy 
Electronic absorption spectroscopy is one of the most useful spectroscopic methods for 
the analysis of retinoids because of their characteristic absorption spectra due to the 
conjugated double bond system. The absorption of each isomer can be investigated 
particularly easily when the UV detector is coupled to HPLC. 
Under standard conditions the shape of the spectrum is determined by the number of 
double bonds, the substituents, cis-/trans-isomerism and by the solvent and its pH.  
The UV spectra were measured in different eluent mixtures, in hex/iPrOH with or 
without TFA as buffer, the fractions from normal phase HPLC, in acetonitrile/water 
(CH3CN/H2O) or methanol/water (MeOH/H2O) the fractions from reversed phase 
HPLC and in ethanol (EtOH) the pure substances, directly after reaction, without 
separation of the isomers by HPLC.  
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Table. 5. UV absorption maximum of selected RAs in different solvents. 
 λmax1 (nm) λmax2(nm) solvent 
40 243 355 EtOH 
 247 353 CH3CN/H2O 
41 233/288 355 EtOH 
 235/288 362 CH3CN/H2O 
74 227 290 EtOH 
 - 279 CH3CN/ H2O 
10 233 289 EtOH 
 - 298 CH3CN/H2O 
75 250 314 EtOH 
 252 318 CH3CN/H2O 
 252 320 hex/iPrOH 
11 256 332 EtOH 
 255 320 CH3CN/H2O 
 257 339 CH3OH/H2O 
 250 320 hex/iPrOH/TFA 
 
The wavelength shift noted in most retinoids is caused by the polarity of the solvents 
(solvatochromism). In the presence of hydroxylic solvents, the lone pairs on the 
carbonyl function act as an electron donor to the hydrogen of the solvent to form a 
hydrogen bond. The shift of the long-wavelength maximum (assigned to be produced by 
the n-pi* transition) to lower wavelengths when changing to more polar solvents is a 
measure of the strength of the hydrogen bond in the solvent.58 This effect can be seen in 
the UV spectra taken in EtOH (Table 5). In aqueous solution, the acidic species to be 
measured can dissociate and the measured spectrum is that of the ion. For this reason 
the acidity of the sample, as well of the eluents contribute to the UV absorption. 
The shorter wavelength band is known to be produced by the pi−pi* transitions.58 This 
absorption band is shifted bathochromically, in the opposite direction of the n-pi* 
transition band, when going from hexane to ethanol and water. Another bathochromic 
shift is seen for both absorption maxima when additional double bonds are conjugated, 
as in the case of the 4-oxo retinoids (Table 5). 
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Figure 28. UV spectrum of 11 in hex/iPrOH/TFA (95:5:0.5). 
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Figure 29. UV spectrum of 75 in hex/iPrOH (97:3). 
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Figure 30. Comparison between the UV spectra of all-trans-11 and the corresponding ester all-trans-75. 
The UV spectrum of 11 shows two maxima at 250 and 320 nm in hex/iPrOH/TFA 
(95:5:0.5), while the corresponding ester 75 in hex/iPrOH (97:3) show almost the same 
absorption pattern, with a very small hypsochromic shift (Figure 30). The change from 
linear all-trans-configuration to an angular cis-isomer results in the increase of the 
intensity of the short-wavelength band, as seen especially in the case of the 9-cis- and 
the 9,11-di-cis-isomers.  
As expected, the acid 10 and its ester 74, show the absorption maximum at shorter 
wavelength (all-trans-10 at 298 nm and all-trans-74 at 278 nm) in CH3CN/H2O 60:40. 
A similar UV absorption spectrum was recorded for the 4-acetoxy dehydro-retinoid 97, 
with two maxima in EtOH at 229 and 289 nm, because the conjugated system in 97 is 
the same as in 74.  
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Figure 31. UV spectra of all-trans-74 and all-trans-10 in CH3CN/H2O (60:40).  
Comparison of the dh-RAs (74, 75) with the RAs (40, 41) demonstrates convincingly 
that the conjugation between the polyene chain and the terminal group is broken. The 
hypsochromic shift of 74 to 40 amounts to 80 nm, while 75 is shifted by 25 nm to a 
lower wavelength compared to 41. Characteristic for the 4-oxo retinoids is the presence 
of two absorption maxima, while the retinoids non-oxidized at C-4 give one absorption 
maximum.  
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Figure 32. UV spectra of 74, 75, 40, 41 in CH3CN/H2O (60:40). 
When a phenyl group, as in 79 and 83, replaces the methyl substituent at C-13 the UV 
spectrum does not change significantly because the conjugated system is hardly 
changed. The isolated phenyl substituent does not contribute significantly to the UV 
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spectrum; the expected absorption band at 260 nm is covered by the more intensive 
absorption of the polyenes.  
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Figure 33. UV spectrum of 83 in hex/iPrOH/TFA (96:4:0.1). 
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Figure 34. UV spectrum of 83 in hex/iPrOH (90:10). 
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Figure 35. UV spectrum of HPLC fractions of 78 (in MeOH/H2O 90:10). 
The absorption spectrum of the phenyl substituted derivative 78 is similar to the methyl 
derivative 74, because no additional conjugation due to the phenyl group is possible in 
the molecule. The maximum at 295 nm was measured in CH3OH/H2O for each fraction 
eluted from the Chiracel OD column. Because the double bond configuration was not 
clearly identified for all HPLC fractions, these are shown together in Figure 35. 
5.3 Mass Spectrometry 
Mass spectrometry was used for the characterization of the synthesized RA derivatives 
and to determine the deuterium content of labeled retinoids. It is not possible to 
distinguish between the isomers by mass spectrometry. The electron ionization method 
(EI) at high and low resolution proved the structure of all newly synthesized retinoids. 
The fragmentation pattern caused by the electron impact of the retinoids and by their 
thermal decomposition products were analyzed together.  
Most peaks in the low mass region arise from complicated multiple fragmentation 
reactions. Apart from uncharacteristic, though abundant, ions of low mass caused by the 
cleavage of the polyene chain, a number of common peaks were detected in all new 
retinoids. Some of the mass spectra are shown below. The characteristic pattern of the 
deuterated samples was compared with those of the non-deuterated ones.  
The fragmentation pattern of 4-oxo-dh-RAs and the dh-RAs are very similar especially 
in the low mass region, because of the fragmentation of the polyene chain. Some of the 
ions can be seen in almost all derivatives, e.g. m/z = 55, 69, 77, 91/95, 105, 119/123, 
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133, 145/149, 159, 173/177. In the high mass region, the differences are clearly related 
to the molecular structure.  
Some of the possible ions formed from 11 are shown in Figure 36. The isoprenoid chain 
can split alternatively at the C-C single or double bonds.  
O
H
+
-CH2 -CH2 -CH2 -CH2 -CH2
[M+-CH3-CH-CH2-COOH]
-CH2
[215] [201] [187] [173] [159] [145]
 
Figure 36. Isoprene chain splitting in 108. 
From investigations of the mass spectra of carotenoids, it was demonstrated that the 
double bond system can undergo a 8 e- or 12 e- cyclization to form toluene, xylene or 
even naphthalene derivatives.59 When this mechanism was applied to the retinoid chain, 
as exemplified in Figure 37 and Figure 40 for the model compound 108, several 
aromatic ions were identified in the mass spectra. cis-/trans-isomerizations, known to 
occur in polyenes by thermal activation, has to precede before this mechanism can 
occur. The exact configuration and conformation of the chain preceding the cyclization 
is unknown, so the arrangement of the chain drawn in Figure 37 is arbitrary. 
O
O O
OO
cyclisation 
8 e- system
91133
.
.
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Figure 37. Mechanism of an 8 e- cyclization of a model compound (108). 
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Figure 38. MS [EI] spectrum of the 4-oxo-13,14-dh-RAs (11). 
 
The ester 75 (Figure 39) shows a similar ionization pattern in the low mass region, only 
very few of the signals differ from those of the acid analog. Cleavage of the terminal 
part of the polyene chain containing the ester group caused modifications of the MS 
pattern. Splitting of a methyl group from the molecular ion (m/z = 330) gives m/z = 315, 
from which methanol can be eliminated to give m/z =283. Further cleavage of a 
molecule of water gives m/z =265.  
Cleavage of the methoxy group (m/z = 31) from the molecular ion gives the ion 299.  
Splitting at C-12/C-13 gives the ion with m/z = 229, [M+-CH3CHCH2COOCH3] which 
was also observed in the mass spectrum of the acid 11. Further fragmentation of this ion 
is shown in Figure 36.  The ion with m/z = 163 is a very intensive peak; it was attributed 
to the cyclohexene substituted molecule resulting from the rupture of the C-8/C-9 bond.  
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Figure 39. MS [EI] spectrum of the 4-oxo-13,14-dh-RA ester 75. 
The cyclohexene ring can undergo a retro-Diels-Alder reaction in the mass spectrometer 
and lose ethene (m/z = 28) as exemplified in Figure 40 for 10. The signal at m/z = 215 
can be explained by formation of the fragment [M+-CH3-CO2-C2H4]. The dienophile of 
the retro-Diels-Alder reaction can also undergo a 8 electron cyclization. The formed 
aromatic product isopropenylbenzene with m/z = 119, was identified in the mass 
spectrum. The formation of other aromatic ions in the mass spectrometer, like C6H5
+ 
(m/z = 77), C7H7
+ (m/z = 91) were also identified. The molecular ion (m/z = 302) is first 
loosing one methyl group to give the ion with m/z = 287, followed by CO2 elimination, 
or McLafferty rearrangement of the acid group with one proton from C-20 to m/z = 243.  
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Figure 40. Retro-Diels-Alder followed by 8 e- cyclization of 10 (R = COOH). 
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Figure 41. MS [EI] spectrum of 13,14-dh-RA 10. 
The loss of one methyl group [M+-15] is characteristic for all retinoids. 
The dihydro retinoids 11 and 75 were labeled with deuterium for biological studies. MS 
analysis of deuterated samples makes the tracing of further metabolization products 
easier and allows analysis in biological matrices with very small amounts of 
compounds. A higher degree of labeling should be achieved by using DCl in the workup 
instead of other H-containing acids.  
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Figure 42. MS pattern of 4-oxo-13,14-dh-RA (11) and its labeled derivative 90. 
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Figure 43. MS pattern of ester 75 and deuterated ester 89. 
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Figure 44. MS pattern of 13,14-dh-RA (10) and its labeled derivative 88. 
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The phenyl substituted retinoids are giving ions characteristic for the cleavage of the 
polyene chain, in the lower mass region and aromatically substituted ions in the higher 
region. It also seems that after initial fragmentations, the large phenyl group was 
cleaved off together with the terminal acid or ester group.  
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Figure 45. MS [EI] spectra of 79 and 78. 
Other modified retinoids, synthesized here, also showed the peak characteristic for a 
polyene as discussed before. All details are given in the experimental data.  
5.4 NMR Spectroscopy 
Nuclear magnetic resonance (NMR), particularly 1H NMR spectroscopy, plays a major 
role in identifying and elucidating molecular structures in retinoid chemistry. Besides 
MS, UV and IR spectroscopy, NMR analysis was used to confirm the structure of the 
new vitamin A metabolite and of the newly synthesized retinoids. The structure and 
spatial arrangement of the retinoid isomers was established by 1H and 2D NMR 
spectroscopy, as will be discussed below. All spectra were referenced to TMS or d4-
MeOH. The two main retinoid structures, 11 and 10, both possible intermediates in the 
metabolism of vitamin A, will be discussed in detail. All other retinoid derivatives show 
almost the same signal pattern, with very small displacement of the protons or carbon 
atoms near the newly introduced groups in comparison with the core structures.  
5.4.1 4-Oxo-13,14-dh-RA (11) 
The separated fractions of 11 were analyzed immediately after elution from the HPLC 
column and solvent evaporation. The olefinic regions of the 1H NMR spectra are shown 
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in Figures 46-49. Although basis line separation was achieved and all isomers should 
have been pure, for two of them, 11-cis- and 9,11-di-cis-11, the 1H NMR spectrum 
show small signals belonging to other isomers. Small fractions of 11-cis-11 isomerized 
into all-trans-11 and 9,11-di-cis-11 into 9-cis-11. All fractions were kept in the dark, 
under nitrogen and stored in the refrigerator (0-4 °C). 1H NMR spectra of 11-cis-11 and 
9,11-di-cis-11 taken after two days show that no further isomerization took place under 
these conditions. However, the clean 1H NMR spectrum of 9-cis-11 showed after 
several days partial isomerization into all-trans-11. This process also revealed itself in 
changes of the peak ratios of the HPLC chromatograms when samples were stored for 
longer time.  
Steric repulsion between the methyl group C-16/C-17 and the hydrogen atoms at C-7 
and between the methyl C-18 and the hydrogen 8-H are present in the molecule and fix 
the conformation of the C-6/C-7 bond. This has been demonstrated for several 
carotenoids incorporating a cycloxene ring.59 These steric interactions were shown to 
produce a downfield shift of the protons for which the internuclear distances are smaller 
than the sum of their van der Waals radii.59 However, the steric repulsion is partly 
relieved by a bending of the planar zigzag chain with the methyl groups pointing 
towards the convex side of the molecule. This effect will be discussed below.  
A comparison of the chemical shift data of the trans-/cis-isomers indicate that shift 
changes occur only for the protons attached or in close geometrical proximity to the 
corresponding cis bond. The terminal group on the chain does not play a significant role 
as seen by the comparison between the chemical shifts of the acid 11 and its 
corresponding methyl ester 75 (Table 6 and 7). 
Table 6. Chemical shifts for the polyene chain of 11 and 75. 
11 7-H 8-H 10-H 11-H 12-H 13-H 14-H 
all-trans 6.27 6.34 6.15 6.49 5.78 2.77-2.75 2.33 
9-cis 6.24 6.82 6.09 6.52 5.68 2.72-2.71 2.30 
11-cis 6.32 6.41 6.52 6.37 5.42 3.23-3.18 2.32 
9,11-di-cis 6.32 6.86 6.57 6.37 5.35 3.12-3.11 2.14 
75        
 all-trans 6.23 6.31 6.10 6.44 5.74 2.86-2.76 2.36-2.32 
9-cis 6.25 6.79 6.04 6.47 5.66 2.82-2.72 2.32-2.25 
11-cis 6.27 6.35 6.43 6.33 5.38 3.27-3.16 2.33-2.25 
9,11-di-cis 6.21 6.82 6.38 6.37 5.30 3.28-3.16 2.36-2.25 
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Table 7. Chemical shifts of methyl and methylene protons of 11. 
11 2-H 3-H 16-H/17-H 18-H 19-H 20-H 
all-trans 1.86 2.49 1.20 1.81 1.94 1.1 
9-cis 1.88 2.51 1.21 1.85 1.95 1.14 
11-cis 1.87 2.50 1.21 1.82 1.94 1.14 
9,11-di-cis 1.89 2.41 1.21 1.84 2.01 1.03 
 
The different isomers were distinguished from each other by the shift changes of the 
protons close or part of the cis double bonds. For instance, a significant shift of the 
proton 8-H is only observed in the isomers where 9-H/10-H are in cis-configuration, as 
for 9-cis-11 and 9,11-di-cis-11, respectively. The shift difference to all-trans-11 is 
+0.48 ppm for the 9-cis-isomer and +0.52 ppm for the 9,11-di-cis-isomer. The signal of 
10-H is shifted considerably downfield only in the isomers for which the protons 11-
H/12-H are cis-configurated. For the 11-cis-isomer this shift is +0.37 ppm and for the 
9,11-di-cis-isomer +0.42 ppm compared to the all-trans-isomer. Although the 
configuration at C-5 is identical in all isomers, the methyl groups at this position show a 
small downfield shift of +0.04 ppm and +0.03 ppm in the 9-cis- and 9,11-di-cis-isomers, 
because of the steric interactions with the proton 11-H. Another indicator for steric 
hindrance due to a cis double bond in its proximity is the proton 13-H. As seen in 
Figure 50, this proton is oriented to the center of the cavity formed by the polyene 
chain. This configuration is geometrically favored to avoid higher interactions when the 
methyl group will be oriented to the cavity center. This is the reason for the downfield 
shift of 13-H by +0.46 ppm in the 11-cis- and 9,11-di-cis-isomers. These characteristic 
shifts agree with the geometrical configuration determined by the 2D NMR spectra, 
mostly the NOESY spectra (see below).  
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Figure 46. 1H NMR spectrum of all-trans-11. 
 
Figure 47. 1H NMR spectrum of 9-cis-11.  
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Figure 48. 1H NMR spectrum of 11-cis-11. 
 
Figure 49. 1H NMR spectrum of 9,11-di-cis-11. 
The structures of the different isomers can also be assigned from the coupling constant 
of the proton signals.  
The coupling constant between 7-H/8-H shows a characteristic trans-coupling of 16.2 
Hz for all isomers, whereas for all other protons this constant depends on the 
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geometrical orientation of the rest of the conjugated double bonds. With values between 
10.9 and 11.4 Hz the coupling between 10-H and 11-H is very similar for all isomers, 
because 10-H is always trans to 11-H to avoid steric hindrances with the neighboring 
protons. Furthermore, the isomer differentiation at C-11/C-12 can be derived from 
11-H/12-H and 12-H/13-H as shown in Table 8. A characteristic cis coupling of 11 Hz 
between 11-H/12-H is seen in 11-cis-11 and 9,11-di-cis-11, while a bigger coupling 
constant of ca. 15 Hz is seen when this bond is in trans-configuration. The proton 12-H 
gives a double doublet for the all-trans- and 9-cis-isomers, with a small downfield shift 
(∆δ = +0.1 ppm) for the proton in all-trans-11 compared to 9-cis-11, whereas the 11-
cis- and 9,11-di-cis-isomers give a triplet, with 12-H in 11-cis-11 downfield shifted by 
∆δ = +0.17 ppm compared to the 9,11-di-cis-isomer.  
Table 8 Coupling constants (in Hz) for the olefinic protons in 11. 
11 all-trans 9-cis 11-cis 9,11-di-cis 
7-H, 8-H 16.2 16.2 16.2 16.2 
10-H, 11-H 11.0 11.2 11.4 10.9 
11-H, 12-H 15.0 14.9 11.5 11.5 
12-H, 13-H 7.7 7.6 10.5 10.1 
 
The final evidence for the configuration of the isomers was obtained from the H,H-
NOESY experiments. A summary of these spectra is shown in Figure 50.  
NOESY signal between the protons 10-H/12-H, 11-H/19-H and 11-H/20-H indicate a 
linear configuration, which was assigned to the all-trans-isomer. When 19-H is showing 
a cross peak with the neighbor proton 10-H, the substituents on C-9/C-10 must be in cis 
configuration, while a cross peak between 19-H and 11-H indicates a trans-
configuration of this double bond. On the other hand, NOESY signal between 8-H and 
10-H is the sign for the trans-configuration of the substituents at C-9/C-10, while a 
cross peak between 8-H and 11-H is showing the cis configuration of this double bond. 
With this information, the configuration of the C-9/C-10 double bond can easily be 
assigned. When 10-H and 12-H are giving a cross peak in the NOESY spectrum, they 
are on the same side of the chain and the two conjugated double bonds at which 10-H 
and 12-H are attached have the same geometry. A cross peak between 11-H and 12-H is 
possible when these two protons are in cis orientation, while 10-H and 12-H give a 
NOESY signal, when 11-H and 12-H are in trans-orientation.  
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Figure 50. NOESY determined coupling mechanisms in 11. 
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Taking all these observations into consideration, the configuration of the isomers can be 
assigned. In all isomers NOESY signals were observed between 7-H/17-H, 7-H/19-H 
and 8-H/18-H because of the trans-configuration at C-7/C-8 double bond. Additional 
cross peaks between 12-H/14-H and 12-H/20-H are noted in all spectra. This means that 
in all isomers, the most stable configuration in solution is that one for which the methyl 
group C-20 is pointing away from the cavity formed by the polyene chain, while the 
proton at C-13 is oriented towards the center of this cavity, to overcome steric 
interactions with the other alkene protons. The all-trans-configuration was assigned for 
the spectra where the following additional cross peaks were present: 8-H/10-H, 
10-H/12-H, 11-H/19-H and 11-H/13-H. The 9-cis-isomer shows cross signals for 
10-H/19-H and 8-H/11-H indicating the cis configuration at C-9/C-10 double bond 
whereas cross peaks between 11-H/13-H and 10-H/12-H indicate a C-11/C-12 trans 
double bond. Cross peaks between 8-H/10-H and 11-H/19-H show a trans C-9/C-10 
double bond, while coupling between 10-H/13-H and 11-H/12-H is a sign of a cis 
configuration of the C-11/C-12 double bond, all together proving the 11-cis-isomer. The 
9,11-di-cis-isomer gave cross peaks in the NOESY spectrum between 8-H/11-H and 
10-H/19-H for the cis C-9/C-10 double bond and 10-H/13-H, 11-H/12-H for the cis 
C-11/C-12 double bond.  
5.4.2 13,14-Dihydro-RA (10) 
The 13,14-dh-RA (10) and its ester 74 were analyzed by NMR spectroscopy as 
described for the 4-oxo derivative 11. The conjugated double bond system contains one 
double bond less than 11, the 4-oxo keto group. The absence of this function is 
responsible for the upfield shift of all signals in 10, as seen in Table 9. 
Table 9. Chemical shifts of the polyene chain protons of 10 and 74. 
10 7-H 8-H 10-H 11-H 12-H 13-H 14-H 
all-trans 6.05 6.02 5.96 6.45 5.64 2.79-2.66 2.25-2.37 
9-cis 6.20 6.60 5.89 6.51 5.58 2.76-2.65 3.31-2.24 
11-cis 6.15 6.13 6.31 6.32 5.29 3.26-3.10 2.33-2.20 
9,11-di-cis 6.14 6.58 6.25 6.38 5.22 3.29-3.12 2.31-2.24 
74        
all-trans 6.09 6.04 5.98 6.42 5.62 2.80-2.75 2.41-2.36 
9-cis 6.13 6.57 5.88 6.50 5.55 2.80-2.72 2.40-2.26 
11-cis 6.14 6.14 6.30 6.31 5.26 3.24-3.16 2.36-2.28 
9,11-di-cis 6.17 6.60 6.21 6.41 5.19 3.25-3.17 2.40-2.26 
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Table 10. Chemical shifts of the different methyl and methylene protons of 10. 
10 2-H 3-H 4-H 16-H/17-H 18-H 19-H 20-H 
all-trans 1.53-1.40 1.72-1.55 2.01 1.01 1.67 1.87 1.10 
9-cis 1.51-1.47 1.68-1.61 2.04 1.03 1.72 1.95 1.07 
11-cis 1.53-1.40 1.72-1.55 2.01 1.01 1.69 1.88 1.05 
9,11-di-cis 1.51-1.47 1.68-1.61 2.04 1.02 1.70 1.89 1.05 
 
The methylene and methyl chemical shift differences between the isomers of 10 are 
minimal. The protons 4-H are shifted downfield by ∆δ = +0.03 ppm in 9-cis- and 9,11-
di-cis-10 compared to the all-trans-isomer, because of steric repulsion. For the same 
reason, 18-H is shifted downfield by ∆δ = +0.05 ppm in the 9-cis-, by ∆δ = +0.03 ppm 
in the 9,11-di-cis- and only by ∆δ = +0.02 ppm in the 11-cis-isomer. The proton 19-H in 
9-cis-10 is shifted downfield by ∆δ = +0.08 ppm compared to the same proton in the all-
trans-isomer, while for the 11-cis- and 9,11-di-cis-isomers just minimal shifts of +0.01 
ppm and +0.02 ppm are registered. 
The proton attachment to the double bonds resulted in the same multiplicity pattern as 
in 11, however shifted to higher fields. In comparison with the all-trans-isomer, 8-H of 
9-cis- and 9,11-di-cis-10 was strongly shifted downfield, while 10-H was shifted 
downfield in the 11-cis- and 9,11-di-cis-isomers. The same characteristic signal pattern 
as described for 11, was seen for 12-H of 10 (double doublet with coupling constants of 
7.6 Hz and 15 Hz for the all-trans- and 9-cis-isomers, and a triplet with a 10.5 Hz 
coupling constant for the 11-cis- and 9,11-di-cis-isomers).  
Although not all new retinoid derivatives prepared in this thesis were preparatively 
separated on HPLC (HPLC separation was undertaken in analytical amounts for 
biological assays), their configuration was assigned from the 1H and 2D spectra of the 
isomeric mixture. When Wittig reaction was performed with the separated isomers of 
aldehyde precursor 47, the product 10 contained only two diastereomers, all-trans-/11-
cis-10 or 9-cis-/9,11-di-cis-10, for which the chemical shift was easily assigned.  
As described in detail for 11, the configuration of the isomers of all other retinoids 
synthesized here, was assigned by chemical shifts, vicinal coupling constants and the 
NOESY experiments.  
 
In conclusion, NMR spectroscopy is the best method for configuration assignment of 
new retinoids.  
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6 Circular Dichroism  
6.1 Introduction 
When linearly polarized light interacts with a molecule, this experiences an oscillating 
electric and magnetic field.60 The positive nucleus and the negative electrons start to 
oscillate, but when the light wavelength 
λ
 is smaller than 1000 nm, the frequencies 
become to large and the heavy nucleus cannot oscillate significantly. The electron cloud 
is polarized along the direction of the oscillating electric field vector E
r
. As any 
oscillating charge, part of the energy used for polarization of the electron cloud is 
emitted again. If the light energy is large enough, no energy is emitted again, and the 
molecule will be promoted to a higher excited state. The absorbed energy hν  equals the 
energy difference between the ground S0 and the excited state Si (
ν  = Ei - E0)/h ). This 
equation gives the position of an absorption line in the spectrum. A chiral compound is 
rotating the plane of linearly polarized light, or the oscillating direction of the electric 
field vector E
r
.60  
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Figure 51. A) Plane polarized light resolved into two circularly polarized components R and L, with the 
same intensity and phase, the resultant will lie in the plane. B) Right circularly polarized light is less 
intense (more absorbed) than left circularly polarized light, the resultant electric vector follows an ellipse, 
and the corresponding light is elliptically polarized.60 
When light passes through an absorbing optically active substance, the left and right 
circularly polarized rays travel at different speeds (cL ≠ cR) which leads to different 
wavelength (
λ
L ≠ 
λ
R) and the rays are absorbed to a different extent, i.e. with different 
absorption coefficients (ε L ≠ ε R). The difference ∆ ε  = ε L - ε R is called circular dichroism 
(CD) and can be measured by a CD spectrometer as differential absorption of left and 
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right hand circularly polarized components of light when plane polarized light is 
transformed into elliptically polarized light.60  
The Beer-Lambert-Bouguer law can be used for the description of the circular 
dichroism as follows: 
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where A is the absorbancy, c the sample concentration, l the path length, I0 the intensity 
of the incoming light, and IL and IR the intensities of the left, respectively right 
circularly polarized light leaving the cell. If c is given in mol · L-1 and l in cm then ε  is 
called the molar absorption coefficient or molar absorptivity.60  
When the incoming light interacts with a chiral substance, the exiting light has different 
intensities IL ≠ IR. If the right hand circularly polarized component is less intense, i.e. is 
absorbed more, than the left circularly polarized component, the electric vector of the 
light follows an elliptical path, corresponding to the elliptically polarized light (Figure 
51). The shape of the ellipse is mathematically determined by the angle ψ  = arctan (b/a) 
(a is maximum diameter and b is the minimum diameter of the ellipse), which is called 
ellipticity.60 Measurements have shown that: 
ψ  = 33 ∆A 
Another method for quantitative characterization of chiroptical properties measures the 
rotation of the plane of linearly polarized light traveling through a substance. This 
method is the least reliable for structure elucidation, although it is often used as a 
criterion for enantiomeric purity. The measured rotation α depends on the sample 
concentration c (or density) and the length of the tube l. The specific rotation in solution 
can be calculated as: 
[ ]
lc ⋅
⋅
=
α
α
100
 
Biot noticed that this value depends on the temperature and very characteristically on 
the wavelength 
λ
. When proceeding from long to short wavelengths, α increases with 
A/
λ
 which he called normal optical rotatory dispersion (ORD).60 Biot noticed also that 
the value of α rises more slowly with shorter wavelengths, an effect termed anomalous 
optical rotatory dispersion.  
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The three effects described here: CD, ellipticity and anomalous ORD are called Cotton 
effect (CE). 
Using the sign of the CE, information about the conformation of a molecule can be 
derived, i.e. the sign of the torsion angle around a bond, but not about the absolute 
configuration.62 The Cotton effect is a property of the chromophoric system, which is 
determined either by its own absolute configuration or by the sum of interactions with 
many chirally arranged atoms or bonds.  
There are several theoretical rules to assign the absolute configuration of a molecule.66b 
In the case of dh-RA derivatives obtained in this synthetic work, the chromophores 
themselves are achiral. The CD spectrum can be the result of interactions of the 
chromophores, or, when the energy difference between the chromophores is too large, 
they cannot interact anymore and only of the chiral arrangement of the substituents at 
the chiral center is producing the CD spectrum. In the first case, one can use the exciton 
coupling method to assign of the absolute configuration of a molecule; in the second 
case it is hard to define an exact theoretical methodology. 
α β
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Figure 52. Exciton coupling of two chromophores.60 
When the exciton chirality method is employed, the determination of the absolute 
configuration is equivalent to the determination of the absolute sense of chirality 
between the chromophores. In this case, the geometry of the molecule (relative 
orientation of the chromophores) plays a decisive role in determining the sign of the 
CD. If the transition moments between the two chromophores are arranged in a 
clockwise fashion, defined as positive, the CD is bisignate with a first positive CE and a 
second negative CE, which means also a CD with a positive sign and positive chirality, 
and vice versa. The distance between the peak and trough of a split CD curve is defined 
as amplitude (A) and either a positive or a negative sign is assigned to it depending on 
whether the first CE is positive or negative.60  
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When the difference between the absorption maxima of the chromophores is large, the 
amplitude of the CD spectra is very small. The amplitude decreases with increasing 
energy difference between the chromophores. This was calculated and verified 
experimentally for several molecules with different chromophores.60 On the other hand, 
if the energy gap is too big, the chromophores do not interact anymore, and the exciton 
chirality method for prediction of the CD sign cannot be used.  
Although the difference between the absorption maximum of the chromophores 
attached to the chiral center of 13,14-dihydro-retinoids synthesized in this work can be 
theoretically calculated, it was still not clear if the exciton chirality method can be used, 
because the value of ∆λ value is quite large (60 nm). To have a safer and more reliable 
prediction method of the CD spectra, molecular modeling calculations were performed.  
6.2 Experimental Determination of Circular Dichroism 
The synthetic mixture of 4-oxo-13,14-dh-RA (11), was first characterized by MS, IR, 
UV and NMR spectroscopy. After chiral separation on a Chiracel OJ column (see 
Chapter 4, Figure 16) and cis-/trans-configuration assignment for each HPLC fraction 
by NMR spectroscopy (see Chapter 5), the fractions were analyzed by CD 
spectroscopy. All diastereomers of 11 show a bisignate CD spectrum. Fractions 1, 2, 3 
and 5 gave a first positive CE and the first CE for the other fractions was negative (see 
Figure 53). 
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Figure 16. Chiral separation of racemic 4-oxo-13,14-dh-RA (11) on Chiracel OJ, hex/iPrOH/TFA 
95:5:0.1. Fraction 1: R-11-cis-; fraction 2: S-9,11-di-cis-; fraction 3: S-all-trans-; fraction 4: S-9-cis-; 
fraction 5: R-9-cis-; fraction 6: S-11-cis-; fraction 7: R-all-trans-; fraction 8: R-9,11-di-cis-11. 
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Figure 53. Experimental CD spectra of different HPLC fraction of 11. Fraction 1: R-11-cis-; fraction 2: 
S-9,11-di-cis-; fraction 3: S-all-trans-; fraction 4: S-9-cis-; fraction 5: R-9-cis-; fraction 6: S-11-cis-; 
fraction 7: R-all-trans-; fraction 8: R-9,11-di-cis-11. 
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Chiral HPLC comparison with the product of the (S)-enantioselective synthesis of 11 
(Figure 17, Chapter 4.3) shows that the peaks 2, 3, 4 and 6 are the S-enantiomers. 
Combining the information of these two analyses, one can see that although fraction 1, 
2, 3, 5 gave a first positive CE, different enantiomers are assigned for each of them: 
fraction 1 and 5 are the R-enantiomers while 2, 3 are the S-enantiomers, indicating that 
the chromophore orientation in each enantiomers of 11 is different.  
Table 11. Assignment of chiral HPLC of 11. 
fraction 1 2 3 4 5 6 7 8 
enantiomer R S S S R S R R 
first CE + + + - + - - - 
 
These experimental results provide the most important information on the absolute 
configuration of the molecules investigated. To gain additional information about the 
spatial-arrangement and conformation of all diastereomers of 11, detailed 
conformational analysis were performed by computational modeling.  
6.3 Theoretical Calculations of Circular Dichroism Spectra 
The theoretical elucidation of absolute configuration by quantum chemical calculations 
consists first of a conformational analysis of the molecule under consideration. The 
second step is the calculations of the electronic circular dichroism spectra.  
The geometry of each isomer of 11 was first optimized to the lowest energy 
conformation by DFT calculations using Becke’s three parameter hybrid Hartree-Fock 
DFT method (B3) in combination with the Lee-Yang-Parr correlation functional (LYP) 
and the 6-31G(d) basis set (B3LYP/6-31G(d)).56 A pre-optimization step was performed 
using the PM3 method,56 which proves to give quite similar results as B3LYP. 
Electronic excitation energies and rotational strengths were calculated by DFT TD using 
the same method and basis set as for geometry optimization, calculations being 
performed for 20 excited states. For all these calculations the GAUSSIAN 03 program 
was used. The velocity form of RV (rotatory strength) and the wavelengths of the 
corresponding electronic transitions were used for the simulation of the CD spectra.  
The theoretical definition of rotatory strength is given by a product of the electric and 
the magnetic transition moment vectors60 
),cos( mmR µµ ⋅⋅=  
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where µ and m are the magnitudes of the electric and magnetic dipole transition 
moments, respectively, and the cosine of the angle between these vectors. The 
determination of µ and m will not be discussed here. These parameters are unsigned so 
the CD sign is given by the cosine of the angle between them. If the angle is pointed (or 
even 0 for parallel vectors) then the cosine and the CD is positive. For an obtuse angle 
(maximum antiparallel vectors) the CD is negative because RV is negative. 
The experimental rotational strength is the 
λ
 -weighted, integrated CD multiplied by a 
factor f.61 
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For the optimized configurations of S-11, rotational strengths were calculated using the 
methods and the program mentioned; the results are summarized in Table 12.  
Table 12. Calculated absorption maxima (λ), oscillator strengths (f), and rotational strengths (Rv velocity 
in cgs (10-40 erg-esu-cm/Gauss)) by the B3LYP method, basis set 6-31G(d). 
 f Rv  f Rv 
S-4-oxo-all-trans-13,14-dh-RA (11) S-4-oxo-11-cis-13,14-dh-RA (11) 
393 0.0001 0.1258 393 0.0001 2.1163 
362 1.3799 59.8105 361 1.2637 96.8946 
294 0.0967 7.9377 294 0.0920 13.5793 
254 0.0110 -34.5073 255 0.0113 -38.9707 
246 0.1264 -7.315 246 0.0867 -58.3732 
243 0.0119 -0.0209 245 0.0243 -17.5179 
237 0.0018 -5.5108 239 0.0036 2.7951 
231 0.0018 -0.1832 232 0.0039 -0.5907 
226 0.0034 4.9066 227 0.0043 1.7843 
212 0.0009 2.6285 212 0.0132 17.2557 
212 0.0018 4.579 212 0.0034 2.1139 
211 0.1661 -14.2487 211 0.1510 -7.1954 
203 0.0010 -5.2925 204 0.0045 -12.1002 
201 0.0000 0.0396 203 0.0002 -2.5772 
S-4-oxo-9-cis-13,14-dh-RA (11) S-4-oxo-9,11-di-cis-13,14-dh-RA (11) 
393 0.0001 -1.255 392 0.0002 3.2031 
364 1.0701 -86.0883 368 1.0714 39.7879 
294 0.1547 -18.5397 296 0.1696 10.9178 
252 0.0179 55.0903 253 0.0077 -3.3452 
248 0.0993 59.6329 252 0.0149 -48.6742 
243 0.0023 1.227 249 0.0502 -12.6714 
237 0.0022 1.1779 243 0.0005 -0.5348 
233 0.0073 -4.0644 236 0.0098 2.7419 
228 0.0031 -2.0693 229 0.0038 0.54 
214 0.1530 -23.0284 216 0.1388 7.0725 
212 0.0016 4.7428 213 0.0018 -14.8302 
212 0.0403 23.2884 212 0.0262 -6.1459 
205 0.0537 11.5501 208 0.0022 -7.5779 
201 0.0000 -0.1763 206 0.0265 -4.1724 
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The wavelength shift in the simulated CD spectra, compared with the measured ones, 
could be due to solvent effects, which were neglected in our calculations.  
The simulated and experimental CD spectra were compared and, surprisingly, for two 
isomers, all-trans- and 11-cis-11, the calculated CD spectra show the reverse sign.  
For a rigid molecule, the typical procedure to calculate the CD spectra consists first in 
finding the conformation with least energy. Because of the molecular flexibility and the 
probability that the molecules can adopt several geometries, several conformations were 
analyzed separately by adjusting the dihedral angles between the bonds at the chiral 
center and by inverting the cyclohexene ring.  
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Figure 54. Calculated CD spectra for all diastereomers of 11 (red line: R enantiomer, black line: S 
enantiomer). 
The initial calculations showed that the first energy minimum for all-trans-11 was just a 
local and not the global minimum. For the new conformation found for the all-trans-
isomer, the CD spectrum was again calculated and this time was in accordance with the 
experimental CD spectrum (Figure 53 and 54). This example demonstrates convincingly 
that, especially for flexible molecules, one should calculate more than one 
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conformation, to be sure that the found conformation has the lowest energy. For this 
reason for all other isomers of 11 at least two alternative conformations with different 
energies were investigated.  
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Figure 55. Envelope conformation of the cycloxene ring and different orientation of substituents at C-13 
for the calculated global minimum conformation of 11. 
The calculated structures revealed some close through-space H-H interactions. The 
calculated distance between the protons 10-H and 13-H in the 11-cis-isomer is 2.07 Å 
and in the 9,11-di-cis-isomer 2.13 Å, while in the all-trans- and 9-cis-isomers 13-H 
does not show any important H-H interactions with other protons. The carboxyl group 
points away from the ellipse formed by the alkene chain in all isomers except in the 
9,11-di-cis case where it is oriented towards the inside. This “closed” geometry can 
influence also the biological properties of this isomer because the carboxyl group can 
not interact anymore so easily with the amino acids of the receptor pocket; access to the 
pocket could be also hindered.  
The differences between the global minimum and the first found local minimum are 0.7 
kcal/mol for 9-cis-11, 0.9 kcal/mol for 11-cis-11, 1.6 kcal/mol for all-trans-11 and 5.2 
kcal/mol for 9,11-di-cis-11. Also between the isomers, the energy differences are not 
significantly larger, especially between the most stable isomers. As expected, for the all-
trans- and the 9-cis-isomer, the difference is only small (0.9 kcal/mol). This means that 
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the stability of the 9-cis-isomer is not very high and it can isomerize easily. The 11-cis-
isomer with an energy difference of 1.6 kcal/mol follows next, and with 2.6 kcal/mol 
the 9,11-di-cis-compound displays the highest energy difference compared to the all-
trans-isomer. These energies refer to the most stable conformations (compared to global 
minimum energy) found for each isomer.  
 
 
  
R-9-cis-11 S-9-cis-11 
Figure 56. Calculated conformations for the enantiomers of 9-cis-11 top: global minimum, bottom: first 
local minimum. In both molecules the chiral center at C-13 was fixed and the molecule looked at from the 
same point of view.  
Comparing all calculated conformations leads to the following generalizations: the 
cyclohexenone ring can exist in two conformations, C-2 pointing up or down. The 
conjugated chain prefers an elliptical form and the geometry at C-13 is also changing 
due to free rotation around the single bonds. As one can see in Figure 55, none of the 
four isomers is adopting the same conformation at their minimum energy level.  
As assumed, the differences of the spatial arrangement at the chiral center in each 
isomer causes the circularly polarized light to be absorbed with different intensity 
giving different Cotton effects for each isomer. In Figure 56 these observations are 
exemplified for two calculated conformations (global minimum and first local 
minimum) of 9-cis-11. The sign of the CD spectra for these two conformations is 
reversed. C-13 was fixed and the view on the molecule was kept constant for all 
conformations, so that 13-H is oriented in the direction of the view. A 90° rotation of 
the alkene chain around C-12/C-13 results in different conformations, corresponding to 
different energy levels, of the same isomer. From the theoretical formula for RV follows: 
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when the angle between the electric- and magnetic dipole moment (m and µ) is 
increasing to 90°, the cosine is changing the sign and the CE sign is also reversing. 
These observations are valid for the other isomers of 11 as well. 
The double bond chain is also playing a significant role in the sign of the CD spectra. In 
Figure 57 are shown two adopted conformations for all-trans-, 9,11-di-cis- and 9-cis-11, 
for which the calculated CD spectra have inverse sign. The CD spectra for the 
conformations with the global energy level of all four isomers of 11 are shown in Figure 
54. 
 
 
all-trans-11 
 
 
9,11-di-cis-11 
  
9-cis-11 
Figure 57. Calculated conformations for 11. Left: global minimum, right: local minimum. 
After several optimization steps on the modeled geometries of 11, different 
conformations were found with energy differences between 5.1 and 0.7 kcal/mol. All 
these conformers contribute in different proportions to the final CD spectrum. Since the 
CD spectrum of a compound depends on the molecular geometry, the experimental CD 
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spectrum should be considered as the average overall CD behavior of all relevant 
conformations. Obviously, for a flexible molecule the number of different spatial 
orientations is high. To obtain an exact theoretical spectrum, the CD average spectra of 
all conformers that are populated was calculated using the Boltzmann weighted 
average.62 Taking into account the calculated minimum energies one can calculate the 
equilibrium constant between the two conformations A and B by the standard 
expression: 
A B
K
 
STHKRTG ∆−∆=−=∆ ln  
For all-trans-11, ∆G is 1.6 kcal/mol giving a 94 % population of the conformation with 
the lowest energy, for 9,11-di-cis-11 the energy difference is even larger, 5.1 kcal/mol, 
which gives the most stable conformer in more than 99.9 %, while ∆G for the 9-cis-
isomer (0.65 kcal/mol) corresponds to 75 % population of the lowest energy level. 
Taking these distributions for the two conformers in the gas phase at 25 °C for each 
isomer into account the most populated energy levels gave the structure for which the 
CD spectra was also measured. After the optimizations steps, the calculated CD spectra 
of the conformations with the global minimum energy were in accordance with the 
experiment, except for the 11-cis-isomer. This isomer was further investigated.  
More than 10 conformations were calculated to gather more information about other 
possible energy levels, which can contribute to the final conformer distribution. From 
all calculated conformations, 5 minima (see Figure 58) were found with energy 
differences between 0.7-4.0 kcal/mol. The CD spectra of these conformers show 
different signs. 
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Conformation EG-EL 
[kcal/mol] 
A -4.05 
B -3.32 
C -2.00 
D -0.89 
E 0.00 
 
E  
Figure 58. Calculated conformations of the 5 minima found for S-11-cis-11 in order of decreasing energy 
(A, B, C, D correspond to local minima EL, E corresponds to the global minimum EG). 
In conformation A and B, although the chain keeps the same geometry and just the ring 
orientation is changed because of the free rotation around the C-6/C-7 bond, the CD 
spectra show a first positive CE in B and a first negative CE in the A conformation, 
respectively. This proves definitely that the geometry of the ring also plays a role in the 
CD and not only the geometry of the substituents directly bonded to the chiral center 
C-13. Because of the conjugation, all double bonds from the alkene chain, including the 
ring, form the chromophore, contributing to the CD. In the next conformations C, D and 
E the alkene chromophore has the same geometry, this time rotation around the single 
bond C-13/C-14 and C-14/C-15 gave rise to different conformations with different 
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energies. For these conformations the calculated CD spectra are the same, with a 
positive first CE, in agreement with the first CE seen in the measured CD spectra.  
The overall CD of 11-cis-11 is determined by the weighted contribution of each 
individual conformation at a given temperature and by the intensity of its Cotton effect. 
The intensity of the CE of each conformation has to be considered in a quantitative way 
because the difference in the CE intensities between conformations can be large and 
outweigh population factors.63 The overall CD spectrum was calculated by Boltzmann-
weighted averaging of all calculated conformations. For this the factor B, the population 
distribution, can be calculated by the Boltzmann equation: 
TNk
EEi
LeB
⋅⋅
−
−
=
min
 
where Ei is the energy of local minima for the i conformation, Emin is the global 
minimum, k the Boltzmann constant, NL the Avogadro constant, and T the temperature. 
The rotatory strength of each of the 5 confomations of 11-cis-11 was multiplied by the 
corresponding B factor and averaged to the final RV. This was considered for the 
calculation of the averaged CD spectra, which still had the opposite sign of the 
experimental one. This means that theoretically the conformation of the 11-cis-isomer 
for which the lowest energy level was calculated in the gas phase is not the same as the 
conformation of the isomer in solution, where other factors are playing an additional 
role. That this isomer has different properties than the other three can be also seen from 
the chiral HPLC separation. For all-trans, 9,11-di-cis- and 9-cis-11 the S enantiomers 
are adsorbed less on the column and eluted first, whereas for the 11-cis-isomer, a 
different geometry and other interactions could be responsible for the retention time of 
the S enantiomer being longer than for its R enantiomer, which is also the first of the 
isomers to leave the column.  
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Figure 59. CD spectra of (S)-11-cis-11 (A: Boltzmann averaged CD spectra, B: experimental spectra, C: 
calculated CD for the global minimum conformation, D: calculated CD spectrum of the conformation 
with first local minimum). 
Additional effects that can influence the sign of the CD spectrum and even invert it are 
known from the literature.60 Computer programs for the calculation of CD spectra offer 
a simple alternative for these calculations but cannot estimate all effects influencing the 
CE intensities. It is known that hydrogen bonds to the carbonyl groups stabilize a 
conformer which would otherwise be unfavored and change the CD spectra 
significantly.63 Another fact known in the literature to drastically influence the CD 
spectra and even invert their signs, is the pH.67 This additional influence was also not 
taken in account in the above calculations, although the CD spectrum were measured 
directly in the HPLC solvent which contained added TFA as buffer. It has also been 
shown that excitation of a molecule from a solvated ground state must not lead to the 
energetically most stable solvated conformation of the excited state, but to a 
conformation geometrically identical to the solvated ground state and necessarily 
having an energy higher than the equilibrium conformation of the solvated excited 
 98
state.64 A number of factors are involved in the solvation of the ground and excited 
states, some of them occur in all systems, others only in some.  
As shown for 9-cis-11, the alkene chain can adopt two geometries relative to the chiral 
center. In one of the conformations, Figure 58 (E) and Figure 60 (E), the chain is 
parallel to the hydrogen atom at C-13 and in conformation A (Figure 58 and 60) the 
chain is perpendicular to it. From the retinoid literature33 it is known that the 11-cis-
isomer belongs to the geometrically hindered isomers, because of the interactions 
between 10-H and the C-13 methyl group. This is also seen in the two conformations A 
and E (Figure 61). A more stable conformation, also the global minimum, is favored by 
rotation around C-12/C-13 so that the methyl group is pointing away from the helix 
formed by the side chain, whereas in conformation A, where the methyl group at C-13 
is pointing to the center of the helix, interaction with 10-H is possible and the energy is 
higher. However, when additional effects, like hydrogen bonding due to solvent a 
effect, favor the conformation where 10-H and the methyl group at C-13 are closer, 
conformation A will be present in solution, rather than the most stable conformation in 
the gas phase. Because all these results are derived from calculations in vacuum, it is of 
course possible that in hex./iPrOH/TFA, in which the CD spectra were measured, the 
isopropanol could form additional hydrogen bonds with the RA derivatives. 
Figure 60. Calculated conformations of 11-cis-11. CD for conformation A (local energy minimum) 
shows the same CD as the experiment, for conformation E (global minimum) the sign reverses.  
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While calculating and interpreting the obtained results, the question arose, which part of 
the molecule is really influencing and determining the CD spectrum. The circularly 
polarized light can be absorbed by two chromophores present in the molecule at the 
chiral atom C-13. When the energy gap between these chromophores is too large, they 
will not interact with each other so that the energy of the exited state of the strongest 
chromophor is determining the sign of the CD spectrum. It was mentioned above for 11-
cis-11 that the arrangement of the carboxyl chromophore has no influence on the CD 
spectrum, and just when the alkene chain is rotating around a C-C bond the CD sign 
changes. To confirm the assumption, that the chirality is determined only by the double 
bond system, the molecule without the acid group was modeled, and for the optimized 
structure the CD spectrum was calculated. Additionally, 11 was truncated at each 
double bond and the obtained structures were also geometrically optimized and their 
CD spectra were calculated. The results of all these calculations clearly show that the 
spatial arrangement of the conjugated double bond system exclusively determines the 
sign of the CE and the CD spectrum. The CD spectrum of 109 looks almost the same as 
that of all-trans-11 shown above (Figure 53). 
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Figure 61. Calculated CD spectrum and conformation of all-trans-109. 
For the theoretical prediction of the CD spectra, the program uses implemented 
empirical rules. These rules allow prediction of the CD sign of a molecule based on 
certain geometric characteristics. If other practical factors contribute to a measured CD 
spectrum, the theoretical calculations differ from the experimental ones, and the limits 
or exceptions of the implemented rules are reached.  
In conclusion, these calculations show that the geometry of the cyclohexenone ring in 
combination with the double bond chain determines the sign of the theoretical CD 
spectra, while additional experimental factors contribute to the finally measured CD.  
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6.4 Circular Dichroism of Substituted Retinoids 
6.4.1 CD Spectra of 75 
CD spectroscopy was used to characterize 75 after its separation on the Chiracel OJ 
column. The isomers were assigned to the corresponding fractions taking in 
consideration their peak ratio, known from the 1H NMR analysis, their UV spectra and 
the enantiomer pairs shown by the CD spectra. The absolute configuration was assigned 
by comparison of the CD sign between the corresponding isomers of ester 75 and its 
acid 11. It is known from the literature, that the configuration of similar molecules can 
be assigned by comparison of the CD spectra.66 Furthermore, modeling of the CD 
spectra was also carried out to confirm the assignment.  
The sign of the first CE of each isomer of 75 and the corresponding isomer of 11 were 
compared. For the 11-cis- (fraction 2 and 3) and the all-trans- (fraction 5 and 6) 
isomers, a good separation of the enantiomers was possible. The 9-cis- and 9,11-di-cis-
isomers are eluting as fraction 1 and 4 and possibly coelute with the 11-cis-isomer. For 
this reason these last isomers cannot be characterized by CD spectroscopy. The first CE 
of S-all-trans-11 is positive, meaning that all-trans-75 with a positive first CE is also S-
configurated; this was the case for fraction 5. Fraction 6 corresponds to R-all-trans-75. 
For the 11-cis-isomer, the first CE is positive in fraction 2, which is also the case in the 
first CE of R-11-cis-11. For this reason fraction 2 was assigned the R- and fraction 3 the 
S-11-cis-75 structure, respectively.  
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Figure 62. Chiral HPLC and experimental CD of the separated fractions of 75. 
Molecular modeling geometry optimization of the isomers of 75 and calculation of their 
CD spectra show that the first CE of the acid and its ester, for the same isomer, have the 
same sign, and the CD spectra all agreed. The calculated CD of R-75 gave a negative 
first CE for the all-trans-, 11-cis- and 9,11-di-cis-isomers, while the 9-cis-isomer shows 
a positive first CE, in accordance with the first CE seen for 11. 
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6.4.2 CD Spectra of Phenyl-substituted Retinoids  
Chirality assignment of the HPLC separated fractions of the phenyl substituted retinoids 
was performed by comparison of their experimental and calculated CD spectra. Each 
isomer was first geometry optimized by molecular modeling and the CD spectra were 
then calculated for the most stable conformation. The CD spectra of 11 were also 
considered during this assignment, because of the structural similarities between these 
molecules. The experimental spectra of 79 are shown in Figure 63.  
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Figure 63. Experimental CD spectra of 79 red curve is assigned for R enantiomer, black for the S 
enantiomer. 
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A positive first CE was observed for the R enantiomer of the all-trans-, 11-cis- and 
9,11-di-cis-isomers, as assigned by comparison with the computed CD spectra. The 
experimentally determined enantiomer of 9-cis-79 gave a negative first CE, which by 
comparison with the calculated spectra is assigned to the S configuration. The CD sign 
of the same isomers was in accordance with the CD of 11. This indicates that the phenyl 
group at C-13 does not influence the sign of the CD, in comparison with the methyl 
substituted derivative. This was also seen for the modeled conformation for which the 
spatial arrangement was almost identical. 
Enantiomer assignment of 78 was also derived form the experimental and calculated 
CD spectra, respectively. 
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Figure 64. Calculated CD spectra of 78 (red curve: R enantiomer, black curve: S enantiomer). 
The calculated spectra show for the R enantiomer of all-trans-, 11-cis- and 9-cis-78 a 
negative first CE, while the 9,11-di-cis-isomer displays a positive first CE for the R 
enantiomer. This molecule shows a modified absorption spectrum, compared to all other 
dihydro retinoids, the intensity of the absorption maximum proved to be characteristic 
for each isomer. Three absorption maxima can be seen in all spectra. This can be 
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explained by the additional absorption of the phenyl group around 260 nm, which is not 
hidden anymore under another maximum as seen in the CD spectra of 79. In two of the 
isomers, 11-cis- and all-trans-79, the middle absorption maximum is present as a 
shoulder of the second CE, while in the other two isomers three alternating maxima can 
be detected. The 11-cis-isomer shows a very strong first CE, while the second CE is less 
intensive. The all-trans- and 9-cis-isomers absorb almost with the same intensity, a 
small increase can be observed for their first CE. For the 9,11-di-cis-isomer three well 
separated maxima were noted, the absorbed light intensity increasing from the first to 
the last CE.  
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Figure 65. Experimental CD spectra of 78. 
Taking into account the differences discussed above for each isomer, and keeping in 
mind the isomer ratio determined by NMR spectroscopy, the absolute configuration for 
the separated diastereomers of 78 was assigned as follows. The first fraction (HPLC 
chromatogram in Figure 65) was assigned to the S-9,11-di-cis-isomer and fraction 3, 
with a positive first CE, to the R-9,11-di-cis-isomer. Fraction 2 is postulated to be the S-
all-trans-diastereomer, while fraction 4, with a negative first CE, was assigned to the R 
enantiomer of the same isomer, in agreement with the calculated spectra. Comparing the 
calculated and measured CD spectra of all diastereomers, it is evident that in solution 
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the configuration of the molecule differs slightly from the calculated spatial 
arrangement.  
All enantiomers of 78 cannot be unambiguously assigned, because the diastereomers 
were not completely resolved on the chiral HPLC column and joint elution of several 
diastereomers is possible. This means that the measured CD spectra are produced by 
more than one diastereomer, the one in higher concentration determining the sign of the 
observed CD.  
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7 Receptor-Ligand Interactions of Vitamin A Metabolites 
7.1 Possible Metabolization Pathway of ROH to the New Vitamin A Metabolite 
OH
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Scheme 26. Possible metabolization pathways of retinol (ROH, 1) to 9-cis-4-oxo-dh-RA (9-cis-11). 
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A short overview of retinol metabolism was already mentioned in the introduction of 
this thesis. The possible pathway to the newly discovered retinoic acid metabolite S-9-
cis-11 can be derived from the metabolism known so far. When this project began no 
enzyme was known to reduce the chain double bonds. In the meantime Palczewski19 
described the Retinol Saturase enzyme (RetSat), which performs reduction of the C-
13/C-14 double bond in all-trans-ROH (1), but not in all-trans-RA (3). It is possible 
that this enzyme is participating in the metabolization pathway of the new RA 
metabolite (9-cis-11) characterized here. Still, doubts remain because of the results 
published by Shirley,16 showing that in vivo 9-cis-RA (9-cis-3) is metabolized into 9-
cis-13,14-dh-RA (9-cis-11). Furthermore, oxidation of 1 to 3 could occur by 
mechanisms already known,64 but oxidation at C-4 is not completely understood. 
Cytochrome P450 is active in metabolizing all-trans-3, whereas for 9-cis-3 there is no 
further information about possible metabolization ways.64 It could be that the oxidation 
at C-4 occurs first and is followed by isomerization to the final 9-cis-4-oxo-11 
metabolite. About the isomerization from the all-trans- to the 9-cis-isomers, presently 
only limited information is available. A nonenzymatic process was described for the 
formation of 9-cis-3 from all-trans-3 by low molecular weight compounds (L-cysteine 
methyl ester, glutathione) or proteins (apoferritin) containing free sulfhydryl groups.64 
On the other hand, 9-cis-1 was shown to be present in rat kidneys and can undergo 
oxidation to 9-cis-3 by an enzymatic process.64 It is possible that 9-cis-3 is formed from 
all-trans-3 but also that another pathway, independent of all-trans-3 formation, exists at 
least within some cells and tissues. Further biological studies are necessary for a 
complete understanding of these pathways and on the new vitamin A metabolite 
characterized here. 
7.2 Ligand-Protein Interactions in Retinoid Receptors 
Many important effects of retinoids are mediated by two families of nuclear receptors: 
retinoic acid receptor (RAR) and retinoid X receptor (RXR), each consisting of three 
types (α, β and γ). Several natural retinoids are known to act as retinoid receptor 
ligands. They can be classified as ligands that activate only RARs: all-trans-RA (all-
trans-3), all-trans-3,4-didehydro-RA, all-trans-4-oxo-RA (all-trans-42), all-trans-4-
oxo-RAL, all-trans-4-oxo-ROH. And ligands that activate both RARs and RXRs such 
as 9-cis-3 and 9-cis-42.64 From their binding affinities it is obvious that these two 
classes of receptors are quite distinct from each other. While all nuclear receptors 
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contain the typical domains including a DNA and a ligand-binding domain (LBD), they 
appear to have low amino acid homologies in their LBD.64  
The binding mechanism of retinoids to the LBD of the nuclear receptors RAR and RXR 
has been studied by Moras et al using molecular dynamic simulations.65 
Several LBD crystal structures of different nuclear receptors, including also RAR and 
RXR, have been solved.65a All structures confirm the existence of a helical sandwich 
fold for LBDs and that the ligands induce major structural changes upon binding. The 
existence of a conformational change between an open apo form and a compact closed 
holo form has been shown by comparison of the X-ray structures of apo-RXRα and 
holo-RXRα bound to 9-cis-3.65a Since the effects of active retinoids are transduced by 
their nuclear receptors for which they bind, computational calculations can offer 
information about the nature of ligand-receptor binding of new retinoids.  
A corresponding study was performed here to illustrate and to analyze the difference in 
binding affinity, previous to cell culture binding assays of retinoid nuclear receptors 
with the retinoids synthesized in this work.  
 
 
R-9-cis-11 binding RAR R-9-cis-11 binding RXR 
  
S-9-cis-11 binding RAR S-9-cis-11 binding RXR 
Figure 66. Calculated geometry of 9-cis-11 docked in RAR and RXR. 
In cooperation with Dr. Jean-Marie Wurtz from the Institute of Genetic and Molecular 
and Cellular Biology, Strassbourg, France, exploratory studies on ligand-protein 
interactions were undertaken, using the crystal structure of the nuclear receptors. The 
optimized structure of 9-cis-11 (the optimization being performed with the 
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Quanta/Charmm Molecular Simulation Inc software) was docked into the receptor 
pocket, by modifying the skeleton in order to minimize interactions and the conformer 
energy. The geometry of the enantiomers of 9-cis-11 after docking in the RAR and 
RXR receptors is shown in Figure 66. It seems that the 4-oxo-moiety hampers the 
binding more in RAR than in RXR receptors. While a more compact geometry is 
adopted in the RAR receptor, the LBD of RXR receptor seems to allow a more open 
geometry. From the molecular modeling calculations, no significant differences 
between the enantiomers can be derived, both fitting in the LBD of the retinoid 
receptors. Selectivity for one of the enantiomers has to be proven by receptor bindings 
assays in cell cultures.  
 
Figure 67. The new RA metabolite 9-cis-11 as a ligand in RXR.  
A schematic drawing of the interactions between 9-cis-11 and the amino acids in RXR 
is shown in Figure 68.  
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Figure 68. Ligand-receptor interactions in RXR. (A, B, C: different views of 9-cis-11 in the retinoid 
ligand pocket) 
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The carboxylate group is sandwiched between the phenyl ring of Phe313 on one side, 
and the Ala271, Ala272 on the other. Phe313 shows interactions with the isoprenic 
C-11/C-13, with the methyl group C-20 and the carboxyl function. Amino acids Ala271 
and Ala272 are near the retinoid chain C-12/C-15. Possible interactions can be seen 
between the methyl group C-20 and the carboxylic group from Ala271. The carboxyl 
group of the RA metabolite forms two hydrogen bonds, one with the terminal amino 
group of Arg316 and the second with one of the amino groups of the Ala327- Leu 326 
chain. On the other side of the LBD pocket, more free space can be seen around the 
β-ionone ring. Again, amino acid interactions are observed from two sides. Ile268 and 
Cys269 are close to the cyclohexenone ring, the terminal thio group of Cys269 from one 
side and Cys432 from the other, point to the C-16 and C-17 methyl groups. In the 
vicinity of the β-ionone ring are the amino acids Ile345, Gly429,Cys432, His 435 and 
Leu 436, Val349. The thio group of Cys432 is pointing towards C-6 of the β-ionone 
ring and the imidazol ring of His435 is covering the β-ionone ring. The carbonyl group 
of Ile345 and the amino function of Val349 are pointing towards the 4-oxo function 
from the front side while the ethyl rest from Ile268 can interact with the keto function 
from the back side.  
The accessible volume of the cavity in the RXRa LBD is 489 Å3, and it has been shown 
that the 9-cis-RA occupies only 59 % of this cavity with its 291 Å3 volume.65b The free 
space in the ligand pocket could accommodate larger side groups of synthetic analogues 
of 9-cis-RA, offering interesting possibilities for the design of new specific ligands. 
This is one of the reasons why RA derivatives incorporating larger substituents at C-13 
were synthesized in this study. To get a first impression whether these modified RAs 
could fit into the receptor pocket their volumes were calculated and compared with the 
available space in the ligand pocket.  
Table 13 shows the calculated volume for all RA isomers synthesized in this 
investigation. Calculations were performed using the GAUSSIAN03 program and the 
B3LYP/6-31G(d) method,56 as described in Chapter 6, after geometry optimization of 
the isomers. 
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Table 13. Calculated molecular volumes of selected retinoids. 
4-oxo-RA (42) Å3  RA (3) Å3 
all-trans- 459  all-trans- 385 
9-cis- 422  9-cis- 436 
4-oxo-dh-RA (11) Å3  dh-RA (10) Å3 
all-trans- 442  all-trans- 426 
11-cis- 409  11-cis- 353 
9-cis- 489  9-cis- 451 
9,11-di-cis- 466  9,11-di-cis- 463 
4-oxo-dh-13-ph-RA (83) Å3  dh-13-ph-RA (82) Å3 
all-trans- 423  all-trans- 509 
11-cis- 519  11-cis- 420 
9-cis- 515  9-cis- 456 
9,11-di-cis- 592  9,11-di-cis- 514 
4-oxo-dh-13-iPr-RA (81) Å3  dh-13-iPr-RA (80) Å3 
all-trans- 492  all-trans- 470 
11-cis- 467  11-cis- 466 
9-cis- 410  9-cis- 474 
9,11-di-cis- 480  9,11-di-cis- 412 
 
The calculated volume is the result of surface density approximations and for this 
reason is different from the volume measured by X-ray diffraction, as can be seen for 9-
cis-RA. To have a reference for all derivatives, the volume for 9-cis-RA, which is 
known to fit into the RAR and RXR, was also calculated and compared with all others. 
From these calculations it is not possible to make a general affirmation on the volume 
order in the isomer series. Depending on the substituents at C-13 and on the 4-oxo 
function the isomer volume changed, so that no correlation can be made between the 
isomers, the substituent and the 4-oxo derivatives. For 11 and 80, the 9-cis-isomer has 
the biggest volume, for 10, 83 and 82 the 9,11-di-cis-isomer is the largest isomer, while 
for 81 the all-trans-isomer occupies most space. All other isomers have volumes 
between 592 Å3 (9,11-di-cis-83) and 353 Å3 (11-cis-10). 
The known retinoids all-trans-RA and 9-cis-RA were also calculated. It is an important 
aspect of these calculations that the volume is not correlated with receptor-ligand 
binding. Although the 9-cis-isomer proved to have a bigger calculated volume than all-
trans-RA, the former is not binding the RXR. It has been noticed that 9-cis-RA adopts 
different conformations in RAR and RXR; in the last receptor the isomer exhibits a 
pronounced bent compared with the open conformation in RAR.65c The receptor pocket 
of RXR selects 9-cis-RA but excludes all-trans-RA due to its flexibility limit.65c The 
calculated volumes in the gas phase do not apply in the receptor pocket anymore. 
Before docking in the LBD the retinoid skeleton can adopt different geometries and 
 113 
adjust to the amino acid pocket. Which interaction favors or disfavors the binding 
ability and the adopted geometry requires a deeper conformational analysis subsequent 
to the X-ray analysis of the ligands in the receptor's cavity. The most reliable 
information on the binding abilities of the new retinoids is still experimental data. Cell 
culture experiments with the new RA derivatives and the retinoid receptors are hence 
under investigation.  
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8 Molecular Modeling - Proton Affinity Calculations 
In this research project several phosphonates and phosphonium salts were synthesized 
for the Horner-Wadsworth-Emmons and Wittig reaction, respectively. During these 
experiments the phosphonium salts proved to be more suitable for deprotonation than 
the phosphonates, comparing the reactive positions present in the molecule. To gain 
more information about the deprotonation differences between phosphonates and 
phosphonium salts, DFT calculations of these molecules were performed. All 
computations were carried out with the GAUSSIAN 03 program, all structures were 
studied using the 6-31G(d) basis set and the B3LYP level of theory.56 Geometry 
optimizations were performed without restrictions.  
For each optimized structure, the proton affinity was then calculated on the basis of the 
energy difference between the protonated and unprotonated species, means, the 
thermodynamic acidity was measured. Under equilibrium conditions, the 
thermodynamically most stable product will be the predominant or even exclusive 
product.40b Calculations on the kinetic acidity (which reaction path has the lower 
activation barrier and which product is formed faster) were not undertaken here.  
 
R H+ R-+
 
E[R] = E [H+] + E [R-] or  (1) 
E[H+] = E [R]- E[R-]   
 
The gas-phase proton affinity for each molecule is shown in Table 14. The energy 
needed for a proton to be extracted from the molecule corresponds to the affinity of this 
proton to the molecule and is calculated as the energy difference between the neutral 
molecule and the corresponding anion. For example, deprotonation of phosphonium salt 
66 at C-1 requires 291.2 kcal/mol while deprotonation at C-3 would need 317.5 
kcal/mol to proceed. This means that, under basic conditions, deprotonation at C-1 is 
favored by 26.2 kcal/mol compared to the proton at C-3. In phosphonate 105, this 
energy difference between C-4 and C-2 is only 4.8 kcal/mol, while in the phosphonate 
27, where three positions can be deprotonated, the energy deference between C-6 and 
C-2 is 11.1 kcal/mol and 9.8 kcal/mol between C-6 and C-3, respectively.  
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Table 14. Proton affinity for acidic CH-positions of selected derivatives. 
MeO
2
C PPh
3
+
I
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1
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MeO
2
C P(OMe)
2
O
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66 27 105 
Energy [kcal/mol] 66 27 105 
E1[H
+]  -291.24 -374.82 -393.86 
E2[H
+] -317.48 -385.96 -389.03 
E3[H
+]  -384.66  
  
The energy needed for deprotonation at a specific site was calculated using formula (1) 
as follows: 
 for 66 
E1 [H
+] = E [66 (CH2)]- E [66 (CH
-)] at C-1 
E2 [H
+] = E [66 (CH2)]- E [66 (CH
-)] at C-3 
for 27 
E1 [H
+] = E [27 (CH2)]- E [27 (CH
-)] at C-6 
E2 [H
+] = E [27 (CH2)]- E [27 (CH
-)] at C-2 
E3 [H
+] = E [27 (CH2)]- E [27 (CH
-)] at C-3 
for 105 
E1 [H
+] = E [105(CH2)]- E [105(CH
-)] at C-2 
E2 [H
+] = E [105(CH2)]- E [105(CH
-)] at C-4 
The energy needed to remove a proton from a phosphonate is higher in comparison with 
that for the phosphonium salt, which implies that a stronger base has to be used in the 
Wittig-Horner reaction, which makes also more difficult to distinguish which position 
will be deprotonate.  
Table 15 Proton affinity calculations. 
Energy [kcal/mol] 66 27 105 
E1[H
+]-E2[H
+] 26.2 11.1 4.8 
E1[H
+]-E3[H
+]  9.8  
E2[H
+]-E3[H
+]  1.3  
 
These calculations show that the difference between the proton affinities for the two 
acidic methylenic groups of phosphonium salt 66 is higher than that in the phosphonates 
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implying that a competing deprotonation reaction occurs more readily in 27 and 105, 
than in 66. Additionally in the phosphonate 27 the protons at C-2 and C-3 have almost 
identical affinity. The deprotonation energy difference is only 1.3 kcal/mol. 
Thus, theoretical calculations of thermodynamic acidity prove to be very useful for the 
prediction of the relative acidity of methylenic groups in the vicinity of various 
functional groups, allowing a rational selection of the base to be employed and better 
design of the reagents used in Wittig, HWE reaction respectively.  
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9 The New Vitamin A Metabolite: Structure and 
Conformation Assignment  
The target molecule to be synthesized and characterized in this thesis was a new vitamin 
A metabolite, for which the structure of 9-cis-4-oxo-13,14-dihydro-RA (11) had been 
proposed.18 This molecule was first identified in mouse liver as a major endogenous 
vitamin A metabolite. Mice, fed with different amounts of retinyl palmitate, showed a 
dose dependent decrease in the all-trans-RA level in serum, kidney and brain, whereas 
the levels of 9-cis-4-oxo-13,14-dh-RA, ROH and retinyl esters were dose dependently 
elevated in serum, kidney and liver. This indicates that the new metabolite could play an 
important role in vitamin A metabolism and that under special conditions, like excess 
RA concentration, new metabolization pathways are possible.  
To gain sufficient material for further investigations and structure assignment of 11 the 
synthesis summarized in Scheme 27 was developed in this thesis.  
PCC
DMSO
O
O
O
O
O
Ph
3
PBr
- +
 1) KOtBu, THF
2) C2H2O4aq
 
22 23  
O
O
O
COOH
PPh
3
MeO
2
C
-+ I
1) LiHMDS, THF
2) KOH, EtOH/H2O
63
 
53  11 
Scheme 27. Synthetic approach to the new vitamin A metabolite. 
Oxidation of β-ionone (22) to 4-oxo-β-ionone (23) followed by Wittig reaction with 49 
gave the two isomers of aldehyde 53. This was used further in a second Wittig reaction 
with racemic phosphonium salt 63 to obtain rac-11. Enantioselective synthesis of S-11 
was possible with phosphonium salt S-63 (reaction details are given in Chapter 3). The 
 118
diastereomers of 11 were completely resolved on a Chiracel OJ-H column and all 
fractions were analyzed by NMR, CD, UV and IR spectroscopy and MS spectrometry.  
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Figure 69. HPLC Spheroclone ODS 3µm, 150 x 2 mm, H2O/MeOH, pH = 5.5 (curve a: synthetic 4-oxo-
9-cis-13,14-dihydro-RA with internal standard (IS RO101670), curve b: polar fraction of liver extracts 
from NMRI mice, curve c: known retinoids; fraction 1: 4-oxo-13-cis-RA , 2: 4-oxo-all-trans-RA, 3: IS 
RO101670, 4: 3,4-dehydro-RA, 5: 13-cis-RA, 6: 9-cis-RA, 7: all-trans-RA). 
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Figure 70. Chiral HPLC separation of 11 on Chiracel OJ 10 µm, 0.46 x 25 cm, hex/iPrOH/TFA 95:5: 0.1 
(curve a: isolated vitamin A metabolite, curve b: product of racemic synthesis). 
The retention time of authentic and synthetic 9-cis-11 on different HPLC columns, 
reversed and normal phase conditions, was also identical. HPLC chromatograms of 
synthetic 9-cis-11, polar fraction of a liver extract containing the new retinoid 
metabolite and a mixture of known polar retinoids are shown in Figure 69. Chiral 
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separation of the racemic product 11 and the purified isolated metabolite is shown in 
Figure 70. 
The isomers of 11 were assigned from the 2D-NMR spectra (for a detailed discussion 
see Chapter 5). 1H NMR, MS and UV spectra of the isolated new RA metabolite were 
in accordance with the spectra of synthetic 9-cis-11. The olefinic region of the 1H NMR 
spectrum of the isolated and synthetic 9-cis-11 is shown in Figure 71.  
 
 
Figure 71. Olefinic region of the 1H NMR spectra of authentic18 and synthetic vitamin A derivative 11. 
CD measurements of the isolated new vitamin A metabolite did not give relevant 
information about its absolute configuration because of limited amount of sample 
available for this experiment. The absolute configuration assigned by comparison of 
calculated and experimental CD spectra of synthetic S-9-cis-11 (Figure 72) was proven 
 120
by comparison of the retention time in HPLC separation of the synthetic S-11 and 
isolated metabolite (Figure 70). 
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Figure 72. Experimental (A) and calculated (B) CD spectrum of S-9-cis-11.  
The proposed structure 9-cis-13,14-dihydro-retinoic acid for the new vitamin A 
metabolite isolated by Nau and coworkers18 was confirmed by synthetic and analytic 
methods. Enantioselective synthesis together with molecular modeling calculations of 
the CD spectra were used to determine the absolute configuration. 
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10 Summary and Conclusion 
The aim of this work was the full characterization of a new isolated vitamin A 
metabolite 11 (13: R1 = O, R2, R3 = CH3, R
4 = COOH). This was achieved in a 
interdisciplinary project, where synthesis, chromatographic and spectroscopic analysis, 
molecular modeling and first biological investigations were performed.  
For the proposed structure of the new vitamin A metabolite, several synthetic methods 
were investigated. All isomers of rac- and S-11 were obtained for comparison with 
isolated retinoid metabolite. Wittig reaction beginning with 14 proved to give the best 
results. The isomer ratio attended by this synthesis was 1.1:1.1:1.9:1.0 for all-trans-/9-
cis-/11-cis-/9,11-di-cis-11 (HPLC of S-enantioselective synthesis).  
R
1
O
R
2
R
1
R
2
R
3
R
4
 
14 13 
Scheme 28. Synthesis of new 13,14-dihydro retinoids. 
This methodology was used further for the synthesis of other possible metabolic 
precursors of 11, e.g. acid 10 (13: R1 = H,H, R2, R3 = CH3, R
4 = COOH). Both 
derivatives 11 and 10 were labeled with deuterium at C-9 (R2). These retinoids were 
needed for biological investigations and follow up of their metabolization by LC/MS. 
Another possible metabolite 4-hydroxy-13,14-dh-RA (98, Scheme 28 13: R1 = OH, H, 
R2, R3 = CH3, R
4 = COOH) was prepared starting from 4-OAc protected ionone (14: R1 
= OAc, H, R2 = CH3). The synthesis stopped at the ester precursor 97 because of the 
instability of the corresponding allylic hydroxyl derivate 98.  
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Besides the new phosphonium salt 66, further phosphonium salts, e.g. 72 and 73 were 
synthesized here.  
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66 72 73 
These were used in Wittig reaction with aldehydes 47 and 53, respectively, for the 
synthesis of modified 13,14-dihydro retinoids like 76, 77, 78, 79.  
COOMe  COOMe
O
 
76 77 
COOH
 
O
COOH
 
82 83 
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Biological properties of the newly obtained 13,14-dihydro retinoids will be analyzed 
and compared with those of the known retinoids in the group of Prof. Nau. First 
molecular modeling calculations were performed with all isomers of 13 to gain 
information about the possible adopted geometries in the retinoid receptor pocket, the 
occupied volume and the possible interactions with the amino acids of the retinoid 
receptor.  
Because all retinoids synthesized here were obtained as isomeric mixtures, 
chromatographic separation (reversed and normal phase HPLC) was used for their 
separation. Acids 11, 82 and 83 and their corresponding esters were resolved on chiral 
HPLC. 
For characterization of the isomers or isomeric mixtures, NMR, IR, UV/Vis and CD 
spectroscopy and MS spectrometry were used. The isomers were assigned by 1D and 
2D-NMR spectroscopy.  
Assignment of the absolute configuration of each HPLC fraction of 11, 82 and 83 was 
accomplished by CD spectroscopy; the experimental CD spectra were compared with 
the calculated ones. Molecular modeling calculations of the CD spectra were helpful to 
predict the absolute configuration of 11, which enabled the design of a target 
enantioselective synthesis of the S-enantiomer. 
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11 Experimental Section 
11.1 Instrumentation and general experimental considerations 
Thin Layer Chromatography: Macherey-Nagel & Co (Düren) “Polygram Sil 
G/UV254” silica gel plates were used for analytical thin layer chromatography. 
Column chromatography was performed on Merck (Darmstadt) silica gel 60 (70-230 
mesh) or aluminum oxide activated with 8 % w/w water. 
Melting points were determined on a Meltemp II apparatus from Laboratory Devices. 
The melting points are uncorrected. 
NMR Spectroscopy: 1H NMR and 13C NMR were recorded using a Bruker AC-200 
(1H NMR 200.1 MHz, 13C NMR 50.3 MHz), Bruker DRX-400 or Varian (1H NMR 
400.1 MHz, 13C NMR 100.6 MHz) spectrometer. Chemical shifts are reported in ppm 
downfield from internal tetramethylsilane. Spin multiplicities are indicated by the 
following symbols (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet). For 
13C NMR spectroscopy, solvent signals CDCl3 (δ = 77.0 ppm), MeOH-d4 (δ = 49.3 
ppm), or acetone-d6 (δ = 29.3 ppm) were used as internal standards. 
IR spectra were recorded on a Nicolet DX320 FT-IR spectrometer as KBr pellets or on 
a Bruker Tensor 27 using the diamond ATR technique. 
UV/Vis spectra were obtained using a Hewlett-Packard 8452 A diode array, a Varian 
Cary 100 Bio or a Jasco V-570 spectrometer.  
HPLC: Chiral HPLC was performed on Chiracel OD, OJ, AS, AD and Chiralpak IA, 
IB columns (analytical columns 0.46 x 25 cm, preparative on a Chiracel OJ 4.6 x 250 
cm column) from Daicel Chemical Industries LTD, using a Jasco PU-1580 pump and 
Jasco CO-1560 Column Thermostat. Detection was performed using a Jasco MD-190 
Multiwavelenght and a Jasco CD –1595YS detector.  
HPLC was also performed on Lichrosorb RP-18 (7 µm) and Purospher RP-18 
endcapped (5 µm) 0.46 x 25 cm columns and semi-preparative (2.3 x 25 cm) on 
Nucleosil 100-7 C18 (7 µm) column using a Hitachi L-6200 Intelligent Pump and 
Hitachi L-3000 Photo Diode Array Detector or Hitachi L-4200 UV/Vis Detector. All 
solvents were HPLC grade solvent, except for the preparative separation. Retinoic acid 
metabolites and the corresponding synthetic samples were analyzed by HPLC equipped 
with two LC-10AD Pumps and a SPD-10AVVP UV/Vis Detector from Shimadzu, 
Duisburg. The analytical column was a Spherisorb ODS2, 2.1 x 150 mm, 3 µm particle 
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size, protected with a security guard from Phenomenex, C18 ODS cartridge, 4 mm x 2 
mm.  
Mass spectra were recorded on a Finnigan MAT95 mass spectrometer using electron 
ionization (EI, 70 eV), GC/MS spectra were recorded on a Jeol GCMate spectrometer.  
Elemental analyses were carried out at the Institut für Pharmazeutische Chemie and the 
Institut für Anorganische und Analytische Chemie, TU Braunschweig.  
Circular dichroism spectra were measured on a JASCO J-720L spectrometer. 
Whenever necessary, experiments with the different retinoids and their precursors were 
carried out under argon using yellow light. All other experiments were carried out under 
N2 or air.  
 
11.2 General experimental procedures 
 
General procedure 1: 
To a stirred suspension of phosphonium salt 52 (2 equiv.) in anhydrous THF was added 
KOtBu (2 equiv.) under argon. An immediate color change from white to yellow-orange 
was observed. After 30 min at room temp., a solution of the ketone in anhydrous THF 
was added dropwise and stirring was continued for 24 h. Aqueous oxalic acid solution 
(7 equiv.) was added. After 1 h, the two phases were separated and the aqueous phase 
was extracted several times with ether. The organic phase was washed with NaHCO3 
solution and dried with Na2SO4. After solvent removal, the dark red, oily product was 
purified by column chromatography.  
 
General procedure 2: 
LiHMDS was prepared from HMDS (1 equiv.) and nBuLi (1 equiv.) in anhydrous THF 
at –78 °C, under argon. After 20 min stirring, phosphonium salt (1 equiv.) was added. 
After additional 20 min at –78 °C, the cooling bath was removed and the yellow slurry 
was stirred for further 10 min. To the formed clear orange solution the aldehyde (0.8 
equiv.) in anhydrous THF was added dropwise. The reaction mixture became dark red. 
When no starting material was detected by TLC or GC analysis anymore, water was 
added and the aqueous phase extracted several times with diethyl ether. The organic 
phase was washed with brine solution, dried with Na2SO4 and the solvent removed. The 
residue was purified by column chromatography on aluminum oxide.  
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General procedure 3: 
To a solution of retinoic acid ester (1 equiv.) in ethanol was added 2.5 M KOH (10 
equiv.) solution in ethanol/water. The mixture was heated to 70 °C for 3 h. After 
cooling to room temp., the red solution was extracted twice with diethyl ether. The 
aqueous phase was acidified carefully to pH 4-5 with diluted acetic acid or 2 M HCl and 
extracted with diethyl ether. This organic phase was washed with water and brine 
solution, dried with Na2SO4, and the solvent evaporated. The retinoic acid derivatives 
were obtained as yellow oils. Further separation of the isomers was performed by 
HPLC. 
 
General procedure 4: 
The 3-substituted glutaric acid (1 equiv.) in acetic acid anhydride (4 equiv.) was heated 
to reflux for 12 h. After cooling to room temp., the reaction mixture was brought to a 
basic pH by adding 2 M aqueous NaOH solution. Extraction of the aqueous phase with 
diethyl ether, and drying the organic phase with Na2SO4, followed by solvent 
evaporation gave the 3-substituted glutaric acid anhydride.  
 
General procedure 5: 
A solution of 3-substituted glutaric acid anhydride in methanol was heated to reflux for 
3 h. The solvent was evaporated to yield the half acid ester. In most cases, this material 
was directly used without further purification. In cases where NMR analysis showed 
impurities, an additional work-up step followed. To the product was added 1 M NaOH 
solution and diethyl ether. Extraction and separation of the aqueous phase, followed by 
acidification with 2 M HCl to pH 2 and extraction with ether, drying of the organic 
phase with Na2SO4 and evaporation of the solvent gave pure half acid ester.  
 
General procedure 6: 
A mixture of the mono glutarate (1 equiv.) and dry lead tetra-acetate (1.12 equiv.) in dry 
CCl4 was heated to reflux under nitrogen. The mixture was irradiated with two 150 W 
lamps for 10 min and irradiation was continued while iodine (1.45 equiv.) was added in 
portions during 45 min. The mixture was filtered and the filtrate was washed with 
aqueous Na2S2O8 solution, aqueous Na2CO3 solution and water. The organic phase was 
dried with Na2SO4 and the solvent evaporated. The oily iodo-ester was used 
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immediately without further purification. Within time, the colorless product 
decomposes and becomes dark, for this reason, the product should be directly used in 
the next reaction. 
 
General procedure 7: 
To a solution of iodo-ester in benzene was added a solution of triphenylphosphine in 
benzene. After stirring the yellow solution overnight at room temp., the mixture was 
heated slowly to 70-80 °C for 2 d. The solvent was evaporated and diethyl ether was 
added to precipitate the phosphonium salt. Recrystallization from acetone/diethyl ether 
gave the pure white or light yellow phosphonium salt.  
11.3 Experimental procedures 
 
(R)-3-methyl monomethyl glutarate (64): 
 To dimethyl-3-methyl glutarate (21.97 g, 125.44 mmol) suspended in an aqueous 
solution of phosphate buffer (pH 8, 147 mL), was added pig liver esterase (PLE, 1342 
units, 8.6 mg, 152 units/mg) under vigorous stirring. The pH was kept constant by 
adding 1 N NaOH (5.02 g, 0.125 mmol in 125 mL water). After consumption of 1 
equivalent of base overnight, the pH was adjusted to 9 and the aqueous phase was 
extracted with ether. The water phase was acidified to pH 2 and extracted again with 
ether. This ether phase was dried and the solvent evaporated to give the half acid-ester 
64 (18.58 g, 116.85 mmol, 92 %, lit.70 yield: 86 %) as a colorless oil.  
rac-3-methyl monomethyl glutarate (64):  
General procedure 4 with glutaric acid (6.5 g, 44.5 mmol) in acetic anhydride (18.2 g, 
178.1 mmol, 16.8 mL) to yield 3-methyl glutaric anhydride (3.58 g, 28 mmol, 63 %). 
This was further reacted with methanol (10 mL) as described in general procedure 5 to 
give the half acid-ester 64 (3.9 g, 24.4 mmol, 87 %). 
MeO
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C CO
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64 
The spectroscopic data agree with those given in the literature.38,69,68 
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4-Iodo-3-methyl methyl butarate (65):  
General procedure 6 with 64 (13.96 g, 87.5 mmol), I2 (32 g, 126 mmol), Pb(OAc)4 (43.4 
g, 98 mmol) and CCl4 (500 mL) gave 65 (12.81 g, 53.2 mmol, 61 %, lit.
70 yield: 92 %). 
The enantioselective synthesis of S-65 ([α]D = -0.53 ° in CHCl3, c = 1.706 mg/mL) was 
performed using R-64 (bought from Fluka or prepared as described above) . 
MeO
2
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65 
1
H NMR (CDCl3): δ = 3.69 (s, 3H, COOCH3), 3.31-3.23 (m, 2H, 4-H), 2.45 (dd, 2J2,2 = 
15.8, 3J2,3 = 6.6 Hz, 1H, 2-H), 2.25 (dd, 
2
J2,2 = 15.8 Hz, 
3
J2,3
 = 7.2 Hz, 1 H, 2-H), 2.05-
1.98 (m, 1H, 3-H), 1.05 (d, 3J5,3 = 6.6 Hz, 3H, 5-H). 
13
C NMR (CDCl3): δ = 172.4 (s, C-1), 51.6 (q, COOCH3), 40.8 (d, C-3), 31.7 (t, C-2), 
20.6 (q, C-5), 15.8 (t, C-4). 
MS [EI, 70 eV]: m/z (%) = 242 (5) [M+], 210 (15) [M+-CH3O], 169 (10) [M
+-
CH2COOCH3], 115 (100) [M
+-I], 83 (15), 73 (70), 59 (30), 55 (45). 
IR (ATR): ν~ = 2956-2844 cm-1 (w), 1732 (s, C=O), 1467 (m), 1435 (m), 1356 (m), 
1288 (m), 1254 (m), 1196 (s, COOCH3), 1136 (s, COOCH3), 1003 (m). 
UV (CHCl3): λmax (lg ε) = 252 nm (2.74). 
 
(3-Methoxycarbonyl-2-methyl-propyl)-triphenylphosphonium iodide (66): 
General procedure 7 with 65 (11.81 g, 48.76 mmol), triphenylphosphine (12.8 g, 49 
mmol) in benzene (80 mL) gave 66 (18.1 g, 36 mmol, 74 %) as a colorless solid. (m.p. 
134 °C). When the chiral precursor S-65 was used, S-66 was enantioselectively obtained 
[α]D = +0.98 ° in CHCl3, c = 1.43 mg/mL. 
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66 
1
H NMR (CDCl3): δ = 7.95-7.65 (m, Ar-H), 4.09 (ddd, 2J1,1 = 15.8, 2J1,P = 12.5, 3J1,2 = 
8.5 Hz, 1H, 1-H), 3.85 (ddd, 2J1,1 = 15.8, 
2
J1,P = 14.3, 
3
J1,2 = 4.2 Hz, 1H, 1-H), 3.61 (s, 
3H, COOCH3), 2.78 (dd, 
2
J3,3 = 17.0, 
3
J3,2 = 6.7 Hz, 1H, 3-H), 2.56 (ddd, 
2
J3,3 = 17.0, 
3
J3,2 = 6.4, 
4
J3,P = 2.8 Hz, 1H, 3-H), 2.50-2.40 (m, 1H, 2-H), 1.03 (d, 
3
J5,2 = 6.7 Hz, 3H, 
5-H). 
13
C NMR (CDCl3): δ = 172.6 (s, C-4), 135.0, 133.7, 133.3, 130.5, 130.4 (d, Ar), 118.5 
(s, Ar), 51.6 (q, COOCH3), 41.3 (t, JC,P = 12.9 Hz, C-3), 28.2 (t, JC,P = 50 Hz, C-1), 26.0 
(d, JC,P = 3.4 Hz, C-2), 21.0 (q, JC,P = 4.8 Hz, C-5). 
MS [ESI]: m/z (%) = 377 (100) [M+-I], 277 (40). 
UV (CHCl3): λmax (lg ε) = 276 nm (3.69), 294 (3.50), 364 (3.19). 
IR (ATR): ν~ = 3078-2792 cm-1 (w), 1721 (s, C=O), 1585 (w), 1483 (w), 1434 (s, P-
phenyl), 1363 (m), 1311 (m), 1257 (m), 1216 (s), 1154 (s), 1107 (s), 1054 (m), 997 (s), 
882 (w), 814 (m), 786 (s, C6H5), 786 (s, C6H5), 714 (s, C6H5), 687 (s, C6H5). 
Elemental analysis: C24H26O2PI (504.35) calcd. C 57.19, H 5.20; found C 57.20, H 
5.15.  
 
rac-3-Phenyl monomethyl glutarate (111): 
General procedure 4 with 3-phenyl glutaric acid (10 g, 48 mmol), acetic anhydride (19.6 
g, 192 mmol, 18 mL) gave 3-phenyl glutaric anhydride which was reacted as described 
in general procedure 5 to give 111 (6.86 g, 36.1 mmol, 75 %) as a colorless solid (m.p. 
99-100 °C). 
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Spectroscopic data correspond to the literature.71 
 
4-Iodo-3-phenyl methyl butarate (112): 
General procedure 6 with 111 (7.92 g, 35.67 mmol), Pb(OAc)4 (17.72 g, 40 mmol), 
CCl4 (230 mL), I2 (13.18 g, 51.9 mmol) gave the oily iodo-ester 112 (9.43 g, 31.02 
mmol, 87 %) which was used immediately without further purification in the next 
reaction.  
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1
H NMR (CDCl3): δ = 7.31-7.17 (m, 5H, Ar), 3.56 (s, 3H, COOCH3), 3.45-3.35 (m, 
3H, 3-H, 4-H), 2.93 (dd, 2J2,2 = 16.1, 
3
J2,3 = 5.5 Hz, 1H, 2-H), 2.68 (dd, 
2
J2,2 = 16.1, 
3
J2,3 
= 7.6 Hz, 1H, 2-H). 
13
C NMR (CDCl3): δ = 171.2 (s, C-1), 141.0 (s, C-5), 128.2 (d, Ar), 126.9 (d, Ar), 
126.7 (d, Ar), 51.2 (q, OCH3), 43.4 (d, C-3), 39.7 (t, C-2), 11.8 (t, C-4). 
MS [EI, 70 eV]: m/z (%) = 273 (10) [M+-CH3O], 231 (10) [M
+-CH3COOCH2], 177 
(100) [M+-I], 145 (20), 135 (40), 117 (100), 104 (40), 91 (20), 77 (10), 59 (15), 51 (10). 
UV (CHCl3): λmax (lg ε) = 258 nm (3.00).  
IR (ATR): ν~ = 3058-2840 cm-1 (w), 1729 (s, C=O), 1496 (w), 1453 (m), 1431 (s), 1351 
(s), 1277 (s), 1227 (s), 1188 (w), 1163 (s), 1123 (s), 1044 (w), 978 (m), 956 (m), 881 
(m), 788 (w), 757 (s), 743 (s), 697 (s), 541 (s). 
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(3-Methoxycarbonyl-2-phenyl-propyl)-triphenylphosphonium iodide (73):  
General procedure 7 with 112 (9.43 g, 31 mmol) and triphenylphosphine (23.58 g, 93 
mmol) in benzene (80 mL) gave phosphonium salt 73 (13 g, 23 mmol, 74 %) as a pale 
yellow solid (m.p. 145 °C). 
MeO
2
C PPh
3
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73 
1
H NMR (CDCl3): δ = 7.77-7.55 (m, 15H, Ar-P), 7.18-7.05 (m, 5H, Ar), 4.69 (ddd, 
2
J1,1 = 16.0, 
2
J1,P = 11.9, 
3
J1,2 = 11.0 Hz, 1H, 1-H), 4.24 (ddd, 
2
J1,1 = 16.0, 
2
J1,P = 14.4, 
3
J1,2 = 2.7 Hz, 1H, 1-H), 3.59 (s, 3H, OCH3), 3.58-3.53 (m, 1H, 2-H), 3.45 (dd, 
2
J3,3 = 
17.4, 3J3,2 = 8.7 Hz, 1H, 3-H), 2.82 (dt, 
2
J3,3 = 17.4, 
3
J3,2 = 
4
J3,P = 4.7 Hz, 1H, 3-H). 
13
C NMR (CDCl3): δ =172.4 (s, C-4), 140.1 (s, JC,P = 2 Hz, C-5), 134.6 (d, JC,P = 3 Hz, 
Ar-P), 133.8 (d, JC,P = 10.2 Hz, Ar-P), 130.1 (d, JC,P = 12.7 Hz, Ar-P), 129.0 (d, Ar), 
128.1 (d, Ar), 127.7 (d, Ar), 118.3 (s, JC,P = 86 Hz, Ar-P), 51.8 (q, COOCH3), 42.5 (t, 
JC,P = 15.6 Hz, C-3), 37.4 (d, JC,P = 3 Hz, C-2), 28.8 (t, JC,P = 50 Hz, C-1). 
MS [ESI]: m/z (%) = 439 (100) [M+-I]. 
UV (CHCl3): λmax (lg ε) = 275 nm (3.70), 294 (3.55), 361 (3.26). 
IR (ATR): ν~ = 3050-2856 cm-1 (w), 1744 (s, C=O), 1586 (w), 1487 (w), 1436 (s), 1415 
(m), 1361 (m), 1311 (w), 1216 (s), 1190 (m), 1151 (s), 1022 (w), 995 (m), 962 (m), 862 
(w), 745 (s), 721 (s), 689 (s). 
Elemental analysis: C29H28O2PI (566.42) calcd. C 61.48, H 4.97; found C 61.21, H 
5.04.  
 
rac-3-Isopropyl monomethyl glutarate (113):  
General procedure 4 with 7041 (13.55 g, 77.87 mmol) in acetic anhydride (45 mL) 
yielded 3-isopropyl-glutaric acid anhydride (10.7 g, 68.52 mmol, 88 %) which was 
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reacted with methanol (145 mL) as described in general procedure 5 to yield the half 
acid-ester 113 (16.19 g, 86.12 mmol, 62 %).  
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113 
The spectroscopic data agree with the literature.28 
 
4-Iodo-3-isopropyl methyl butarate (114):  
General procedure 6 with 113 (16.19 g, 90 mmol), I2 (35.56 g, 140 mmol), Pb(OAc)4 
(44.3 g, 100 mmol) and CCl4 (360 mL) gave 65 (15.5 g, 57.6 mmol, 64 %). 
MeO
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114 
1
H NMR (400 MHz, CDCl3): δ = 3.68 (s, 3H, COOCH3), 3.35 (dd, 2J4,4 = 10.1, 3J4,3 = 
4.7 Hz, 1H, 4-H), 3.29 (dd, 2J4,4 = 10.1, 
3
J4,3 = 5.7 Hz, 1H, 4-H), 2.46 (dd, 
2
J2,3 = 16.2, 
3
J2,3 = 5.3 Hz, 1H, 2-H), 2.35 (dd, 
2
J2,2 = 16.2, 
3
J2,3 = 7.7 Hz, 1H, 2-H), 1.80-1.70 (m, 
1H, 5-H), 1.70-1.65 (m, 1H, 3-H), 0.92 (d, 3J7,5 = 
3
J6,5 = 6.6 Hz, 6H, 6-H, 7-H). 
13
C NMR (100 MHz, CDCl3): δ = 173.1 (s, C-1), 51.6 (q, COOCH3), 42.4 (d, C-3), 
36.4 (t, C-2), 30.7 (d, C-5), 19.6, 19.1 (q, C-6, C-7), 12.6 (t, C-4). 
IR (ATR): ν~ = 2960-2875 cm-1 (w), 1778 (m), 1734 (s, C=O), 1463 (m), 1435 (m), 
1370 (m), 1336 (m), 1254 (s), 1235 (s), 1195 (s, COOCH3), 1169 (s, COOCH3), 1140 
(s), 1014 (m), 890 (w). 
UV (CHCl3): λmax (lg ε) = 252 nm (2.92). 
 
133 
(3-Methoxycarbonyl-2-isopropyl-propyl)-triphenylphosphonium iodide (72):  
General procedure 7 with iodo-ester 114 (15.5 g, 57.6 mmol), triphenylphosphine 
(22.64 g, 86.4 mmol) in benzene (80 mL) gave 72 (4.93 g, 9.26 mmol, 16 %) as a 
colorless solid (m.p. 134 °C). 
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72 
1
H NMR (400 MHz, CDCl3): δ =7.96-7.45 (m, Ar-H), 3.83-3.70 (m, 1H, 1-H), 3.53 (s, 
3H, COOCH3), 2.55-2.17 (m, 3H, 2-H, 3-H), 1.65-1.55 (m, 1H, 5-H), 0.93, 0.88 (d, 
3
J6,5 
= 3J7,5 = 6.7 Hz, 6H, 6-H, 7-H). 
13
C NMR (100 MHz, CDCl3): δ =173.1 (s, COOCH3), 135.1, 133.8, 133.3, 131.3, 
130.5 (d, Ar), 118.5 (s, Ar), 51.8 (q, COOCH3), 35.5 (d, C-2), 34.9 (t, C-1, C-3), 31.7 
(d, C-5), 19.6, 18.1 (q, C-6, C-7). 
MS [ESI]: m/z (%) = 405 (100) [M+-I], 277 (20). 
UV (CHCl3): λmax (lg ε) = 240 nm (4.21). 
IR (ATR): ν~ = 3050-2871 cm-1 (w), 1726 (s, C=O), 1586 (w), 1483 (w), 1435 (s, P-
phenyl), 1337 (w), 1183 (w), 1158 (m), 1110 (s), 994 (m), 904 (w), 789 (s, C6H5), 745 
(s, C6H5), 719 (s, C6H5), 540 (s, C6H5). 
HRMS: C26H30O2P (405.50) calcd. 405.198344; found 405.19889 ± 0.84 ppm. 
 
E-(2-Hydroxy-pent-3-enyl)-phosphonic acid diisopropyl ester (26):  
To a solution of diisopropyl methyl phosphonate (16.5 g, 91.66 mmol) - prepared by 
Arbuzov reaction of triisopropyl phosphonate (16.9 g, 81 mmol) with freshly distilled 
methyl iodide (12.06 g, 85 mmol) - in 90 mL anhydrous THF was added dropwise 
nBuLi (6.35 g, 100.83 mmol, 63 mL, 1.6 M in hexane) at –78 °C under nitrogen. After 
30 min stirring, freshly distilled croton aldehyde (6.42 g, 91.66 mmol, 7.6 mL) was 
added. The mixture was stirred for 40 min and quenched by addition of aqueous NH4Cl 
solution. Extraction with diethyl ether, washing with brine solution, drying of the ether 
134 
phase with Na2SO4, and solvent evaporation gave 26 (16.89 g, 67.6 mmol, 74 %, lit.
72 
yield: 64 %). The spectroscopic data correspond to the literature.72 
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E-6-(Diisopropoxy-phosphoryl)-3-methyl-hex-4-enoic acid ethyl ester (27):  
A mixture of 26 (16.89 g, 67.6 mmol), ethyl orthoacetate (76.6 g, 472 mmol, 86 mL) 
and propionic acid (0.3 g, 4.05 mmol, 0.3 mL) was heated at 140 °C for 3 h, the formed 
ethanol being removed by destillation. Unreacted ethylorthoacetate and propionic acid 
were distilled at 145-150 °C. Purified by bulb to bulb distillation at 103 °C/0.4 torr 
yielded 27 (11.4 g, 35.6 mmol, 53 %, lit.72 yield: 76 %) as a colorless oil.  
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27 
1
H NMR (CDCl3): δ = 5.51-5.32 (m, 2H, 4-H, 5-H), 4.64-4.56 (m, 2H, CH(CH3)2), 
4.05 (q, 3J = 7.1 Hz, COOCH2CH3), 2.64-2.61 (m, 1H, 3-H), 2.42 (dd, 
2
J6,P = 21.6, 
3
J6,5 = 7.2 Hz, 2H, 6-H), 2.26 (dd, 
2
J2,2 = 14.9, 
3
J2,3 = 7.0 Hz, 1H, 2-H), 2.17 (dd, 
2
J2,2 = 
14.9, 3J2,3 = 7.0 Hz, 1H, 2-H), 1.25-1.11 (m, 15H, CH(CH3)2 COOCH2CH3), 0.98 (d, 
3
J7,3 = 6.8 Hz, 3H, 7-H). 
13
C NMR (CDCl3): δ =172.1 (s, C-1), 139.0 (d, C-4), 118.3 (d, C-5), 70.0 (d, 
CH(CH3)2), 60.0 (t, COOCH2CH3), 41.3 (t, C-2), 33.4 (d, C-3), 31.3 (t, C-6), 23.8 (q, 
CH(CH3)2), 19.7 (q, C-7), 14.1 (q, COOCH2CH3). 
MS [GC-MS]: m/z (%) = 320 (15) [M+], 305 (5), 278 (15), 263 (15), 236 (60), 190 
(100), 162 (30), 149 (25), 123 (15), 109 (35), 80 (20), 67 (15), 43 (30). 
IR (ATR): ν~ = 2978-2873 cm-1 (w), 1732 (m), 1456 (w), 1385 (m), 1373 (m), 1245 
(m), 1178 (m), 1141 (m), 1106 (m), 973 (s), 887 (m), 777 (m). 
UV (CHCl3): λmax (lg ε) = 242 nm (2.31). 
135 
E-6-(Diisopropoxy-phosphoryl)-3-methyl-hex-4-enoic-acid-3'-methyl-oxetan-3'-
ylmethyl ester (33):  
To a solution of 27 (3 g, 9.37 mmol) in ethanol (50 mL) was added a solution of KOH 
(1 g, 17.8 mmol) in water (20 mL), and the mixture was heated to reflux for 3 h. After 
extraction with diethyl ether and water, the aqueous phase was acidified to pH 2, and 
extracted with diethyl ether. This organic phase was dried with Na2SO4; solvent 
evaporation gave acid 32 (2.49 g, 8.53 mmol, 91 %) as a colorless oil.  
To 32 (1.37 g, 4.68 mmol) in dry diethyl ether (30 mL) was added 3-(hydroxymethyl)-
3-methyloxetan (0.52 g, 5.1 mmol), DMAP (0.06 g, 0.47 mmol) and 
dicyclohexylcarbodiimide (DCC, 1.51 g, 5.1 mmol). The mixture was stirred at 25 °C 
for 1 h on a water bath. Filtration and evaporation of the solvent gave a viscous oil 
which was purified by bulb to bulb distillation (60-65 °C/0.06 torr), to yield 33 (1.3 g, 
3.45 mmol, 74 %). 
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33 
1
H NMR (CDCl3): δ = 5.58-5.38 (m, 2H, 4-H, 5-H), 4.71-4.65 (m, 2H, CH(CH3)2), 
4.51 (d, 4J2',4' = 
4
J4',2' = 6.0 Hz, 2H, 2'-H, 4'-H), 4.38 (d, 
4
J2',4' = 
4
J4',2' = 6.0 Hz, 2H, 2'-H, 
4'-H), 4.16 (s, 2H, 5'-H), 2.72-2.70 (m, 1H, 3-H), 2.49 (dd, 2J6,P = 21.7, 
3
J6,5 = 7.0 Hz, 
2H, 6-H), 2.40 (dd, 2J2,2 = 14.9, 
3
J2,3 = 7.0 Hz, 1H, 2-H) 2.31 (dd, 
2
J2,2 = 14.9, 
3
J2,3 = 7.6 
Hz, 1H, 2-H), 1.33 (d, 3J = 6.7 Hz, 12H, CH(CH3)2), 1.30 (s, 3H, 6'-H), 1.07 (d, 
3
J7,3 = 
6.8 Hz, 3H, 7-H). 
13
C NMR (CDCl3): δ =172.3 (s, C-1), 139.0 (d, C-4), 118.7 (d, C-5), 79.5 (t, C-2', C-
4'), 70.1 (d, CH(CH3)2), 68.5 (t, C-5'), 41.3 (t, C-2), 39.0 (s, C-3'), 34.7 (d, C-3), 31.5 (t, 
C-6), 24.0 (q, CH(CH3)2), 21.2 (q, C-7), 19.9 (q, C-6'). 
MS [GC-MS]: m/z (%) = 376 (30) [M+], 361 (10), 334 (20), 304 (7), 275 (30), 262 
(10), 233 (10), 211 (45), 191 (75), 162 (50), 144 (100), 109 (35), 85 (23), 67 (30), 43 
(43). 
IR (ATR): ν~ = 2978-2871 cm-1 (w), 2119 (m), 1736 (m), 1700 (m), 1656 (m), 1533 
(w), 1453 (m), 1377 (m), 1239 (m), 1177 (m), 1142 (m), 1107 (m), 976 (s), 890 (m). 
136 
UV (CHCl3): λmax (lg ε) = 240 nm (2.55), 257 (2.48). 
HRMS: C18H33O6P (376.43) calcd. 376.201477; found 376.20003 ± 0.61 ppm. 
 
[4-Methyl-5-(4'-methyl-2',6',7'-trioxa-bicyclo[2.2.2]-oct-1'-yl)-pent-2-enyl]-
phosphonic acid diisopropyl ester (34):  
To a solution of oxetane ester 33 (2.2 g, 5.83 mmol) in dry dichloromethane (15 mL) 
was added BF3   Et2O (0.2 g, 1.45 mmol, 0.18 mL,) at -15 °C. After stirring for 8 h at -15 
°C, the reaction was quenched with triethylamine (0.6 g, 5.83 mmol, 0.8 mL). The 
solvent was removed under high vacuum and the crude product was purified by column 
chromatography on basic alumina with dichloromethane to give 34 (1.5 g, 4 mmol, 69 
%) as a colorless oil. The product decomposed during analysis and test reactions.  
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34 
1
H NMR (acetone-d6): δ = 5.63-5.56 (m, 1H, 3-H ), 5.35-5.26 (m, 1H, 2-H), 4.64-4.55 
(m, 2H, CH(CH3)2), 3.85 (s, 3'-H, 5'-H, 8'-H), 2.52-2.48 (m, 1H, 4-H), 2.43 (dd, 
2
J1,P = 
21.7, 3J1,2 = 7.0 Hz, 2H, 1-H), 1.68 (dd, 
2
J5,5 = 14.1, 
3
J5,4 = 5.3 Hz, 1H, 5-H), 1.51 (dd, 
2
J5,5 = 14.1, 
3
J5,4 = 8.0 Hz, 1H, 5-H), 1.27 (d, 
3
J = 4.8 Hz, 6H, CH(CH3)2), 1.26 (d, 
3
J = 
4.8 Hz, 6H, CH(CH3)2), 1.02 (d, 
3
J6,4 = 6.8 Hz, 3H, 6-H), 0.79 (s, 3H, 9'-H). 
13
C NMR (acetone-d6): δ =142.0 (d, C-3), 117.8 (d, C-2), 109.4 (s, C-1'), 72.8 (t, C-3', 
C-5', C-8'), 70.1 (d, CH(CH3)2), 44.0 (t, C-5), 32.5 (t, C-1), 31.8 (d, C-4), 30.2 (s, C-4'), 
24.3 (q, CH(CH3)2), 20.7 (q, C-6), 14.4 (q, C-9'). 
MS [GC-MS]: m/z (%) = 376 (40) [M+], 361 (10), 346 (14), 333 (25), 319 (7), 304 (8), 
293 (20), 275 (30), 262 (10), 248 (10), 233 (7), 211 (57), 191 (100), 184 (14), 173 (16), 
164 (35), 144 (70), 123 (10), 109 (40), 81 (50), 67 (30), 55 (38), 43 (50). 
IR (ATR): ν~ = 2977-2876 cm-1 (w), 1459 (w), 1398 (w), 1246 (m), 1206 (m), 1178 
(m), 1053 (m), 972 (s), 889 (m). 
UV (CH3CN): λmax (lg ε) = 272 nm (2.48). 
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4-(Dimethoxy-phosphoryl)-3-methyl tert-butyl butarate (106):  
To a solution of dimethyl methyl phosphonate (1.75 g, 14.08 mmol, 1.52 mL) in 
anhydrous THF (15 mL) was added nBuLi (8.8 mL of 1.6 M solution in hexane, 14.08 
mmol) at -78 °C. After 30 min, tert-butyl crotonate (1 g, 7.04 mmol) was added 
dropwise, and the reaction was stirred at -78 °C for additional 2 h. The mixture was 
extracted with diethyl ether. The organic phase was washed with aqueous NH4Cl and 
dried with Na2SO4. After evaporation of the solvent, the oily product was distilled at 
103-107 °C/0.06 torr to give 106 (0.87 g, 7.04 mmol, 47 %, lit.73 yield: 70 %). 
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106 
1
H NMR (CDCl3): δ = 3.74 (dd, 3JH,P = 10.8, 5JH,4 = 1.5 Hz, 6H, PO(OCH3)2), 2.42-
2.35 (m, 1H, 3-H), 2.22-2.15 (m, 2H, 2-H), 1.95-1.85 (m, 1H, 4-H), 1.74-1.64 (m, 1H, 
4-H), 1.45 (d, 5JH,2 = 1.5 Hz, 9H, COOC(CH3)3), 1.11 (d, 
3
J5,3 = 6.2 Hz, 5-H). 
13
C NMR (CDCl3): δ =170.9 (s, C-1), 79.7 (s, COOC(CH3)3), 51.6 (q, PO(OCH3)2), 
42.7 (t, JC,P = 13 Hz, C-2), 30.4 (t, JC,P = 140 Hz, C-4), 27.5 (q, COOC(CH3)3), 25.2 (d, 
JC,P = 3.8 Hz, C-3), 20.4 (q, JC,P = 8 Hz, C-5). 
MS [GC-MS]: m/z (%) = 210 (20) [M+-tBu], 193 (100), 151 (60), 124 (80), 57 (40). 
IR (ATR): ν~ = 2975-2852 cm-1 (w), 1723 (s, CO), 1459 (w), 1367 (m), 1308 (m), 1247 
(m), 1144 (s), 1059 (s), 1024 (s), 838 (s), 809 (s). 
UV (CHCl3): λmax (lg ε) = 241 nm (1.83). 
 
4-[1-(2,6,6-Trimethylcyclohexen-1-yl)]but-3-en-1-ynal (46):  
To a solution of LDA [prepared from diisopropylamine (2.16 mL, 15 mmol) and nBuLi 
(9.5 mL of 1.6 M solution in hexane, 15 mmol)] in anhydrous THF (40 mL) at –78 °C 
under argon, stirred for 30 min was added dropwise 22 (2.88 g, 15 mmol, mL) in 
anhydrous THF (15 mL). After 1 h stirring at –78 °C, diethyl chlorophosphate (2.12 
mL, 15 mmol) was added and the cooling bath removed. After 3 h, the reaction mixture 
138 
was transferred by cannula to a LDA solution [prepared from diisopropylamine (4.59 
mL, 30 mmol) and nBuLi (1.6 M in hexane, 30 mmol, 20.4 mL)] in anhydrous THF (85 
mL) at –78 °C. After 1 h, DMF (2.19 g, 30 mmol, 2.3 mL) was added and the mixture 
was allowed to come to room temp. After 1 h, the mixture was poured into a mixture of 
an ice cold solution of aqueous KH2PO4 and diethyl ether, and stirred for another 10 
min. The layers were separated and the organic phase washed with brine and dried with 
Na2SO4. The solvents were removed and the crude product was purified by column 
chromatography on silica gel with pentane to yield 46 (50 mg, 0.25 mmol, 6 %, lit.39 
yield: 67 %). 
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46 
1
H NMR (200 MHz, CDCl3): δ = 9.35 (s, 1H, 1-H), 7.05 (dd, 3J5,4 = 16.1, 5J5,9' = 0.7 
Hz, 1H, 5-H), 5.68 (d, 3J4,5 = 16.1 Hz, 1H, 4-H), 2.07 (t, 
3
J3',4' = 5.9 Hz, 2H, 3-H'), 1.77 
(d, 5J9',5 = 0.7 Hz, 3H, 9-H'), 1.70-1.41 (m, 4H, 4-H', 5-H'), 1.06 (s, 6H, 7-H', 8-H'). 
13
C NMR (50 MHz, CDCl3): δ = 176.6 (d, C-1), 149.4 (d, C-5), 136.8 (s, C-1'), 136.3 
(s, C-2'), 108.3 (d, C-4), 96.0 (s, C-2), 89.6 (s, C-3), 39.7 (t, C-5'), 34.0 (s, C-6'), 33.6 (t, 
C-3'), 28.7 (q, C-7', C-8'), 21.6 (q, C-9'), 18.8 (t, C-4'). 
MS [GC-MS]: m/z (%) = 202 (60) [M+], 187 (100) [M+-CH3], 173 (20) [M
+-CHO], 159 
(70), 145 (50), 131 (80), 117 (63), 105 (58), 91 (75), 77 (60), 69 (38), 53 (30). 
IR (ATR): ν~ = 2929 cm-1 (m), 2865 (m), 2170 (s, C≡ C), 1714 (w), 1654 (s, C=O), 
1589 (m), 1456 (m), 1382 (w), 1362 (w), 1294 (w), 1174 (m), 1128 (m), 959 (m), 905 
(w), 860 (m), 829 (m). 
 
13-d3-β-Ionone (84):  
To a solution of β-ionone (22, 9 g, 46.88 mmol) in D2O (28 g) and pyridine (50 mL) 
was added 0.1 % NaOD in D2O (3 mL). After stirring for 1 h at room temp. the product 
was extracted with ether and washed with water. The organic phase was dried with 
139 
Na2SO4, and the solvent was evaporated. The product 84 (9.34 g, 46.8 mmol, 100 %, 
lit.42 yield: 98 %) was obtained as a colorless oil with d3:d2:d1:d0 ratio of 79:18:2:1 
determined by mass spectrometry. 
All spectroscopic data correspond to the literature.42 
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4-Oxo-β-ionone (23):  
In a three-necked flask equipped with reflux condenser and two funnels, DMSO (10 
mL) was heated to 100 °C. Simultaneously were added during 3 h, 22 (19.2 g, 100 
mmol, 20.3 mL) and a solution of PCC (64.7 g, 0.3 mol) in DMSO (110 mL). After 
additional heating for 2 h, the mixture was cooled to room temp. and poured into diethyl 
ether (200 mL). After decantation, the black slurry was washed 3 times with ether. The 
combined organic phases were added to a solution of brine (100 mL), 2 N HCl (50 mL) 
and ice and extracted twice with diethyl ether. Washing of the organic phase with brine, 
drying with Na2SO4 and solvent removal followed by recrystallization from hexane 
gave yellow crystals of 23 (15.46 g, 75 mmol, 49 %, m.p. 53 °C, lit.27 yield: 52 %, m.p. 
51-52 °C). NMR spectra correspond to the literature.27 
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23 
MS (EI, 70 eV): m/z (%) = 206 (50) [M+], 191 (10) [M+-CH3], 163 (100) [M
+-CH3CO], 
150 (15) [M+-CH3COCH2], 149 (20) [M+-CH3CO, -CH3] , 135 (24) [M+-CH3COCH2, 
-CH3], 43 (73) [CH3CO
+]. 
IR (KBr): ν~ = 2956 – 2870 cm-1 (m, CH3, CH2, CH), 1660 (s, C=O). 
140 
UV (CHCl3): λmax (lg ε) = 230 nm (3.73), 242 (2.92), 280 (4.05). 
 
13-d3-4-Oxo-β-ionone (91):  
13-d3-β-Ionone (84, 6.35 g, 32.5 mmol) was oxidized with PCC (21.02 g, 97.5 mmol), 
in dry DMSO (50 mL) as described for 23, to give 91 (2.85 g, 13.6 mmol, 53 %) with 
d3:d2:d1:d0 ratio of 9:41:29:9 determined by mass spectrometry. 
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91 
1
H NMR (CDCl3): δ = 7.25 (br d, 3J7,8 = 16.5 Hz, 1H, 7-H), 6.19 (d, 3J8,7 = 16.5 Hz, 
1H, 8-H), 2.54 (t, 3J3,2 = 6.9 Hz, 2H, 3-H), 2.35 (s, undeuterated CH3, 13-H), 2.34-2.31 
(m, partially deuterated CH2D and CHD2, 13-H), 1.90 (t, 
3
J2,3 = 6.9 Hz, 2H, 2-H), 1.80 
(d, 5J12,7 = 1.0 Hz, 3H, 12-H), 1.2 (s, 6H, 10-H, 11-H).  
13
C NMR (CDCl3): δ = 198.4 (s, C-4), 197.3 (s, C-9), 157.6 (s, C-6), 140.2 (d, C-7), 
133,5 (d, C-8), 131.3 (s, C-5), 37.2 (t, C-2), 35.4 (s, C-1), 34.1 (t, C-3), 27.8 (q, C-13), 
27.2 (q, C-10, C-11), 13.3 (q, C-12). 
MS [GC-MS]: m/z (%) = 209 [M+ , 9 % d3], 208 [M
+ , 29 % d2], 207 [M
+ , 41 % d1], 
206 [M+, 21 % d0], 194/193/192/191, 166/165/,164/163, 150 (14), 136 (17), 121 (37), 
107 (12), 91 (12), 77 (10), 55 (12). 
IR (ATR): ν~ = 2957-2870 cm-1 (m), 1660 (s), 1601 (w), 1450 (m), 1416 (m), 1369 (m), 
1351 (m), 1335 (m), 1296 (m), 1252 (m), 1206 (m), 1178 (m), 1143 (m), 1094 (m), 
1031 (m), 1011 (m), 978 (s), 882 (m), 686 (w), 569 (m). 
UV (CHCl3): λmax (lg ε) = 240 nm (3.90), 280 (4.01). 
 
β-Ionylidene-acetaldehyde (47):  
General procedure 1 with 52 (13.37 g, 31.3 mmol) in anhydrous THF (60 mL), KOtBu 
(3.5 g, 31.3 mmol), 22 (3 g, 15.6 mmol) in anhydrous THF (30 mL), oxalic acid 
141 
solution (13.78 g, 109.3 mmol, in 110 mL water). Column chromatography with 
pentane/diethyl ether 10:1 on Alox (activity III, 8 % water w/w) gave 9-cis- (Rf = 0.55) 
and all-trans-47 (Rf = 0.42) in 1.0:1.5 ratio (2.83 g, 13 mmol, 83 %).  
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all-trans-47 
1
H NMR (400 MHz, CDCl3): δ = 10.13 (d, 3J11,10 = 8.1 Hz, 1H, 11-H), 6.74 (dt, 3J7,8 = 
16.2, 5J7,4 = 
5J7,14 = 0.8 Hz, 1H, 7-H), 6.21 (d, 
3
J8,7 = 16.2 Hz, 1H, 8-H), 5.93 (br d, 
3
J10,11 = 8.1 Hz, 1H, 10-H), 2.31 (d, 
4
J15,10 = 1.1 Hz, 3H, 15-H), 2.04 (br t, 
3
J4,3 = 6.0 Hz, 
2H, 4-H), 1.72 (d, 5J14,7 = 0.8 Hz, 3H, 14-H), 1.62 (m, 2H, 3-H), 1.47 (m, 2H, 2-H), 1.05 
(s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 191.2 (d, C-11), 154.8 (s, C-9), 137 (s, C-6), 135.6 
(d, C-8), 135.5 (d, C-7), 132.6 (s, C-5), 128.7 (d, C-10), 39.5 (t, C-2), 34.2 (s, C-1), 33.1 
(t, C-4), 28.8 (q, C-12/C-13), 21.6 (q, C-14), 19 (t, C-3), 12.9 (q, C-15). 
UV (CHCl3): λmax (lg ε) = 252 nm (4.04), 304 (4.23). 
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9-cis-47 
1
H NMR (CDCl3): δ = 10.16 (d, 3J11,10 = 8.1 Hz, 1H, 11-H), 7.09 (d, 3J8,7 = 16.0 Hz, 
1H, 8-H), 6.63 (dt, 3J7,8 = 16.0, 
5
J7,4 = 
5
J7,14 = 0.8 Hz, 1H, 7-H), 5.86 (dd, 
3
J10,11 = 8.1, 
4
J10,15 = 0.9 Hz, 1H, 10-H), 2.1 (d, 
4
J15,10 = 1.1 Hz, 3H, 15-H), 2.06 (m, 2H, 4-H), 1.75 
(d, 5J14,7 = 1.1 Hz, 3H, 14-H), 1.65-1.60 (m, 2H, 3-H), 1.50-1.47 (m, 2H, 2-H), 1.06 (s, 
6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 190.1 (d, C-11), 155 (s, C-9), 137.2 (s, C-6), 136.5 
(d, C-7), 132.5 (s, C-5), 127.8, 127.73 (d, C-10, C-8), 39.5 (t, C-2), 34.2 (s, C-1), 33.1 
(t, C-4), 28.9 (q, C-12, C-13), 21.7 (q, C-14), 21.1 (q, C-15), 19 (t, C-3). 
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UV (CHCl3): λmax (lg ε) = 248 nm (3.86), 286 (3.85). 
isomeric mixture: 
MS [GC-MS]: m/z (%) = 218 (40) [M+], 203 (15) [M+-CH3], 189 (20), 175 (20), 161 
(20), 147 (45), 133 (35), 119 (100), 107 (40), 95 (40), 91 (30), 77 (30), 69 (15), 55 (15). 
IR (ATR): ν~  = 2959 cm-1 (m), 2924 (m), 2864 (m), 2825 (w),2764 (w), 2723 (w), 
1664 (C=O, s), 1608 (m), 1448 (m), 1378 (m), 1359 (m), 1206 (m), 1114 (m), 967 (m). 
 
15-d3-β-Ionylidene-acetaldehyde (85):  
General procedure 1 with 52 (13.19 g, 30.7 mmol) in anhydrous THF (60 mL), KOtBu 
(3.44 g, 30.7 mmol), 84 (3.0 g, 15.36 mmol) in anhydrous THF (40 mL), aqueous oxalic 
acid (13.5 g, 107.5 mmol, 110 mL water). Column chromatography on Alox (activity 
III, 8 % water w/w) with pentane/diethyl ether 10:1, gave a mixture of 9-cis- (Rf = 0.54) 
and all-trans-85 (Rf = 0.43) as a yellow oil (1.18 g, 5.3 mmol, 35 %).  
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all-trans-85 
1
H NMR (400 MHz, CDCl3): δ = 10.17 (d, 3J11,10 = 8.0 Hz, 1H, 11-H), 6.74 (d, 3J7,8 = 
16.2 Hz, 1H, 7-H), 6.22 (d, 3J8,7 = 16.2 Hz, 1H, 8-H), 5.93 (d, 
3
J10,11 = 8.0 Hz, 1H, 10-
H), 2.31 (s, undeuterated CH3, 15-H), 2.28-2.27 (m, partially deuterated CH2D and 
CHD2, 15-H), 2.05 (t, 
3
J4,3 = 5.8 Hz, 2H, 4-H), 1.73 (s, 3H, 14-H), 1.67-1.57 (m, 2H, 3-
H), 1.51-1.47 (m, 2H, 2-H), 1.05 (s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 191.1 (d, C-11), 154.8 (s, C-9), 136.9 (s, C-6), 135.6 
(d, C-8), 135.4 (d, C-7), 132.5 (s, C-5), 128.6 (d, C-10), 39.6 (t, C-2), 34.1 (s, C-1), 33.1 
(t, C-4), 28.8 (q, C-12, C-13), 21.6 (q, C-14), 19 (t, C-3). 
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9-cis-85 
1
H NMR (400 MHz, CDCl3): δ = 10.13 (d, 3J11,10 = 8.0 Hz, 1H, 11-H), 7.10 (d, 3J8,7 = 
16.0 Hz, 1H, 8-H), 6.63 (d, 3J7,8 = 16.0 Hz, 1H, 7-H), 5.86 (d, 
3
J10,11 = 8.0 Hz, 1H, 10-
H), 2.30 (s, undeuterated CH3, 15-H), 2.28-2.27 (m, partially deuterated CH2D and 
CHD2, 15-H), 2.13-2.11 (m, 2H, 4-H), 1.75 (s, 3H, 14-H), 1.67-1.57 (m, 2H, 3-H), 1.51-
1.47 (m, 2H, 2-H), 1.04 (s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 189.9 (d, C-11), 155.0 (s, C-9), 137.1 (s, C-6), 136.4 
(d, C-8), 132.4 (s, C-5), 128.6, 127.7 (d, C-10, C-7 ), 39.4 (t, C-2), 34.1 (s, C-1), 33.1 (t, 
C-4), 28.8 (q, C-12, C-13), 21.7 (q, C-14), 18.9 (t, C-3). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 221 [M+, 16 % d3], 220 [M
+, 29 % d2], 210 [M
+, 40 % d1], 
218 [M+, 12 % d0], 204 (18) [M
+-CH3], 190 (22), 176 (23), 149 (60), 133 (40), 123 (60), 
120 (100), 107 (98), 97 (40), 91 (37), 79 (28), 69 (20), 67 (15), 55 (28). 
IR (ATR): ν~ = 2957-2744 cm-1 (m), 1659 (s), 1606 (m), 1450 (s), 1378 (s), 1300 (s), 
1198 (m), 1147 (m), 1103 (m,), 967 (m).  
UV (CHCl3): λmax (lg ε) = 233 nm (3.83), 283 (4.01). 
 
4-Oxo-β-ionylidene-acetaldehyde (53):  
General procedure 1 with 52 (12.46 g, 29.13 mmol) in anhydrous THF (200 mL), 
KOtBu (3.26 g, 29.13 mmol), 23 (3.0 g, 14.56 mmol) in anhydrous THF (50 mL), 
aqueous oxalic acid (12.85 g, 101.92 mmol, 100 mL water). Column chromatography 
on Alox (activity III, 8 % water w/w, pentane/diethyl ether 3:2, gave a mixture of 9-cis- 
(Rf = 0.42) and all-trans-53 (Rf = 0.34) as a yellow oil (1.0:1.5 ratio, 2.15 g, 9.3 mmol, 
63 %).  
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all-trans-53 
1
H NMR (400 MHz, CDCl3): δ = 10.17 (d, 3J11,10 = 7.9 Hz, 1H, 11-H), 6.76 (br. d, 3J7,8 
= 16.4 Hz, 1H, 7-H), 6.33 (dd, 3J8,7 = 16.4, 
4
J8,10 = 0.7 Hz, 1H, 8-H), 6.02 (br. d, 
3
J10,11 = 
7.9 Hz, 1H, 10-H), 2.54 (m, 2H, 3-H), 2.36 (d, 4J15,10 = 1.2 Hz, 3H, 15-H), 1.89 (m, 2H, 
2-H), 1.82 (d, 5J14,7 = 1.1 Hz, 3H, 14-H), 1.2 (s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 198.8 (s, C-4), 191.1 (d, C-11), 159.2 (s, C-6), 152.7 
(s, C-9), 138.3 (d, C-8), 132.5 (d, C-7), 131.0 (s, C-5), 130.7 (d, C-10), 37.2 (t, C-2), 
35.6 (s, C-1), 34.1 (t, C-3), 27.4 (q, C-12, C-13), 13.5 (q, C-14), 12.8 (q, C-15). 
IR (KBr): ν~ = 2962 cm-1 (m), 2927 (m), 2858 (m), 2774 (w), 2729 (w), 1667 (C=O, s), 
1616 (m), 1595 (m), 1447 (m), 1387 (w), 1376 (w), 1351 (m), 1333 (m), 1203 (m), 
1148 (m), 1092 (m). 
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9-cis-53 
1
H NMR (400 MHz, CDCl3): δ = 10.14 (d, 3J11,10 = 7.7 Hz, 1H, 11-H), 7.22 (d, 3J8,7 = 
16.2 Hz, 1H, 8-H), 6.65 (dd, 3J7,8 = 16, 
5
J7,14 = 1.1 Hz, 1H, 7-H), 6.00 (dd, 
3
J10,11 = 7.7, 
4
J10,15 = 1.1 Hz, 1H, 10-H), 2.54 (m, 2H, 3-H), 2.13 (d, 
4
J15,10 = 1.1 Hz, 3H, 15-H), 1.9 
(m, 2H, 2-H), 1.85 (d, 5J14,7 = 1.1 Hz, 14-H), 1.2 (s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 198.8 (s, C-4), 189.7 (d, C-11), 159.2 (s, C-6), 152.8 
(s, C-9), 133.7 (d, C-7), 131.1 (s, C-5), 130.6 (d , C-8), 129.7 (d, C-10), 37.3 (t, C-2), 
35.7 (s, C-1), 34.2 (t, C-3), 27.5 (q, C-12, C-13), 20.9 (q, C-15), 13.6 (q, C-14). 
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isomeric mixture: 
MS [GC-MS]: m/z (%) = 232 (18) [M+], 217 (10) [M+-CH3], 203 (20) [M
+-COH], 189 
(11) [M+-COH, -CH3], 161 (12), 148 (15), 133 (22), 119 (14), 105 (14), 95 (100) 
[CH+=CHCH(CH3)=CHCH=O]. 
UV (CHCl3): λmax (lg ε) = 276 nm (4.02), 336 (4.13). 
IR (KBr): ν~ = 2962 cm-1 (m), 2924 (m), 2869 (w), 1663 (C=O, s), 1619 (m), 1447 (m), 
1334 (m), 1202 (m), 1117 (m), 1031 (m), 970 (m). 
 
15-d3-4-Oxo-β-ionylidene-acetaldehyde (86):  
General procedure 1 with 52 (11.67 g, 27.26 mmol) in anhydrous THF (60 mL), KOtBu 
(3.05 g, 27.26 mmol), 91 (2.85 g, 13.63 mmol) in anhydrous THF (40 mL), aqueous 
oxalic acid (12.02 g, 95.41 mmol, 100 mL water). Column chromatography on Alox 
(activity III, 8 % water w/w), pentane/diethyl ether 3:2, gave a mixture of 9-cis- (Rf = 
0.42) and all-trans-86 (Rf = 0.34) as a yellow oil (1.95 g, 8.3 mmol, 61 %). 
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all-trans-86 
1
H NMR (400 MHz, CDCl3): δ = 10.17 (d, 3J11,10 = 7.8 Hz, 1H, 11-H), 6.76 (d, 3J7,8 = 
16.3 Hz, 1H, 7-H), 6.33 (d, 3J8,7 = 16.3 Hz, 1H, 8-H), 6.02 (d, 
3
J10,11 = 7.8 Hz, 1H, 10-
H), 2.56-2.51 (m, 2H, 3-H), 2.37-2.34 (m, partially deuterated CDH2, 15-H), 2.18-2.17 
(m, partially deuterated CD2H, 15-H), 1.88-1.92 (m, 2H, 2-H), 1.82 (s, 3H, 14-H), 1.20 
(s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 198.6 (s, C-4), 191.0 (d, C-11), 159.1 (s, C-6), 152.6 
(s, C-9), 138.2 (d, C-8), 132.4 (d, C-7), 130.9 (s, C-5), 130.6 (d, C-10), 37.2 (t, C-2), 
35.6 (s, C-1), 34.1 (t, C-3), 27.3 (q, C-12/C-13), 13.4 (q, C-14), 12.8 (q, partially 
deuterated C-15). 
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9-cis-86 
1
H NMR (400 MHz, CDCl3): δ = 10.14 (d, 3J11,10 = 7.8 Hz, 1H, 11-H), 7.24 (d, 3J8,7 = 
16.2 Hz, 1H, 8-H), 6.65 (d, 3J7,8 = 16.2 Hz, 1H, 7-H), 6.00 (d, 
3
J10,11 = 7.8 Hz, 1H, 10-
H), 2.56-2.51 (m, 2H, 3-H), 2.37-2.34 (m, partially deuterated CDH2, 15-H), 2.18-2.17 
(m, partially deuterated CD2H, 15-H), 1.92-1.88 (m, 2H, 2-H), 1.85 (s,3H, 14-H), 1.22 
(s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 198.6 (s, C-4), 189.5 (d, C-11), 159.2 (s, C-6), 152.7 
(s, C-9), 133.6 (d, C-7), 130.9 (s, C-5), 130.4 (d , C-8), 129.5 (d, C-10), 37.1 (t, C-2), 
35.5 (s, C-1), 34.1 (t, C-3), 27.4 (q, C-12, C-13), 20.8 (q, partially deuterated C-15), 
13.5 (q, C-14). 
MS [GC-MS]: m/z (%) = 235 [M+, 4 % d3], 234 [M
+, 18 % d2], 233 [M
+, 40 % d1], 232 
[M+, 38 % d0], 217 (15), 204 (20), 189 (20), 163 (15), 148 (20), 133 (20), 119 (20), 105 
(20), 95 (100), 77 (20), 69 (20), 55 (18), 41 (22). 
IR (ATR): ν~ = 2961-2738 cm-1 (w), 1657 (s), 1614 (m), 1445 (w), 1351 (m), 1333 (m), 
1311 (w), 1199 (m), 1146 (m), 1117 (m), 1091 (m), 1030 (m), 969 (m). 
UV (CHCl3): λmax (lg ε) = 250 nm (4.08), 302 (4.25). 
 
13,14-Dihydro-retinoic acid methyl ester (74):  
General procedure 2 with LiHMDS [prepared from nBuLi (1.78 mL, 2.84 mmol) and 
HMDS (0.458 g, 0.59 mL, 2.84 mmol) in anhydrous THF (20 mL)], 66 (1.43 g, 2.84 
mmol), 47 (0.5 g, 2.27 mmol) in anhydrous THF (10 mL). Column chromatography on 
Alox (activity III) with pentane/diethyl ether 5:1 gave all-trans-, 9-cis-, 11-cis-, 9,11-di-
cis-74 (0.58 g, 1.77 mmol, 78 %) in 1.75:1.0:3.0:1.0 ratio by NMR analysis, as yellow 
oil. When all-trans-47 was reacted with 66, all-trans- and 11-cis-74 were obtained in 
1.0:1.5 ratio, while 9-cis-47 gave 9-cis- and 9,11-di-cis-74 in 1:1 ratio. 
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all-trans-74 
1
H NMR (400 MHz, CDCl3): δ = 6.42 (ddd, 3J11,12 = 15.0, 3J11,10 = 11.1, 5J11,19 = 0.8 
Hz, 1H, 11-H), 6.09 (d, 3J7,8 = 16.4 Hz, 1H, 7-H), 6.04 (d, 
3
J8,7 = 16.4 Hz, 1H, 8-H), 
5.98 (d, 3J10,11 = 11.1 Hz, 1H, 10-H), 5.62 (dd, 
3
J12,11 = 15.0, 
3
J12,13 = 7.7 Hz, 1H, 12-H), 
2.80-2.75 (m, 1H, 13-H), 2.41-2.36 (m, 2H, 14-H), 2.02-1.98 (m, 2H, 4-H), 1.90 (s, 3H, 
18-H), 1.71 (d, 5J19,11 = 0.8 Hz, 3H, 19-H), 1.65-1.59 (m, 2H, 3-H), 1.48-1.45 (m, 2H, 2-
H), 1.09 (d, 3J20,13 = 6.8 Hz, 3H, 20-H), 1.01 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.8 (s, C-15), 137.9 (d, C-12), 137.8 (s, C-6), 
137.7 (d, C-8), 134.7 (s, C-5), 129.4 (d, C-10), 128.9 (s, C-9), 126.3 (d, C-7), 125.8 (d, 
C-11), 41.6 (t, C-14), 39.6 (t, C-2), 34.2 (s, C-1), 34.1 (d, C-13), 33.0 (t, C-4), 28.9 (q, 
C-16, C-17), 21.6 (q, C-19), 20.3 (q, C-20), 19.3 (t, C-3), 12.5 (q, C-18).  
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11-cis-74 
1
H NMR (400 MHz, CDCl3): δ = 6.31 (br t, 3J11,12 = 3J11,10 = 11.8 Hz, 1H, 11-H), 6.30 
(d, 3J10,11 = 10.7 Hz, 1H, 10-H), 6.15-6.14 (m, 2H, 7-H, 8-H), 5.26 (t, 
3
J12,11 = 
3
J12,13 = 
9.2 Hz, 1H, 12-H), 3.24-3.16 (m, 1H, 13-H), 2.36-2.28 (m, 2H, 14-H), 2.01 (t, 3J4,3 = 6.2 
Hz, 2H, 4-H), 1.90 (s, 3H, 18-H), 1.68 (d, 5J19,11 = 0.7 Hz, 3H, 19-H), 1.65-1.59 (m, 2H, 
3-H), 1.48-1.45 (m, 2H, 2-H), 1.06 (d, 3J20,13 = 6.7 Hz, 3H, 20-H), 1.02 (s, 6H, 16-H, 
17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.8 (s, C-15), 137.9 (d, C-8), 137.8 (s, C-6), 136.3 
(s, C-5), 135.4 (d, C-12), 129.1 (s, C-9), 126.8 (d, C-7), 124.5 (d, C-11), 124.3 (d, C-
10), 41.9 (t, C-14), 39.6 (t, C-2), 34.2 (s, C-1), 33 (t, C-4), 29.4 (d, C-13), 28.9 (q, C-16, 
C-17), 21.7 ( q, C-19), 20.9 (q, C-20), 19.3 (t, C-3), 12.3 (q, C-18). 
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9-cis-74 
1
H NMR (400 MHz, CDCl3): δ = 6.57 (d, 3J8,7 = 16.1 Hz, 1H, 8-H), 6.50 (dd, 3J11,12 = 
15.0, 3J11,10 = 11.1 Hz, 1H, 11-H), 6.13 (d, 
3
J7,8 = 16.1 Hz, 1H, 7-H), 5.88 (d, 
3
J10,11 = 
11.1 Hz, 1H, 10-H), 5.55 (dd, 3J12,11 = 15.0, 
3
J12,13 = 7.6 Hz, 1H, 12-H), 2.80-2.72 (m, 
1H, 13-H), 2.26-2.4 (m, 2H, 14-H), 2.01 (t, 3J4,3 = 6.0 Hz, 2H, 4-H), 1.91 (s, 3H, 19-H), 
1.72 (s, 3H, 18-H), 1.66-1.58 (m, 2H, 3-H), 1.53-1.45 (m, 2H, 2-H), 1.05 (d, 3J20,13 = 6.7 
Hz, 3H, 20-H), 1.02 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.5 (s, C-15), 138.04 (s, C-6), 137 (d, C-12), 
134.8 (s, C-5), 129.9 (d, C-8), 129.1 (s, C-9), 128.02 (d, C-10), 128 (d, C-7), 124.6 (d, 
C-11), 41.8 (t, C-14), 39.5 (t, C-2), 34.15 (s, C-1), 33.9 (d, C-13), 33 (t, C-4), 28.9 (q, 
C-16, C-17), 21.7 (q, C-18), 20.8 (q, C-20), 20.4 (q, C-19), 19.2 (t, C-3). 
COOMe
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16 17
18
19
20
21
 
9,11-di-cis-74 
1
H NMR (400 MHz, CDCl3): δ = 6.60 (d, 3J8,7 = 15.9 Hz, 1H, 8-H), 6.41 (t, 3J11,10 = 
3
J11,12 = 11.2 Hz, 1H, 11-H), 6.21 (d, 
3
J10,11 = 11.2 Hz, 1H, 10-H), 6.17 (d, 
3
J7,8 = 15.9 
Hz, 1H, 7-H), 5.19 (t, 3J12,11 = 
3
J12,13 = 10.3 Hz, 1H, 12-H), 3.25-3.17 (m, 1H, 13-H), 
2.40-2.26 (m, 2H, 14-H), 2.03 (t, 3J4,3 = 6.0 Hz, 2H, 4-H), 1.97 (s, 3H, 19-H), 1.73 (s, 
3H, 18-H), 1.66-1.58 (m, 2H, 3-H), 1.53-1.45 (m, 2H, 2-H), 1.08 (d, 3J20,13 = 6.8 Hz, 
3H, 20-H), 1.03 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.8 (s, C-15), 138.1 (s, C-6), 135.5 (d, C-12), 
133.3 (s, C-5), 129.7 (d, C-8), 129.3 (s, C-9), 128.6 (d, C-7), 123.2 (d, C-11), 122.8 (d, 
149 
C-10), 41.5 (t, C-14), 39.5 (t, C-2), 34.1 (s, C-1), 32.96 (t, C-4), 29.1 (d, C-13), 28.9 (q, 
C-16, C-17), 21.72 (q, C-18), 20.8 (q, C-19), 20.2 (q, C-20),19.2 (t, C-3). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 316 (18) [M+], 301 (9) [M+-CH3], 260 [M
+-C3H4O], 243, 
227 (10) [M+-CH3-C3H6O2], 215 (10), 206 (5), 193 (8), 180 (10), 177 (30), 159 (17), 
149 (17), 135 (20), 123 (98), 109 (57), 95 (45), 87 (40), 74 (100) [C3H6O2
+], 69 (58), 55 
(42) [C3H3O
+]. 
IR (ATR): ν~ = 2957 cm-1 (m), 2928 (m), 2867 (m), 1781 (C=O, s), 1682 (w), 1454 (m), 
1437 (m), 1360 (m), 1252 (m), 1167 (s), 1008 (m), 968 (s). 
UV (EtOH): λmax (lg ε) = 227 nm (3.90), 290 (4.45). 
HRMS: C21H32O2 (316.48) calcd. 316.24023; found 316.20350 ± 2.27 ppm. 
 
19-d3-13,14-Dihydro-retinoic acid methyl ester (87):  
General procedure 2 with LiHMDS [prepared from nBuLi (3.53 mL, 5.65 mmol) and 
HMDS (0.91 g, 1.18 mL, 5.65 mmol) in anhydrous THF (50 mL) at –78 °C], 66 (2.85 g, 
5.65 mmol), 85 (1.0 g, 4.52 mmol) in anhydrous THF (10 mL). Column 
chromatography with pentane/diethyl ether 1:1 on Alox (activity III, 8 % water w/w) 
gave 87 (0.65 g, 2.04 mmol, 45 %) as a yellow oil.  
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all-trans-87 9-cis-87 
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11-cis-87 9,11-di-cis-87 
1
H NMR (CDCl3): δ = 1.73, 1.71, 1.69 (s, partially deuterated CHD2, CH2D and 
undeuterated CH3, 19-H), all other signals correspond to 74. 
13
C NMR (CDCl3): δ = 21.71, 21.69, 21.65, 21,59 (q, partially deuterated CHD2, CH2D 
and undeuterated CH3, C-19), all other signals correspond to 74. 
MS [EI, 70 eV]: m/z (%) = 319 (60) [M+, 15 % d3], 318 (100) [M
+, 31 % d2], 317 (90) 
[M+, 35 % d1], 316 (40) [M
+, 17 % d0], 302 (30), 287 (5), 270 (5), 244 (25), 228 (26), 
216 (30), 201 (20), 188 (42), 174 (50), 160 (80), 159 (74), 146 (60), 133 (70), 121 (90), 
120 (80), 107 (65), 95 (60), 91 (55), 81 (70), 69 (78), 55 (63), 43 (25), 41 (80). 
IR and UV spectra were identical with those of 74. 
 
13,14-Dihydro-retinoic acid (10):  
General procedure 3 with 74 (0.56 g, 1.77 mmol), KOH (1.0 g, 17.7 mmol) in ethanol 
(20 mL) and water (10 mL) gave the four isomers all-trans-, 9-cis-, 11-cis-, 9,11-di-cis-
10 (0.55 mg, 1.73 mmol, 98 %) in 1.65:1.0:3.0:1.2 ratio, as a yellow oil. 
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all-trans-10 
1
H NMR (400 MHz, MeOH-d4): δ = 6.45 (ddd, 3J11,12 = 15.0, 3J11,10 = 11.0, 5J11,19 = 
1.0 Hz, 1H, 11-H), 6.05 (d, 3J7,8 = 16.5 Hz, 1H, 7-H), 6.02 (d, 
3
J8,7 = 16.5 Hz, 1H, 8-H), 
5.96 (d, 3J10,11 = 11.0 Hz, 1H, 10-H), 5.65 (dd, 
3
J12,13 = 15.0, 
3
J12,13 = 7.6 Hz, 1H, 12-H), 
2.79-2.66 (m, 1H, 13-H), 2.37-2.25 (m, 2H, 14-H), 2.01 (t, 3J4,3 = 5.9 Hz, 2H, 4-H), 1.87 
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(d, 5J19,11 = 1.0 Hz, 3H, 19-H), 1.67 (s, 3H, 18-H), 1.72-1.55 (m, 2H, 3-H), 1.53-1.40 
(m, 2H, 2-H), 1.09 (d, 3J20,13 = 6.8 Hz, 3H, 20-H), 1.01 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, MeOH-d4): δ = 176.23 (s, C-15), 139.4 (d, C-12), 139.2 (s, C-6), 
139.3 (d, C-8), 130.0 (s, C-5), 131.1 (d, C-10), 129.7 (s, C-9), 127.0 (d, C-7), 126.9 (d, 
C-11), 42.6 (t, C-14), 40.8 (t, C-2), 35.2 (s, C-1), 35.3 (d, C-13), 33.9 (t, C-4), 29.5 (q, 
C-16, C-17), 22.0 (q, C-18), 20.7 (q, C-20), 20.4 (t, C-3), 12.7 (q, C-19). 
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11-cis-10 
1
H NMR (400 MHz, MeOH-d4): δ = 6.32-6.31 (m, 2H, 10-H, 11-H), 6.13 (d, 3J8,7 ≈  16 
Hz, 1H, 8-H), 6.15 (d, 3J7,8 
≈  16 Hz, 1H, 7-H), 5.29 (t, 3J12,11 = 
3
J12,13 
≈  10 Hz, 1H, 12-
H), 3.26-3.10 (m, 1H, 13-H), 2.33-2.20 (m, 2H, 14-H), 2.01 (t, 3J4,3 = 5.9 Hz, 2H, 4-H), 
1.88 (s, 3H, 19-H), 1.69 (s, 3H, 18-H), 1.72-1.55 (m, 2H, 3-H), 1.53-1.40 (m, 2H, 2-H), 
1.05 (d, 3J20,13 = 6.7 Hz, 3H, 20-H), 1.01 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, MeOH-d4): δ = 176.26 (s, C-15), 139.5 (d, C-8), 139.1 (s, C-6), 
135.2 (s, C-5), 136.95 (d, C-12), 129.9 (s, C-9), 127.6 (d, C-7), 125.9 (d, C-10), 125.3 
(d, C-11), 42.8 (t, C-14), 40.8 (t, C-2), 35.2 (s, C-1), 33.9 (t, C-4), 30.5 (d, C-13), 29.5 
(q, C-16, C-17), 22.0 (q, C-18), 21.2 (q, C-20), 20.4 (t, C-3), 12.5 (q, C-19). 
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9-cis-10 
152 
1
H NMR (400 MHz, MeOH-d4): δ = 6.60 (d, 3J8,7 = 16.0 Hz, 1H, 8-H), 6.51 (dd, 3J11,12 
= 15.0, 3J11,10 = 11.1 Hz, 1H, 11-H), 6.20 (d, 
3
J7,8 = 16.0 Hz, 1H, 7-H), 5.89 (d, 
3
J10,11 = 
11.1 Hz, 1H, 10-H), 5.58 (dd, 3J12,11 = 15.0, 
3
J12,13 = 7.6 Hz, 1H, 12-H), 2.76-2.65 (m, 
1H, 13-H), 2.31-2.24 (m, 2H, 14-H), 2.04 (t, 3J4,3 = 6.1 Hz, 2H, 4-H), 1.95 (s, 3H, 19-
H), 1.72 (s, 3H, 18-H), 1.68-1.61 (m, 2H, 3-H), 1.51-1.47 (m, 2H, 2-H), 1.07 (d, 3J20,13 = 
6.7 Hz, 3H, 20-H), 1.03 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, MeOH-d4): δ = 176.3 (s, C-15), 139.3 (s, C-6), 138.6 (d, C-12), 
135.5 (s, C-5), 131.2 (d, C-8), 130.1 (s, C-9), 129.6 (d, C-10), 129.57 (d, C-7), 125.7 (d, 
C-11), 42.6 (t, C-14), 40.8 (t, C-2), 35.2 (s, C-1), 35.2 (d, C-13), 33.9 (t, C-4), 29.5 (q, 
C-16, C-17), 22.05 (q, C-18), 21.02 (q, C-19), 20.7 (q, C-20), 20.4 (t, C-3). 
COOH
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16 17
18
19
20
21
 
9,11-di-cis-10 
1
H NMR (400 MHz, MeOH-d4): δ = 6.58 (d, 3J8,7 = 16.4 Hz, 1H, 8-H), 6.38 (t, 3J11,10 = 
3
J11,12 = 11.5 Hz, 1H, 11-H), 6.25 (d, 
3
J10,11 = 11.5 Hz, 1H, 10-H), 6.14 (d, 
3
J7,8 = 16.4 
Hz, 1H, 7-H), 5.22 (t, 3J12,11 = 
3
J12,13 = 10.5 Hz, 1H, 12-H), 3.24-3.12 (m, 1H, 13-H), 
2.31-2.24 (m, 2H, 14-H), 2.04 (t, 3J4,3 = 6.1 Hz, 2H, 4-H), 1.89 (s, 3H, 19-H), 1.70 (s, 
3H, 18-H), 1.68-1.61 (m, 2H, 3-H), 1.51-1.47 (m, 2H, 2-H), 1.05 (d, 3J20,13 = 6.8 Hz, 
3H, 20-H), 1.02 (s, 6H, 16-H, 17-H).  
13
C NMR (100 MHz, MeOH-d4): δ = 176.3 (s, C-15), 139.3 (s, C-6), 136.1 (d, C-12), 
133.8 (s, C-5), 131.5 (d, C-8), 130.3 (s, C-9), 128.8 (d, C-7), 124.04 (d, C-11), 124.3 (d, 
C-10), 42.9 (t, C-14), 40.8 (t, C-2), 35.2 (s, C-1), 33.9 (t, C-4), 30.35 (d, C-13), 29.5 (q, 
C-16, C-17), 22.02 (q, C-18), 21.2 (q, C-20), 20.7 (q, C-19), 20.4 (t, C-3). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 302 (18) [M+], 287 (10) [M+-CH3], 243 (10) [M
+-
CH2COOH], 227 (5), 215 (10), 205 (5), 187 (9), 173 (10), 159 (18), 145 (20), 133 (15), 
119 (27), 105 (23), 91 (36), 77 (30), 69 (30), 55 (30), 43 (100). 
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IR (ATR): ν~ = 3402 cm-1 (br. COOH), 2961 (m), 2929 (m), 2868 (m), 1706 (s) (C=O), 
1454 (m), 1381 (m), 1172 (m), 1126 (m), 1083 (m), 1045 (m), 968 (m), 880 (w), 762 
(w), 613 (m). 
UV (EtOH): λmax (lg ε) = 233 nm (3.83), 289 (4.14) . 
HRMS: C20H30O2 (302.46) calcd. 302.22458; found 302.22425 ± 1.092 ppm. 
 
19-d3-13,14-Dihydro-retinoic acid (88):  
General procedure 3 with 87 (0.65 g, 2.04 mmol), KOH (1.14 g, 20.4 mmol) in ethanol 
(10 mL) and water (5 mL) gave 88 (0.41 g, 1.34 mmol, 66 %). 
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11-cis-88 9,11-di-cis-88 
1
H NMR (MeOH-d4): δ = 1.73, 1.71, 1.69 (s, partially deuterated CHD2, CH2D and 
undeuterated CH3, 19-H), all other signals correspond to 10. 
13
C NMR (MeOH-d4): δ = 21.71, 21.69, 21.65, 21,59 (q, partially deuterated CHD2, 
CH2D and undeuterated CH3, C-19), all other signals correspond to 10. 
MS [EI, 70 eV]: m/z (%) = 305 (50) [M+, 15 % d3], 304 (90) [M
+, 32 % d2], 303 (87) 
[M+, 35 % d1], 302 (36) [M
+, 16 % d0], 288 (30), 262 (5), 244 (20), 219 (20), 216 (30), 
202 (20), 189 (40), 188 (43), 173 (57), 160 (95), 147 (77), 133 (80), 121 (90), 107 (83), 
91 (100), 81 (80), 69 (100), 55 (90), 51 (40). 
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IR and UV spectra were identical with those of 10. 
 
4-Oxo-13,14-dihydro-retinoic acid methyl ester (75):  
General procedure 2 with LiHMDS [prepared from nBuLi (3.34 mL, 5.34 mmol) and 
HMDS (0.862 g, 1.11 mL, 5.34 mmol) in anhydrous THF (50 mL) at –78 °C], 66 (2.69 
g, 5.34 mmol), 53 (1.0 g, 4.27 mmol) in anhydrous THF (10 mL). Column 
chromatography with pentane/diethyl ether 3:1 on Alox (activity III, 8 % water w/w, Rf 
= 0.27-0.23) gave 75 (0.87 g, 2.64 mmol, 62 %) as a yellow oil. Isomer ratio all-trans-, 
9-cis-, 11-cis-, 9,11-di-cis-75: 2.0:1.0:3.4:1.0 by NMR analysis. When all-trans-53 was 
used, all-trans- and 11-cis-75 were obtained in 1.0:1.5 ratio, while 9-cis-53 gave 9-cis- 
and 9,11-di-cis-75 in 1.0:1.3 ratio. 
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all-trans-75 
1
H NMR (400 MHz, CDCl3): δ = 6.44 (dd, 3J11,12 = 15.0, 3J11,10 = 11.0 Hz, 1H, 11-H), 
6.31 (d, 3J8,7 = 16.2 Hz, 1H, 8-H), 6.23 (d, 
3
J7,8 = 16.2 Hz, 1H, 7-H), 6.10 (d, 
3
J10,11 = 
11.0 Hz, 1H, 10-H), 5.74 (dd, 3J12,11 = 15.0, 
3
J12,13 = 7.7 Hz, 1H, 12-H), 2.86-2.76 (m, 
1H, 13-H), 2.49 (t, 3J3,2 = 6.8 Hz, 2H, 3-H), 2.34 (m, 2H, 14-H), 1.93 (s, 3H, 19-H), 
1.85 (t, 3J2,3 = 6.8 Hz, 2H, 2-H), 1.84 (s, 3H, 18-H), 1.18 (s, 6H, 16-H, 17-H), 1.10 (d, 
3
J20,13 = 6.8 Hz, 3H, 20-H). 
13
C NMR (100 MHz, CDCl3): δ = 199.5 (s, C-4), 172.9 (s, C-15), 161.6 (s, C-6), 141.3 
(d, C-8), 140.6 (d, C-12), 135.4 (s, C-5), 133.7 (d, C-10), 130 (s, C-9), 125.8 (d, C-11), 
124.1 (d, C-7), 41.7 (t, C-14), 37.6 (t, C-2), 36.0 (s, C-1), 34.5 (d, C-13), 34.4 (t, C-3), 
27.9 (q, C-16, C-17), 20.4 (q, C-20), 14.0 (q, C-18), 12.7 (q, C-19). 
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11-cis-75 
1
H NMR (400 MHz, CDCl3): δ = 6.43 (d, 3J10,11 = 11.7 Hz, 1H, 10-H), 6.35 (d, 3J8,7 = 
16.2 Hz, 1H, 8-H), 6.33 (t, 3J11,10 = 
3
J11,12 = 11.2 Hz, 1H, 11-H), 6.27 (d, 
3
J7,8 = 16.2 Hz, 
1H, 7-H), 5.38 (t, 3J12,11 = 
3
J12,13 = 10.4 Hz, 1H, 12-H), 3.27-3.16 (m, 1H, 13-H), 2.52 
(m, 2H, 3-H), 2.33 (m, 2H, 14-H), 1.93 (s, 3H, 19-H), 1.83 (m, 2H, 2-H), 1.86 (s, 3H, 
18-H), 1.19 (s, 6H, 16-H, 17-H), 1.07 ( d, 3J20,13 = 6.7 Hz, 3H, 20-H). 
13
C NMR (100 MHz, CDCl3): δ = 199.5 (s, C-4), 172.9 (s, C-15), 161.5 (s, C-6), 141.4 
(d, C-8), 140.6 (d, C-12), 137.9 (s, C-5), 130.1 (s, C-9), 128.2 (d, C-10), 124.7 (d, C-7), 
124.2 (d, C-11), 41.96 (t, C-14), 37.7 (t, C-2), 36.0 (s, C-1), 34.5 (t, C-3), 29.8 (d, C-
13), 27.9 (q, C-16, C-17), 21.1 (q, C-20), 14.0 (q, C-18), 12.5 (q, C-19). 
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9-cis-75 
1
H NMR (400 MHz, CDCl3): δ = 6.79 (d, 3J8,7 = 16.2 Hz, 1H, 8-H), 6.47 (dd, 3J11,12 = 
14.9, 3J11,10 = 11.2 Hz, 1H, 11-H), 6.25 (d, 
3
J7,8 = 16.2 Hz, 1H, 7-H), 6.04 (d, 
3
J10,11 = 
11.2 Hz, 1H, 10-H), 5.66 (dd, 3J12,11 = 14.9, 
3
J12,13 = 7.6 Hz, 1H, 12-H), 2.82-2.72 (m, 
1H, 13-H), 2.54-2.49 (m, 2H, 3-H), 2.36-2.25 (m, 2H, 14-H), 1.94 (s, 3H, 19-H), 1.88 
(s, 3H, 18-H), 1.87-1.84 (m, 2H, 2-H),1.19 (s, 6H, 16-H, 17-H), 1.09 (d, 3J20,13 = 6.8 Hz, 
3H, 20-H). 
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13
C NMR (100 MHz, CDCl3): δ = 199.3 (s, C-4), 172.7 (s, C-15), 161.3 (s, C-6), 139.2 
(d, C-12), 133.6 (s, C-5), 132.9 (d, C-8), 132.7 (d, C-10), 130.0 (s, C-9), 126.32 (d, C-
7), 125.2 (d, C-11), 41.4 (t, C-14), 37.3 (t, C-2), 35.7 (t, C-3), 34.3 (d, C-13), 34.1 (s, C-
1), 27.6 (q, C-16, C-17), 25.3 (q, C-20), 20.1 (q, C-19), 13.8 (q, C-18). 
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9,11-di-cis-75 
1
H NMR (400 MHz, CDCl3): δ = 6.82 (d, 3J8,7 = 16.2 Hz, 1H, 8-H), 6.38 (d, 3J10,11 = 
11.5 Hz, 1H, 10-H), 6.37 (t, 3J11,10 = 
3
J11,12 = 10.6 Hz, 1H, 11-H), 6.21 (d, 
3
J7,8 = 16.2 
Hz, 1H, 7-H), 5.30 (t, 3J12,11 = 
3
J12,13 = 9.7 Hz, 1H, 12-H), 3.16-3.28 (m, 1H, 13-H), 
2.54-2.49 (m, 2H, 3-H), 2.25-2.36 (m, 2H, 14-H), 2.05 (s, 3H, 19-H), 1.84-1.87 (m, 2H, 
2-H), 1.86 (s, 3H, 18-H), 1.18 (s, 6H, 16-H, 17-H), 1.06 (d, 3J20,13 = 6.7 Hz, 3H, 20-H). 
13
C NMR (100 MHz, CDCl3): δ = 199.3 (s, C-4), 172.7 (s, C-15), 161.4 (s, C-6), 136.6 
(d, C-12), 134.22 (d, C-8), 133.8 (s, C-5), 129.9 (s, C-9), 127.7 (d, C-10), 127.2 (d, C-
7), 123 (d, C-11), 41.7 (t, C-14), 37.3 (t, C-2), 34.1 (s, C-1), 35.7 (t, C-3), 29.2 (d, C-
13), 27.6 (q, C-16, C-17), 20.8 (q, C-20), 20.1 (q, C-19), 13.8 (q, C-18). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 330 (30) [M+], 315 (90) [M+-CH3], 299 (10), 283 (18), 265 
(17), 257 (15), 241 (27), 229 (20), 206 (40), 187 (20), 173 (30), 163 (100), 145 (30), 
137 (35), 133 (50), 121 (57), 199 (60), 109 (50), 95 (50), 91 (70), 77 (50), 67 (42), 55 
(45). 
IR (ATR): ν~ = 2958 cm-1 (m), 2924 (m), 2869 (s), 1736 (C=O, s), 1659 ( C=O, s), 
1582 (w), 1437 (m), 1351 (m), 1279 (m), 1197 (s), 969 (s). 
UV (EtOH): λmax (lg ε) = 255 nm (4.16), 314 (4.08). 
HRMS: C21H30O3 (330.47) calcd. 330.21948; found 330.21939 ± 1,1 ppm. 
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19-d3-4-Oxo-13,14-dihydro-retinoic acid methyl ester (89):  
General procedure 2 with LiHMDS [prepared from nBuLi (3.32 mL, 5.31 mmol) and 
HMDS (0.86 g, 1.11 mL, 5.31 mmol) in anhydrous THF (50 mL) at –78 °C], 66 (2.7 g, 
5.31 mmol), 86 (1.0 g, 4.25 mmol) in anhydrous THF (10 mL). Column 
chromatography with pentane/diethyl ether 5:1 on Alox (activity III, 8 % water w/w) 
gave 89 (0.45 g, 1.35 mmol, 32 %) as a yellow oil.  
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11-cis-89 9,11-di-cis-89 
1
H NMR (CDCl3): δ = 1.95-1.91 (s, partially deuterated CHD2, CH2D and undeuterated 
CH3, 19-H), all other signals correspond to 75. 
13
C NMR (CDCl3): δ = 20.1 and 19.0 (q, 9-cis- and 9,11-di-cis-89 partially deuterated 
C-19), 11.8 and 11.7 (q, all-trans- and 11-cis-89 partially deuterated C-19), all other 
signals correspond to 75. 
MS [EI, 70 eV]: m/z (%) = 333 (8) [M+, 4 % d3], 332 (20) [M
+, 14 % d2], 331 (40) [M
+, 
38 % d1], 330 (38) [M
+, 44 % d0], 315 (100), 299 (15), 283 (20), 265 (20), 257 (18), 241 
(37), 229 (23), 215 (25), 203 (30), 201 (30), 187 (30), 173 (40), 157 (43), 145 (43), 134 
(50), 129 (62), 119 (55), 105 (43), 95 (50), 91 (78), 77 (50), 69 (62), 55 (50), 43 (70). 
IR and UV spectra were identical with those of 75. 
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4-Oxo-13,14-dihydro-retinoic acid (11): 
Method A:  
General procedure 3 with KOH (747 mg, 13.3 mmol), 75 (440 mg, 1.33 mmol) in 
ethanol (10 mL) and water (5 mL) gave 11 (0.38 g, 1.2 mmol, 91 %) as a yellow oil. 
Ratio all-trans-, 11-cis-11: 1.25:1.0; 9-cis-, 9,11-di-cis-11: 1.0:1.2 or as all four isomers 
all-trans-, 11-cis-, 9-cis-, 9,11-di-cis-11 in 2.2:1.0:3.1:1.2 ratio. 
Method B:  
In a Schlenk tube, phosphonium salt 38 (1.75g, 3.16 mmol) was stirred under argon 
with KOtBu (0.44 g, 3.95 mmol) in anhydrous THF (45 mL) for 30 min, followed by 
addition of 43 (0.5 g, 3.16 mmol) in anhydrous THF (30 mL) and stirring of the reaction 
mixture overnight. After extraction with diethyl ether/water, the organic phase was 
dried with Na2SO4, and the solvents were evaporated. The product was purified by 
column chromatography on Alox with pentane/diethyl ether 4:1 (Rf = 0.28) and further 
saponified with KOH in ethanol/water at 70 °C for 3 h to give 11 (70 mg, 0.22 mmol, 7 
%) in all-trans-, 9-cis-, 11-cis-, 9,11-di-cis-ratio = 8.0:1.5:2.0:1.0, determined by 1H 
NMR analysis. 
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all-trans-11 
1
H NMR (MeOH-d4): δ = 6.49 (dd, 3J11,12 = 15.0 Hz, 3J11,10 = 11.0 Hz, 1H, 11-H), 6.34 
(d, 3J8,7 = 16.2 Hz, 1H, 8-H), 6.27 (d, 
3
J7,8 = 16.2 Hz, 1H, 7-H), 6.15 (d, 
3
J10,11 = 11.0 
Hz, 1H, 10-H), 5.78 (dd, 3J12,11 = 15.0, 
3
J12,13 = 7.7 Hz, 1H, 12-H), 2.76 (m, 1H, 13-H), 
2.49 (t, 3J3,2 = 6.9 Hz, 2H, 3-H), 2.35 (dd, 
2
J14,14 = 14.9, 
3
J14,13 = 7.4 Hz, 1H, 14-H), 2.31 
(dd, 2J14,14 = 14.9, 
3
J14,13 = 7.1 Hz, 1H, 14-H), 1.94 (s, 3H, 19-H), 1.86 (t, 
3
J2,3 = 6.9 Hz, 
2H, 2-H), 1.81 (s, 3H, 18-H), 1.20 (s, 6H, 16-H, 17-H), 1.11 (d, 3J20,13 = 6.9 Hz, 3H, 20-
H). 
13
C NMR (MeOH-d4): δ = 201.5 (s, C-4), 175.9 (s, C-15), 164.3 (s, C-6), 142.7 (d, C-
8), 141.8 (d, C-12), 134.7 (d, C-10), 134.3 (s, C-5), 130.22 (s, C-9), 126.6 (d, C-11), 
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124.6 (d, C-7), 42.4 (t, C-14), 38.3 (t, C-2), 36.9 (s, C-1), 35.4 (d, C-13), 35.1 (t, C-3), 
27.9 (q, C-16, C-17), 20.6 (q,C-20), 14.0 (q, C-18), 12.3 (q, C-19). 
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11-cis-11 
1
H NMR (MeOH-d4): δ = 6.52 (d, 3J10,11 = 11.4 Hz, 1H, 10-H), 6.41 (d, 3J8,7 = 16.2 Hz, 
1H, 8-H), 6.37 (t, 3J11,10 = 
3
J11,12 = 11.5 Hz, 1H, 11-H), 6.32 (d, 
3
J7,8 = 16.2 Hz, 1H, 7-
H), 5.42 (t, 3J12,11 = 10.5 Hz, 1H, 12-H), 3.18-3.23 (m, 1H, 13-H), 2.50 (t, 
3
J3,2 = 7.0 Hz, 
2H, 3-H), 2.34 (dd, 2J14,14 = 15.7, 
3
J14,13 = 7.2 Hz, 1H, 14-H), 2.30 (dd, 
2
J14,14 = 15.7, 
3
J14,13 = 6.3 Hz, 1H, 14-H), 1.94 (s, 3H, 19-H), 1.87 (t, 
3
J2,3 = 7.0 Hz, 2H, 2-H), 1.82 (s, 
3H, 18-H), 1.21 (s, 6H, 16-H, 17-H), 1.14 (d, 3J20,13 = 6.2 Hz, 3H, 20-H). 
13
C NMR (MeOH-d4): δ = 201.4 (s, C-4), 175.9 (s, C-15), 164.2 (s, C-6), 142.7 (d, C-
8), 139.1 (d, C-12), 136.0 (s, C-5), 130.3 (s, C-9), 129.4 (d, C-10), 125.2 (d, C-7), 124.8 
(d, C-11), 42.7 (t, C-14), 38.3 (t, C-2), 36.9 (s, C-1), 35.1 (t, C-3), 30.7 (d, C-13), 27.9 
(q, C-16, C-17), 21.2 (q, C-20), 14.0 (q, C-18), 12.25 (q, C-19). 
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9-cis-11 
1
H NMR (MeOH-d4): δ = 6.82 (d, 3J8,7 = 16.2 Hz, 1H, 8-H), 6.52 (dd, 3J11,12 = 14.9, 
3
J11,10 = 11.2 Hz, 1H, 11-H), 6.24 (d, 
3
J7,8 = 16.2 Hz, 1H, 7-H), 6.09 (d, 
3
J10,11 = 11.2 
Hz, 1H, 10-H), 5.68 (dd, 3J12,11 = 14.9, 
3
J12,13 = 7.6 Hz, 1H, 12-H), 2.72 (m, 1H, 13-H), 
2.51 (t, 3J3,2 = 6.9 Hz, 2H, 3-H), 2.32 (dd, 
2
J14,14 = 15.0, 
3
J14,13 = 7.4 Hz, 1H, 14-H), 2.30 
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(dd, 2J14,14 = 15.0, 
3
J14,13 = 7.1 Hz, 1H, 14-H), 1.95 (s, 3H, 19-H), 1.88 (t, 
3
J2,3 = 6.9 Hz, 
2H, 2-H), 1.85 (s, 3H, 18-H), 1.21 (s, 6H, 16-H, 17-H), 1.14 (d, 3J20,13 = 6.2 Hz, 3H, 20-
H). 
13
C NMR (MeOH-d4): δ = 201.5 (s, C-4), 176.0 (s, C-15), 164.3 (s, C-6), 140.4 (d, C-
12), 134.4 (d, C-8), 133.0 (s, C-5), 132.6 (d, C-10), 130.5 (s, C-9), 126.3 (d, C-7), 125.2 
(d, C-11), 42.2 (t, C-14), 38.2 (t, C-2), 36.8 (s, C-1), 35.2 (d, C-13), 35.0 (t, C-3), 27.9 
(q, C-16, C-17), 25.3 (q, C-20), 20.3 (q, C-19), 14.5 (q, C-18). 
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9,11-di-cis-11 
1
H NMR (MeOH-d4): δ = 6.86 (d, 3J8,7 = 16.2 Hz, 1H, 8-H), 6.57 (d, 3J10,11 = 11.5 Hz, 
1H, 10-H), 6.37 (t, 3J11,10 = 
3
J11,12 = 11.5 Hz, 1H, 11-H), 6.32 (d, 
3
J7,8 = 16.2 Hz, 1H, 7-
H), 5.25 (t, 3J12,11 = 
3
J12,13 = 10.8 Hz, 1H, 12-H), 3.1 (m, 1H, 13-H), 2.41 (t, 
3
J3,2 = 6.9 
Hz, 2H, 3-H), 2.21 (dd, 2J14,14 = 14.7, 
3
J14,13 = 6.9 Hz, 1H, 14-H), 2.16 (dd, 
2
J14,14 = 
14.7, 3J14,13 = 7.3 Hz, 1H, 14-H), 2.01 (s, 3H, 19-H), 1.89 (t, 
3
J2,3 = 6.9 Hz, 2H, 2-H), 
1.84 (s, 3H, 18-H), 1.21 (s, 6H, 16-H, 17-H), 1.03 (d, 3J20,13 = 6.7 Hz, 3H, 20-H). 
13
C NMR (MeOH-d4): δ = 201.7 (s, C-4), 175.9 (s, C-15), 164.3 (s, C-6), 138.1 (d, C-
12), 134.5 (s, C-5), 134.2 (d, C-8), 130.7 (s, C-9), 127.7 (d, C-10), 127.2 (d, C-7), 123.5 
(d, C-11), 42.7 (t, C-14), 38.3 (t, C-2), 36.8 (s, C-1), 35.1 (t, C-3), 30.7 (d, C-13), 27.9 
(q, C-16, C-17), 21.1 (q, C-20), 20.3 (q, C-19), 14.0 (q, C-18). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 316 [M+] (65), 301 (100), 283 (40), 265 (27), 261 (30), 247 
(33), 241 (45), 229 (30), 215 (40), 201 (30), 187 (37), 173 (55), 159 (45), 145 (45), 133 
(40), 119 (43), 105 (39), 91 (58), 77 (38), 69 (47), 55 (40). 
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IR (ATR): ν~ = 3431 cm-1 (br, OH), 2965 (m), 2930 (m), 2873 (w), 1779 (m), 1731 (s, 
C=O), 1661 (s, C=O), 1456 (w), 1375 (m), 1333 (m), 1199 (m), 1144 (m), 1089 (m), 
973 (m). 
UV (EtOH): λmax (lg ε) = 256 nm (4.32), 332 (4.28). 
HRMS: C20H28O3 (316.44) calc: 316.20345; found: 316.20366 ± 1.45 ppm. 
 
19-d3-4-Oxo-13,14-dihydro-retinoic acid (90):  
General procedure 3 with 89 (450 mg, 1.35 mmol), KOH (0.76 g, 13.5 mmol) in ethanol 
(10 mL) and water (5 mL) gave 90 in 75 % yield (0.32 g, 1 mmol). 
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11-cis-90 9,11-di-cis-90 
1
H NMR (MeOH-d4): δ = 1.95-1.92 (partially deuterated CHD2, CH2D and 
undeuterated CH3, 19-H), all other signals correspond to 11. 
13
C NMR (MeOH-d4): δ = 20.6, 20.2 (q, 9-cis- and 9,11-di-cis-90 partially deuterated 
CHD2, CH2D and undeuterated CH3, C-19), 12.4, 12.2 (q, all-trans- and 11-cis-90 
partially deuterated CHD2, CH2D and undeuterated CH3, C-19), all other signals 
correspond to 11. 
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MS [EI, 70 eV]: m/z (%) = 319 (8) [M+, 4 % d3], 318 (15) [M
+, 13 % d2], 317 (40) [M
+, 
37 % d1], 316 (36) [M
+, 46 % d0], 301 (78), 283 (38), 265 (20), 257 (10), 241 (40), 231 
(25), 215 (20), 201 (30), 187 (30), 173 (42), 159 (40), 145 (44), 129 (50), 119 (50), 105 
(47), 91 (72), 77 (57), 69 (58), 55 (50), 43 (75), 41 (100). 
IR and UV spectra were identical with those of 11. 
 
13-Phenyl-13,14-dihydro-retinoic acid methyl ester (78):  
General procedure 2 with LiHMDS [prepared from nBuLi (1.78 mL, 2.84 mmol) and 
HMDS (0.46 g, 0.59 mL, 2.84 mmol)], 73 (1.61 g, 2.84 mmol) in anhydrous THF (20 
mL), 47 (0.5 g, 2.27 mmol) in anhydrous THF (10 mL). Column chromatography on 
Alox (8 % water w/w, activity III) with pentane (Rf = 0.65) gave 78 in 85 % yield (0.73 
g, 1.93 mmol). Isomer ratio: all-trans-, 9-cis-, 11-cis-, 9,11-di-cis-78 = 2.15:1.0:3.7:1.1 
(by 1H NMR analysis). 
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all-trans-78 
1
H NMR (CDCl3): δ = 7.40-7.16 (m, Ar), 6.45 (dd, 3J11,12 = 15.0 , 3J11,10 = 12.0 Hz, 1H, 
11-H), 6.14 (d, 3J8,7 = 16.1 Hz, 1H, 8-H), 6.12 (d, 
3
J7,8 = 16.1 Hz, 1H, 7-H), 5.99 (d, 
3
J10,11 = 12.0 Hz, 1H, 10-H), 5.83 (dd, 
3
J12,11 = 15.0, 
3
J12,13 = 7.8 Hz, 1H, 12-H), 3.96 
(dd, 3J13,12 = 7.8, 
3
J13,14 = 6.9 Hz, 1H, 13-H), 3.62 (s, 3H, COOCH3), 2.77 (d, 
3
J14,13 = 
6.9 Hz, 2H, 14-H), 2.02 (t, 3J3,4 = 6.0 Hz, 2H, 4-H), 1.87 (s, 3H, 19-H), 1.67 (s, 3H, 18-
H), 1.65-1.56 (m, 2H, 3-H), 1.50-1.43 (m, 2H, 2-H), 1.03 (s, 6H, 16-H, 17-H). 
13
C NMR (CDCl3): δ = 172.2 (s, C-15), 137.8 (s, C-6), 137.6 (d, C-5), 135.3 (d, C-12), 
130.0 (d, C-8), 129.3 (s, C-9), 129.1 (d, C-10), 129.0-126.0 (Ar), 126.5 (d, C-7), 125.0 
(d, C-11), 51.6 (q, COOCH3), 45.1 (d, C-13), 41.3 (t, C-14), 39.5 (t, C-2), 34.2 (s, C-1), 
33.0 (t, C-4), 28.9 (q, C-16, C-17), 21.7 (q, C-18), 19.3 (t, C-3), 12.6 (q, C-19). 
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11-cis-78 
1
H NMR (CDCl3): δ = 7.40-7.16 (m, Ar), 6.48 (d, 3J10,11 = 11.0 Hz, 1H, 10-H), 6.40 (t, 
3
J11,10 = 
3
J11,12 = 11.5 Hz, 1H, 11-H), 6.16 (d, 
3
J8,7 = 16.2 Hz, 1H, 8-H), 6.02 (d, 
3
J7,8 = 
16.2 Hz, 1H, 7-H), 5.56 (t, 3J12,11 = 
3
J12,13 = 9.8 Hz, 1H, 12-H), 4.40-4.34 (m, 1H, 13-H), 
3.59 (s, 3H, COOCH3), 2.71-2.65 (m, 2H, 14-H), 2.02 (t, 
3
J4,3 = 6.0 Hz, 2H, 4-H), 1.90 
(s, 3H, 19-H), 1.72 (s, 3H, 18-H), 1.62-1.56 (m, 2H, 3-H), 1.50-1.43 (m, 2H, 2-H), 1.03 
(s, 6H, 16-H, 17-H). 
13
C NMR (CDCl3): δ = 172.1 (s, C-15), 137.8 (s, C-6), 137.2 (d, C-5), 132.5 (d, C-12), 
129.3 (s, C-9), 129.0-126.0 (Ar), 127.7 (d, C-8), 127.0 (d, C-10), 126.6 (d, C-7), 125.0 
(d, C-11), 51.6 (q, COOCH3), 41.3 (t, C-14), 40.1 (d, C-13), 39.5 (t, C-2), 34.2 (s, C-1), 
33.0 (t, C-4), 28.9 (q, C-16, C-17), 21.7 (q, C-18), 19.3 (t, C-3), 12.4 (q, C-19). 
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9-cis-78 
1
H NMR (CDCl3): δ = 7.40-7.16 (m, Ar), 6.59 (d, 3J8,7 = 15.9 Hz, 1H, 8-H), 6.55 (dd, 
3
J11,12 = 15.0, 
3
J11,10 = 11.4 Hz, 1H, 11-H), 6.21 (d, 
3
J7,8 = 16.0 Hz, 1H, 7-H), 5.89 (d, 
3
J10,11 = 11.4 Hz, 1H, 10-H), 5.76 (dd, 
3
J12,11 = 15.0, 
3
J12,13 = 7.7 Hz, 1H, 12-H), 3.98-
3.91 (m, 1H, 13-H), 3.62 (s, 3H, COOCH3), 2.74-2.72 (m, 2H, 14-H), 2.02 (t, 
3
J4,3 = 6.0 
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Hz, 2H, 4-H), 1.90 (s, 3H, 19-H), 1.70 (s, 3H, 18-H), 1.65-1.56 (m, 2H, 3-H), 1.50-1.43 
(m, 2H, 2-H), 1.03 (s, 6H, 16-H, 17-H). 
13
C NMR (CDCl3): δ = 172.2 (s, C-15), 137.8 (s, C-6), 135.7 (d, C-5), 134.4 (d, C-12), 
129.4 (s, C-9), 129.0-126.0 (Ar), 127.5 (d, C-10), 126.7 (d, C-7), 126.0 (d, C-8), 125.9 
(d, C-11), 51.6 (q, COOCH3), 45.1 (d, C-13), 41.3 (t, C-14), 39.5 (t, C-2), 34.2 (s, C-1), 
33.0 (t, C-4), 28.9 (q, C-16, C-17), 21.7 (q, C-18), 20.9 (q, C-19), 19.3 (t, C-3). 
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9,11-di-cis-78 
1
H NMR (CDCl3): δ = 7.40-7.16 (m, Ar), 6.54 (d, 3J8,7 = 16.1 Hz, 1H, 8-H), 6.51 (t, 
3
J11,10 = 
3
J11,12 = 11.3 Hz, 1H, 11-H), 6.32 (d, 
3
J10,11 = 12.1 Hz, 1H, 10-H), 6.14 (d, 
3
J7,8 
= 16.1 Hz, 1H, 7-H), 5.49 (t, 3J12,11 = 10.5 Hz, 1H, 12-H), 4.40-4.34 (m, 1H, 13-H), 3.62 
(s, 3H, COOCH3), 2.82-2.79 (m, 2H, 14-H), 2.02 (t, 
3
J4,3 = 6.0 Hz, 2H, 4-H), 1.90 (s, 
3H, 19-H), 1.72 (s, 3H, 18-H), 1.65-1.56 (m, 2H, 3-H), 1.50-1.43 (m, 2H, 2-H), 1.03 (s, 
6H, 16-H, 17-H). 
13
C NMR (CDCl3): δ = 172.1 (s, C-15), 137.8 (s, C-6), 132.5 (d, C-12), 134.0 (d, C-5), 
130.0 (d, C-8), 129.4 (s, C-9), 129.0-126.0 (Ar), 127.0 (d, C-7), 126.0 (d, C-11), 122.5 
(d, C-10), 51.6 (q, COOCH3), 41.3 (t, C-14), 40.1 (d, C-13), 39.5 (t, C-2), 34.2 (s, C-1), 
33.0 (t, C-4), 28.9 (q, C-16, C-17), 21.7 (q, C-18), 20.9 (q, C-19), 19.3 (t, C-3). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 378 (15) [M+], 363, 338, 305 (10), 277, 219 (10), 192 (14), 
177 (85), 162 (32), 149 (23), 131 (70), 123 (100), 121 (80), 104 (70), 91 (72), 77 (83), 
51 (38). 
UV (HPLC, MeOH/H2O 90:10): λmax = 295 nm. 
IR (ATR): ν~ = 3061 cm-1 (w), 3029 (m), 2953 (m), 2928 (m), 2864 (m), 2827 (w), 
1740 (s, C=O), 1494 (m), 1451 (m), 1437 (m), 1359 (w), 1253 (m), 1204 (m), 1161 (m), 
1027 (w), 968 (m), 752 (m), 699 (m). 
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HRMS: C26H34O2 (378.55) calcd. 378.25589; found 378.25615 ± 1.58 ppm. 
 
13-Phenyl-13,14-dihydro-retinoic acid (82):  
General procedure 3 with 78 (0.4 g, 1.02 mmol), KOH (0.57 g, 10.2 mmol) in ethanol 
(10 mL) and water (5 mL) gave 82 as a yellow oil in 97 % yield (0.37 mg, 0.98 mmol). 
The NMR spectra show no or minimal chemical shift differences between ester 78 and 
acid 82, for this reason a detailed assignement of each isomer is not given, the structure 
was assigned by MS-, IR- and UV analysis.  
MS [EI, 70 eV]: m/z (%) = 364 (85) [M+], 349 (15), 321 (10), 305 (30), 279 (10), 231 
(20), 215 (60), 187 (20), 173 (20), 165 (30), 159 (57), 145 (50), 129 (50), 119 (52), 107 
(76), 91 (100), 77 (58), 69 (42), 55 (37), 45 (25). 
UV (HPLC, CH3CN/H2O 80:20): λmax = 348 nm. 
IR (ATR): ν~ = 3401 cm-1 (br. COOH, w), 3062 (w), 3031 (w), 2961 (m), 2931 (m), 
2869 (m), 1708 (C=O, s), 1635 (m), 1495 (w), 1452 (m), 1375 (m), 1256 (m), 1201 (s), 
1161 (s), 1079 (m), 1030 (m), 968 (m), 760 (m), 701 (s). 
HRMS: C25H32O2 (364.53) calcd. 364.24023; found 364.23968 ± 1.86 ppm. 
 
4-Oxo-13-phenyl-13,14-dihydro-retinoic acid methyl ester (79):  
General procedure 2 with LiHMDS [prepared from nBuLi (1.67 mL, 2.67 mmol) and 
HMDS (0.43 g, 0.56 mL, 2.67 mmol)], 73 (1.512 g, 2.67 mmol) in anhydrous THF (20 
mL), 53 (0.5 g, 2.137 mmol) in anhydrous THF (10 mL). Column chromatography on 
Alox (8 % water w/w, activity III) with pentane/diethyl ether 3:1 (Rf = 0.24) gave 79 as 
a yellow oil in 82 % yield (0.161 g, 0.41 mmol). 
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all-trans-79 
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1
H NMR (CDCl3): δ = 7.35-7.18 (m, Ar), 6.46 (dd, 3J11,12 ≈  15, 3J11,10 ≈  11 Hz, 1H, 11-
H), 6.23 (s, 2H, 7-H, 8-H), 6.14 (d, 3J10,11 
≈  11 Hz, 1H, 10-H), 5.93 (dd, 3J12,11 
≈  15, 
3
J12,13 = 7.7 Hz, 1H, 12-H), 4.01-3.94 (m, 1H, 13-H), 3.63 (s, 3H, COOCH3), 2.79-2.77 
(m, 2H, 14-H), 2.49 (t, 3J3,2 ≈ 7 Hz, 2H, 3-H), 1.90 (s, 3H, 19-H), 1.87 ( t, 
3
J2,3 
≈  7 Hz, 
2H, 2-H), 1.82 (s, 3H, 18-H), 1.16 (s, 6H, 16-H, 17-H). 
13
C NMR (CDCl3): δ = 199.3 (s, C-4), 172.0 (s, C-15), 161.3 (s, C-6), 141.0 (d, C-8), 
137.7 (d, C-12), 136.0 (d, C-5), 134.1 (d, C-10), 129.8 (s, C-9), 128.7-126.7 (Ar), 126.8 
(d, C-11), 124.8 (d, C-7), 51.5 (q, COOCH3), 40.5 (t, C-14), 39.8 (d, C-13), 37.4 (t, C-
2), 35.7 (s, C-1), 34.3 (t, C-3), 27.6 (q, C-16, C-17), 13.8 (q, C-18), 12.4 (q, C-19). 
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11-cis-79 
1
H NMR (CDCl3): δ = 7.35-7.18 (m, Ar), 6.53 (d, 3J10,11 ≈  11 Hz, 1H, 10-H), 6.43 (d, 
3
J8,7 
≈  16 Hz, 1H, 8-H), 6.38 (t, 3J11,10 
≈  3J11,12 
≈  11 Hz, 1H, 11-H), 6.36 (d, 3J7,8 
≈  16 
Hz, 1H, 7-H), 5.68 (t, 3J12,11 = 
3
J12,13 = 10.5 Hz, 1H, 12-H), 4.41-4.35 (m, 1H, 13-H), 
3.60 (s, 3H, COOCH3), 2.79-2.77 (m, 2H, 14-H), 2.53 (t, 
3
J3,2 
≈  7 Hz, 2H, 3-H), 1.91 (s, 
3H, 19-H), 1.87 (t, 3J2,3 
≈  7 Hz, 2H, 2-H), 1.84 (s, 3H, 18-H), 1.16 (s, 6H, 16-H, 17-H). 
13
C NMR (CDCl3): δ = 199.34 (s, C-4), 172.1 (s, C-15), 161.2 (s, C-6), 140.9 (d, C-8), 
136.0 (s, C-5), 134.5 (d, C-12), 129.8 (s, C-9), 128.7 (d, C-10), 128.7-126.7 (Ar), 125.4 
(d, C-7), 124.8 (d, C-11), 51.6 (q, COOCH3), 41.1 (t, C-14), 39.8 (d, C-13), 37.3 (t, C-
2), 35.7 (s, C-1), 34.3 (t, C-3), 27.6 (q, C-16, C-17), 13.8 (q, C-18), 12.3 ( q, C-19). 
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9-cis-79 
1
H NMR (CDCl3): δ = 7.35-7.18 (m, Ar), 6.75 (d, 3J8,7 ≈  16 Hz, 1H, 8-H), 6.47 (dd, 
3
J11,12 
≈  15, 3J11,10 
≈  11 Hz, 1H, 11-H), 6.19 (d, 3J7,8 
≈ 16 Hz, 1H, 7-H), 6.08 (d, 3J10,11 
≈  
11 Hz, 1H, 10-H), 5.87 (dd, 3J12,11 
≈  15, 3J12,13 
≈  7 Hz, 1H, 12-H), 4.01-3.97 (m, 1H, 13-
H), 3.61 (s, COOCH3), 2.79-2.77 (m, 2H, 14-H), 2.50 (t, 
3
J3,2 
≈  7 Hz, 2H, 3-H), 1.91 (s, 
3H, 19-H), 1.85 (t, 3J2,3 
≈  7 Hz, 2H, 2-H), 1.84 (s, 3H, 18-H), 1.16 (s, 6H, 16-H, 17-H). 
13
C NMR (CDCl3): δ = 199.4 (s, C-4), 172.1 (s, C-15), 161.2 (s, C-6), 137.7 (d, C-12), 
134.1 (d, C-8), 133.6 (s, C-5), 132.8 (d, C-10), 129.9 (s, C-9), 128.7-126.7 (Ar), 126.7 
(d, C-7), 125.8 (d, C-11), 51.6 (q, COOCH3), 40.5 (t, C-14), 39.8 (d, C-13), 37.3 (t, C-
3), 35.7 (s, C-1), 34.3 (t, C-2), 27.6 (q, C-16, C-17), 20.1 (q, C-19), 15.3 (q, C-18). 
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9,11-di-cis-79 
1
H NMR (CDCl3): δ = 7.35-7.18 (m, 5H, Ar), 6.80 (d, 3J8,7 = 16.3 Hz, 1H, 8-H), 6.53 
(d, 3J10,11 = 11.5 Hz, 1H, 10-H), 6.35 (t, 
3
J11,10 = 
3
J11,12 = 11.5 Hz, 1H, 11-H), 6.27 (d, 
3
J7,8 = 16.3 Hz, 1H, 7-H), 5.59 (t, 
3
J12,11 
≈  3J12,13 
≈  11 Hz, 1H, 12-H), 4.41-4.35 (m, 1H, 
13-H), 3.61 (s, 3H, COOCH3), 2.51 (t, 
3
J3,2 
≈  7 Hz, 2H, 3-H), 2.74-2.71 (m, 2H, 14-H), 
2.01 (s, 3H, 19-H), 1.85 (t, 3J2,3 
≈  7 Hz, 2H, 2-H), 1.84 (s, 3H, 18-H), 1.16 (s, 6H, 16-H, 
17-H). 
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13
C NMR (CDCl3): δ = 199.4 (s, C-4), 172.1 (s, C-15), 161.4 (s, C-6), 136.7 (d, C-12), 
133.6 (s, C-5), 132.8 (d, C-8), 129.9 (s, C-9), 128.7 (d, C-10), 127.5 (d, C-7), 124.2 (d, 
C-11), 51.6 (q, COOCH3), 41.2 (t, C-14), 39.8 (d, C-13), 37.3 (t, C-2), 35.7 (s, C-1), 
34.3 (t, C-3), 27.6 (q, C-16, C-17), 20.7 (q, C-19), 13.7 (q, C-18). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 392 (60) [M+], 377 (90) [M+-CH3], 352 (10), 327 (10), 319 
(20), 303 (22), 285 (30), 245 (15), 229 (45), 215 (20), 203 (70), 173 (33), 145 (30), 133 
(90), 121 (70), 105 (50), 91 (100), 77 (54), 69 (30), 51 (30) 
UV (HPLC, hex/iPrOH 90:10): λmax = 246, 317 nm.  
IR (ATR): ν~ = 3029 cm-1 (w), 2957 (m), 2925 (m), 2866 (w), 1736 (C=O, s), 1658 
(C=O, s), 1582 (m), 1494 (w), 1437 (m), 1352 (m), 1310 (m), 1279 (m), 1197 (m), 1092 
(m), 968 (s), 755 (m), 699 (s). 
HRMS: C26H32O3 (392.54) calcd. 392.2351; found 392.23404 ± 1.27 ppm. 
 
4-Oxo-13-phenyl-13,14-dihydro-retinoic acid (83):  
General procedure 3 with 79 (0.25 g, 0.66 mmol), KOH (0.37 g, 6.6 mmol) in ethanol (5 
mL) and water (3 mL) gave 83 in 92 % yield (0.23 g, 0.61 mmol). The NMR spectra 
show no or minimal chemical shift difference between ester 79 and acid 83, for this 
reason a detailed assignment of each isomer is not given, the structure was assigned by 
low and high resolution MS spectrometry, and IR- and UV-analysis.  
MS [EI, 70 eV]: m/z (%) = 378 (50) [M+], 363 (80) [M+-CH3], 345 (10), 319 (12), 303 
(30), 285 (25), 261 (53), 247 (15), 229 (47), 215 (40), 201 (30), 173 (42), 133 (50), 115 
(57), 91 (100), 77 (50), 69 (48), 51 (30), 43 (60). 
UV (HPLC, CH3CH/H2O 80:20): λmax = 260, 326 nm.  
IR (ATR): ν~ = 3400 cm-1 (br, COOH), 3030 (m), 2965 (s), 2930 (s), 2870 (m), 1711 (s, 
C=O), 1658 (s, C=O), 1494 (m), 1356 (m), 1336 (m), 1201 (m), 1094 (m), 1033 (m), 
971 (m), 760 (m), 701 (m).  
HRMS: C25H30O3 (378.51) calcd. 378.21949; found 378.21946 ± 2.43 ppm. 
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13-Isopropyl-13,14-dihydro-retinoic acid methyl ester (31):  
General procedure 2 with LiHMDS prepared from nBuLi (1.77 mL, 2.83 mmol) and 
HMDS (0.46 g, 0.59 mL, 2.83 mmol)], 72 (1.51 g, 2.83 mmol) in anhydrous THF (30 
mL), 47 (0.5 g, 2.26 mmol) in anhydrous THF (20 mL). Column chromatography on 
Alox (8 % water w/w, activity III) with pentane/diethyl ether 10:1 (Rf = 0.63) gave 31 
(25 mg, 0.07 mmol, 3 %). This RA derivative was much more labile than the others 
synthesized in this study. During spectroscopic analysis it underwent decomposition. 
Assignement of the 1H and 13C chemical shifts to each isomer was not possible from the 
NMR sprectra of the isomeric mixture. 
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31 
MS [GC-MS]: m/z (%) = 344 (100) [M+], 329 (20), 301 (73), 271 (17), 255 (10), 245 
(10), 227 (37), 215 (20), 187 (28), 171 (25), 157 (38), 145 (40), 119 (45), 105 (35), 93 
(25), 69 (55), 55 (35). 
GC-HRMS: C23H36O2 (344.54) calcd. 344.2715; found 344.2740  
 
4-Oxo-13-isopropyl-13,14-dihydro-retinoic acid methyl ester (76):  
General procedure 2 with LiHMDS [prepared from nBuLi (1.69 mL, 2.7 mmol) and 
HMDS (0.44 g, 0.56 mL, 2.7 mmol)], 72 (1.44 g, 2.7 mmol) in anhydrous THF (30 
mL), 53 (0.5 g, 2.16 mmol) in anhydrous THF (10 mL). Column chromatography on 
Alox (8 % water w/w, activity III) with pentane/diethyl ether (Rf = 0.17) gave 76 (22.3 
mg, 0.07 mmol, 3 %). This RA derivative was much more labile than the others 
synthesized in this work. During spectroscopic analysis it underwent decomposition and 
for this reason detailed spectroscopic investigations were impossible.  
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31 
MS [GC-MS]: m/z (%) = 358 (50) [M+], 343 (100), 311 (20), 283 (45), 255 (30), 241 
(55), 229 (30), 215 (90), 203 (75), 171 (55), 157 (70), 145 (50), 133 (70), 105 (50), 91 
(40), 69 (80), 55 (50). 
IR (ATR): ν~ = 2960-2871 cm-1 (w), 1739 (s), 1664 (s), 1584 (w), 1438 (m), 1334 (m), 
1141 (m), 971 (m), 884 (w). 
 
Vinyl-β-ionol (35):  
In a three-necked flask was dissolved 22 (20 g, 104 mmol, 21.2 mL), in anhydrous THF 
(350 mL). After cooling to 0 °C, vinylmagnesium bromide (15.66 g, 180 mmol, 180 mL 
1M solution in THF) was added dropwise during 1 h. Stirring was continued at room 
temp. overnight. The solution was poured into ice-cold aqueous NH4Cl and extracted 
with diethyl ether. The combined organic extracts were washed with saturated NaHCO3 
and brine solution and then dried with Na2SO4. Concentration under reduced pressure 
and bulb to bulb distillation at 89 °C/0.35 mmHg afforded 35 as a colorless oil (19.5 g, 
88 mmol, 80 %, lit.76 yield: 94 %, b.p. 110 °C/1.4 mmHg). Rf (pentane/diethyl ether 
6:1) = 0.49. 
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35 
1
H NMR (CDCl3): δ = 6.08 (d, 3J7,8 = 16.2 Hz, 1H, 7-H), 6.01 (dd, 3J10,11 = 17.3, 
3
J10,11= 10.6 Hz, 1H, 10-H), 5.54 (d, 
3
J8,7 = 16.2 Hz, 1H, 8-H), 5.26 (d, 
3
J11,10 = 17.3 Hz, 
1H, 11-H), 5.07 (d, 3J11,10 = 10.6 Hz, 1H, 11-H), 1.97 (t, 
3
J4,3 = 6.0 Hz, 2H, 4-H), 1.65 
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(s, 3H, 14-H), 1.56-1.63 (m, 2H, 3-H), 1.42 (s, 3H, 15-H), 1.40-1.47 (m, 2H, 2-H), 0.98 
(s, 6H, 12-H, 13-H). 
13
C NMR (CDCl3): δ = 144.3 (d, C-10), 141.9 (s, C-6), 138.9 (d, C-8), 136.8 (s, C-5), 
125.7 (d, C-7), 112.0 (t, C-11), 73.5 (s, C-9), 39.2 (t, C-2), 34.0 (s, C-1), 32.6 (t, C-4), 
28.7 (q, C-12, C-13), 28.0 (q, C-15), 21.3 (q, C-14), 19.2 (t, C-3). 
MS [GC-MS]: m/z (%) = 220 (20) [M+], 202 (80) [M+-H2O], 187 (60) [M
+-H2O-CH3], 
177 (10), 159 (40), 146 (60), 131 (100), 117 (68), 105 (60), 91 (65), 81 (55), 69 (37), 55 
(40), 41 (34). 
IR (ATR): ν~ = 3379 cm-1 (br, OH), 2962 (m), 2926 (m), 2864 (m), 2827 (w), 1454 (m), 
1409 (w), 1360 (m), 1099 (w), 993 (s), 974 (s), 917 (s), 678 (m).  
UV (CHCl3): λmax (lg ε) = 241 nm (3.70), 318 (3.98), 332 (3.87). 
 
β-Ionylidene-ethyl-triphenylphosphonium bromide (37):  
In a Schlenk flask was suspended PPh3HBr (24.47 g, 71.31 mmol) in anhydrous 
methanol (200 mL). A solution of 35 (15.91 g, 71.31 mmol) in anhydrous methanol 
(200 mL) was added dropwise during 30 min. Stirring was continued at room temp. for 
75 h and the solution was concentrated under reduced pressure and high vacuum to give 
a viscous oil. Crystallization from acetone/hexane and further washing with pentane 
afforded 37 (38.33 g, 70.1 mmol, 98 %, lit.74 yield: 64 %) as a yellow solid. (m.p. 135-
137 °C, lit.74 m.p.:135-137 °C). 
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37 
1
H NMR (CDCl3): δ = 7.89-7.66 (m, 15H, Ar), 6.02 (d, 3J7,8 = 16.6 Hz, 1H, 7-H), 5.92 
(d, 3J8,7 = 16.6 Hz, 1H, 8-H), 5.32 (q, 
3
J10,11 = 
3
J10,P = 7.6 Hz, 1H, 10-H), 4.85 (dd, 
2
J11,P 
= 15.5, 3J11,10 = 7.6 Hz, 2H, 11-H), 2.17 (s, 3H, 15-H), 1.97 (t, 
3
J4,3 = 6.0 Hz, 2H, 4-H), 
1.61 (s, 3H, 14-H), 1.60-1.55 (m, 2H, 3-H), 1.44-1.39 (m, 2H, 2-H), 0.94 (s, 6H, 11-H, 
13-H). 
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13
C NMR (CDCl3): δ = 143.9 (s, JC,P = 6 Hz, C-6), 137.1 (s, JC,P = 2 Hz, C-5), 135.5 (d, 
JC,P = 6 Hz, C-8), 134.9 (d, JC,P = 3 Hz, C-19), 133.9 (d, JC,P = 10 Hz, C-18), 130.3 (d, 
JC,P = 12.4 Hz, C-17), 129.6 (s, JC,P = 2 Hz, C-9), 128.7 (d, JC,P = 5 Hz, C-7), 118.2 (d, 
JC,P = 85 Hz, C-16), 112.5 (d, JC,P = 11.5 Hz, C-10), 39.3 (t, C-2), 34 (s, C-1), 32.7 (t, C-
4), 30.8 (q, C-15), 28.8 (q, C-12, C-13), 25.1 (t, JC,P = 49 Hz, C-11), 21.5 (q, C-14), 
19.1 (t, C-3). 
MS [ESI, 70 eV]: m/z (%) = 465 [M+-Br]. 
IR (ATR): ν~ = 3057-2790 cm-1 (m), 1705 (m), 1587 (s), 1485 (s), 1437 (s), 1361 (m), 
1223 (s), 1162 (s), 1111 (s), 1066 (s), 995 (m), 966 (m), 748 (s), 721 (s), 689 (s). 
UV (CHCl3): λmax (lg ε) = 240 nm (4.30), 276 (4.15). 
 
4-Oxo-vinyl-β-ionol (36):  
In a three-necked flask equipped with dropping funnel was dissolved 22 (10 g, 48.5 
mmol,) in anhydrous THF (60 mL). After cooling to 0 °C, vinylmagnesium bromide 
(6.77 g, 77.6 mmol, 78 mL of 1M solution in THF) was added dropwise during 1 h. 
Stirring was continued at room temp. overnight. The reaction mixture was poured into 
ice-cold saturated NH4Cl solution and extracted several times with diethyl ether. The 
combined organic extracts were washed with saturated NaHCO3, brine solution, and 
dried with Na2SO4. Concentration under reduced pressure afforded 36 (6.7 g, 28.6 
mmol, 59 %) as a light yellow oil. The NMR spectra correspond to those given in the 
literature.30c 
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36 
MS [GC-MS]: m/z (%) = 234 (3) [M+], 219 (7) [M+-CH3], 201 (3) [M
+-CH3-H2O], 191 
(100) [M+-CH3CO
+], 179 (10), 163 (20), 149 (15), 135 (20), 121 (20), 107 (16), 91 (15), 
81 (10), 69 (15), 55 (22), 43 (30). 
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IR (ATR): ν~ = 3422 cm-1 (br, OH), 2966 (m), 2928 (m), 2868 (w), 1646 (s, C=O), 
1594 (m), 1452 (m), 1415 (m), 1355 (m), 1335 (m), 1312 (m), 1199 (w), 1123 (m), 
1094 (m), 1030 (m), 973 (m), 919 (s), 689 (m).  
UV (CHCl3): λmax (lg ε) = 236 nm (3.80), 263 (4.00). 
 
4−Οxo-β-ionylidene-ethyl-triphenylphosphonium bromide (38):  
To a solution of PPh3HBr (10.3 g, 28.6 mmol) in anhydrous methanol (100 mL) was 
added 36 (6.7 g, 28.6 mmol) in methanol (100 mL). After stirring for 75 h at room 
temp., the solvent was evaporated and 38 (10.57 g, 18.9 mmol, 66 %, lit.30c yield: 84 %) 
was obtained as a yellow solid. (m.p. 50 °C). The NMR spectra correspond to the 
literature.30c 
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38 
MS [ESI]: m/z (%) = 479 [M+-Br]. 
IR (ATR): ν~ = 2960-2861 cm-1 (w), 1655 (s, C=O), 1588 (w),1480 (s), 1107 (s), 756 
(s), 721 (s), 690 (s).  
UV (CHCl3): λmax (lg ε) = 240 nm (4.30). 
 
Retinoic acid ethyl ester (40):  
A solution of 
β
-formyl ethyl crotonate (2.5 g, 1.751 mL 12.86 mmol) in ethanol (5 mL) 
was cooled to -30 °C. To the reaction mixture was added dropwise during 30 min a 
solution of phosphonium salt 37 (4 g, 7.35 mmol) in ethanol (10 mL) and 0.41 g (17.70 
mmol) Na in ethanol (7.5 mL). After 10 min at -10 °C, the cooling bath was removed 
and the reaction left for 2 h to come to room temp. The pH was adjusted to neutral by 
adding a diluted solution of acetic acid. Extraction with diethyl ether and drying the 
organic phase with Na2SO4 followed by solvent evaporation and column 
chromatography on Alox with pentane/diethyl ether 20:1 gave 40 (1.74 g, 8.55 mmol, 
72 %) as a yellow oil. Rf (pentane/diethyl ether 20:1) = 0.36.  
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Spectroscopic data are in accordance with the literature.75 
 
Retinoic acid (3): 
To ester 40 (1.74 g, 8.55 mmol), dissolved in ethanol (15 mL), was added a solution of 
KOH (4.8 g, 85.5 mmol) in ethanol/water. The mixture was heated to 70 °C for 3 h. 
After cooling to room temp., the mixture was extracted with ether. The aqueous phase 
was acidified to pH 5.5 with dilute acetic acid, and extracted with diethyl ether. This 
organic phase was dried with Na2SO4 and evaporated to give acid 3 (2.5 g, 8.38 mmol, 
98 %). The spectroscopic data were in accordance with literature.76,77 
 
4-Oxo-retinoic acid (42):  
Ester 41 was obtained as described for 40, with 
β
-formyl ethyl crotonate (1.27 mL, 9.36 
mmol) in ethanol (3.1 mL), 38 (3 g, 5.35 mmol) in ethanol (6.3 mL) and Na (0.3 g, 12.9 
mmol) in ethanol (5.5 mL). Purification by column chromatography on silica gel with 
pentane/diethyl ether 3:1 gave 41 (1.34 g, 3.9 mmol, 73 %). Rf (pentane/diethyl ether 
3:1) = 0.18. This product was dissolved in ethanol, and a solution of KOH in 
ethanol/water was added. Heating to 70 °C for 3 h followed by workup gave 42 (1.66 g, 
5.3 mmol, 99 %). The spectroscopic data were in accordance with the literature.30b 
 
4,5-Epoxy-4,5-dihydro-α-ionone (93):  
To meta-chloroperbenzoic acid (20.05 g, 0.07 mol) in dichloromethane (200 mL) was 
added dropwise during 30 min a solution of α–ionone (92, 10 g, 0.056 mol, 11.11 mL) 
in dichloromethane (25 mL). After 3 h stirring, the organic phase was extracted with 
saturated Na2SO3 solution, followed by extraction with Na2CO3 solution, washing with 
brine, and drying with Na2SO4. Column chromatography on silica gel with 
pentane/diethyl ether 1:1 gave 93 (11.3 g, 54.3 mmol, 96 %) as a colorless oil. Rf 
(pentane/diethyl ether 1:1) = 0.54. 
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1
H (400 MHz, CDCl3): δ = 6.72 (dd, 3J7,8 = 16.0, 3J7,6 = 10.2 Hz, 1H, 7-H), 6.10 (d, 
3
J8,7 = 16.0 Hz, 1H, 8-H), 3.10 (t, 
3
J4,3 = 1.9 Hz, 1H, 4-H), 2.30 (s, 3H, 10-H), 2.09 (d, 
3
J6,7 = 10.2 Hz, 1H, 6-H), 1.98-1.91 (m, 4H, 3-H), 1.46-1.38 (m, 2H, 2-H), 1.25 (s, 3H, 
13-H), 0.93, 0.75 (s, 6H, 11-H, 12-H). 
13
C (100 MHz, CDCl3): δ = 198.7 (s, C-9), 146.3 (d, C-7), 134.0 (d, C-8), 59.4 (d, C-
6), 58.7 (s, C-5), 53 (d, C-4), 31.1 (s, C-1), 28.4 (t, C-2), 27.8 (q, C-11 or C-12), 27.4 (q, 
C-11 or C-12), 26.4 (q, C-10), 24.0 (q, C-13), 21.7 (t, C-3). 
MS [GC-MS]: m/z (%) = 208.1 (25), [M+], 193.1 (4) [M+-CH3], 179.1 (45), 165.1 (28), 
151.1 (26), 147.1 (14), 137.1 (10), 123.1 (22), 111.1 (40), 109.1 (81), 107.1 (18), 95.1 
(53), 81.1 (13), 69.1 (16), 55.1 (19). 
IR (ATR): ν~  = 2958 cm-1 (m), 2925 (m), 2869 (s), 1698 (s), 1672 (s), 1622 (s), 1450 
(s), 1361 (s), 1251 (s), 1178 (s), 988 (s), 962 (s), 901 (s), 885 (s), 857 (s), 790 (s), 706 
(s), 652 (s), 603 (s), 576 (s), 545 (s). 
UV (CHCl3): λmax (lg ε) = 244 nm (3.58), 318 (1.95). 
 
4-Hydroxy-β-ionone (94):  
A solution of 1.7M NaOMe (0.197 g, 8.56 mmol Na in 5 mL methanol) was added 
dropwise to 93 (11.3 g, 54.3 mmol) in methanol (80 mL). After stirring for 1 d, the 
reaction was quenched with 2 M HCl solution and extracted with diethyl ether. The 
product was purified by silica gel column chromatography with pentane/diethyl ether 
1:1 to give 94 (9.44 g, 45.4 mmol, 84 %, lit.26 yield: 65 %). Rf (pentane/diethyl ether 
1:1) = 0.19. 
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94 
1
H (400 MHz, CDCl3): δ = 7.20 (br d, 3J8,7 = 16.5 Hz, 1H, 8-H), 6.12 (dd, 3J7,8 = 16.5, 
5
J7,12 = 2.0 Hz, 1H, 7-H), 4.01 (br s, 1H, 4-H), 2.38 (br s, 1H, OH), 2.36 (d, 
5
J13,8 = 2.2 
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Hz, 3H, 13-H), 1.95-1.67 (m, 2H, 3-H), 1.85 (br s, 3H, 12-H), 1.71-1.42 (m, 2H, 2-H), 
1.07, 1.04 (s, 6H, 10-H, 11-H). 
13
C (100 MHz, CDCl3): δ = 198.5 (s, C-9), 142.8 (d, C-8), 139.0 (s, C-6), 134.3 (s, C-
5), 132.8 (d, C-7), 69.6 (d, C-4), 34.6 (t, C-2), 34.5 (s, C-1), 28.7 (q, C-10 or C-11), 28.2 
(t, C-3), 27.4 (C-10 or C-11), 27.2 (q, C-13), 18.3 (q, C-12). 
MS [EI, 70 eV]: m/z (%) = 208.1 (64), [M+], 193.1 (18) [M+-CH3], 175.1 (13), 165.1 
(14), 151.1 (18), 137.1 (24), 134.1 (13), 123.1 (38), 109.1 (100), 91.1 (16), 79.1 (10), 
55.1 (9). 
IR (ATR): ν~ = 3403 cm-1 (m), 2960 (m), 2934 (s), 2866 (s), 1661 (s), 1606 (s), 1449 
(m), 1360 (s), 1253 (s), 1174 (s), 1145 (s), 1077 (s), 1023 (s), 998 (s), 978 (s), 962 (s), 
921 (s), 903 (s), 877 (s), 731 (s). 
UV (CHCl3): λmax (lg ε) = 240 nm (3.51), 286 (3.87). 
 
4-Triethylsilyloxy-β-ionone (115):  
A solution of 94 (9.44 g, 45.4 mmol), triethylamine (5.16 g, 51.1 mmol, 5 mL) and 
DMAP (0.34 g, 2.8 mmol) in dichloromethane (40 mL) was cooled to 0 °C, and TESCl 
(5.17 g, 51.1 mmol, 7.2 mL) was added dropwise. After stirring for 1 d at room temp., 
the reaction mixture was washed with brine, the organic phase was dried with Na2SO4, 
and the solvent evaporated. Column chromatography on silica gel gave 115 (10.8 g, 
33.4 mmol, 74 %) as a colorless oil. Rf (pentane/diethyl ether 5:1) = 0.16. 
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115 
1
H (400 MHz, CDCl3): δ = 7.20 (d, 3J8,7 = 16.5 Hz, 1H, 8-H), 6.12 (d, 3J7,8 = 16.5 Hz, 
1H, 7-H), 4.05 (t, 3J4,3 = 5.7 Hz, 1H, 4-H), 2.29 (s, 3H, 13-H), 1.88-1.63 (m, 2H, 3-H), 
1.78 (s, 3H, 12-H), 1.45-1.38 (m, 2H, 2-H), 1.08, 1.02 (s, 6H, 10-H, 11-H), 0.98 (t, J = 
8.0 Hz, 9H, Si(CH2CH3)3), 0.65 (q, J = 7.6 Hz, 6H, Si(CH2CH3)3). 
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13
C (100 MHz, CDCl3): δ = 198.4 (s, C-9), 143.1 (d, C-8), 138.1 (s, C-6), 135.5 (s, C-
5), 132.8 (d, C-7), 70.8 (d, C-4), 35.4 (t, C-2), 34.5 (s, C-1), 29.0 (t, C-3), 28.2 (q, C-10, 
11), 27.2 (q, C-13), 18.2 (q, C-12), 6.9 (q, Si(CH2CH3)3), 5.0 (t, Si(CH2CH3)3). 
MS [EI, 70 eV]: m/z (%) = 322.3 (100), [M+], 307.2 (12) [M+- CH3], 293.2 (9), 279.3 
(17), 266.2 (15), 251.2 (24), 237.2 (12), 223.2 (56), 193.1 (8), 173.2 (8), 147.1 (11), 
134.1 (12), 115.1 (24), 103.1 (38), 87.1 (40), 75.0 (49), 43.1 (29). 
IR (ATR): ν~  = 2955 cm-1 (m), 2912 (s), 2877 (s),1695 (s), 1674 (s),1610cm-1(s), 1459 
(s), 1415 (m), 1357 (s), 1249 (s), 1174 (s), 1148 (s), 1084 (s), 1051 (s), 1004 (s), 978 
(s), 934 (s), 883 (s), 821 (s), 796 (s), 724 (m), 688 (s), 576 (s). 
UV (CHCl3): λmax (lg ε) = 238 nm (3.52), 289 (3.87). 
HRMS: C19H34O2Si (322.56) calcd. 322.23282; found 322.23307 ± 1.98 ppm. 
 
4-Acetoxy-β-ionone (95):  
A solution of 94 (3.85 g, 18.48 mmol), Ac2O (2.26 g, 2.09 mL, 22.2 mmol) and pyridine 
(2.92 g, 2.98 mL, 36.96 mmol) in dichloromethane (75 mL) was stirred at room temp. 
for 4 h. The reaction mixture was washed with aqueous NaHCO3 solution and a cold 
solution of 2 M HCl. The organic phase was dried with Na2SO4 and the solvent was 
removed. Column chromatography on silica gel with pentane/diethyl ether 10:1 gave 95 
(1.95 g, 7.79 mmol, 42 %, lit.26 yield: 89 %) as a colorless oil. Spectroscopic data 
correspond to the literature.26 
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95 
 
4-Acetoxy-β-ionylidene-acetaldehyde (96):  
General procedure 1 with 52 (6.62 g, 15.44 mmol) in anhydrous THF (70 mL), KOtBu 
(1.73 g, 15.44 mmol), 95 (1.93 g, 7.72 mmol) in anhydrous THF (30 mL), oxalic acid 
solution (6.81 g, 54.04 mmol, in 60 mL water). Column chromatography with 
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pentane/diethyl ether 2:1 on Alox (activity III, 8 % water w/w) gave 9-cis- and all-
trans-96 (1:1 ratio) in 41 % yield (0.87 g, 3.17 mmol). Rf(9-cis) = 0.49, Rf(all-trans) = 
0.41.  
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all-trans-96 
1
H NMR (400 MHz, CDCl3): δ = 10.17 (d, 3J11,10 = 8.1 Hz, 1H, 11-H), 6.69 (d, 3J7,8 = 
16.1 Hz, 1H, 7-H), 6.25 (d, 3J8,7 = 16.1 Hz, 1H, 8-H), 5.96 (br d, 
3
J10,11 = 8.1 Hz, 1H, 
10-H), 5.27-5.24 (m, 1H, 4-H), 2.33 (d, 4J15,10 = 1.1 Hz, 3H, 15-H), 2.08 (s, 3H, 
COCH3), 1.98-1.62 (m, 2H, 3-H), 1.70 (s, 3H, 14-H), 1.50-1.20 (m, 2H, 2-H), 1.06, 
1.05 (s, 6H, 12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 191.3 (d, C-11), 171 (s, OCOCH3), 154.0 (s, C-9), 
143 (s, C-6), 137.4 (d, C-8), 134.3 (d, C-7), 142 (s, C-5), 129.7 (d, C-10), 72.2 (d, C-4), 
34.8 (t, C-2), 34.6 (s, C-1), 29.0 (q, C-12, C-13), 25.3 (t, C-3), 21.4 (q, OCOCH3), 18.5 
(q, C-14), 13.1 (q, C-15). 
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9-cis-96 
1
H NMR (CDCl3): δ = 10.15 (d, 3J11,10 = 8.1 Hz, 1H, 11-H), 7.13 (d, 3J7,8 = 16.1 Hz, 
1H, 7-H), 6.58 (d, 3J8,7 = 16.1 Hz, 1H, 8-H), 5.91 (br d, 
3
J10,11 = 8.1, Hz, 1H, 10-H), 
5.27-5.24 (m, 1H, 4-H), 2.14 (d, 4J15,10 = 1.1 Hz, 3H, 15-H), 2.09 (s, 3H, OCOCH3), 
1.98-1.62 (m, 2H, 3-H), 1.73 (s, 3H, 14-H), 1.50-1.20 (m, 2H, 2-H), 1.10, 1.09 (s, 6H, 
12-H, 13-H). 
13
C NMR (100 MHz, CDCl3): δ = 190.1 (d, C-11), 171 (s, OCOCH3), 154.2 (s, C-9), 
143 (s, C-6), 135.3 (d, C-8), 142 (s, C-5), 129.5 (d, C-7), 128.7 (d, C-10), 72.2 (s, C-4), 
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34.8 (t, C-2), 34.3 (s, C-1), 29.0 (q, C-12, C-13), 25.3 (t, C-3), 21.4 (q, OCOCH3),18.4 
(q, C-14), 21.2 (q, C-15).  
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 276 (37) [M+], 234 (60) [M+-COCH3], 216 (38), 201 (40), 
187 (20), 173 (20), 152 (100), 145 (20), 119 (35), 105 (35), 95 (57), 77 (20), 55 (20), 43 
(60). 
IR (ATR): ν~ = 2959-2864 cm-1 (w), 1730 (s, CO), 1663 (s, CO), 1614 (m), 1447 (w), 
1369 (m), 1232 (s), 1207 (s), 1176 (w), 1152 (w), 1110 (m), 1017 (m), 993 (m), 962 
(m), 915 (m), 865 (m), 731 (s), 648 (w). 
 
4-Acetoxy-13,14-dihydro-retinoic acid methyl ester (97):  
General procedure 2 with LiHMDS [prepared from nBuLi (2.09 mL, 3.61 mmol) and 
HMDS (0.58 g, 0.75 mL, 3.61 mmol)], 66 (1.82 g, 3.61 mmol) in anhydrous THF (30 
mL), 96 (0.8 g, 2.89 mmol) in anhydrous THF (20 mL). Column chromatography on 
Alox (8 % water w/w, activity III) with pentane/diethyl ether 5:1 (Rf = 0.37) gave 97 
(0.14 g, 0.37 mmol, 13 %) as a yellow oil. 
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all-trans-97 
1
H NMR (400 MHz, CDCl3): δ = 6.43 (dd, 3J11,12 = 15.0, 3J11,10 = 11.0 Hz, 1H, 11-H), 
6.10 (d, 3J7,8 = 15.7 Hz, 1H, 7-H), 6.05 (d, 
3
J8,7 = 15.7 Hz, 1H, 8-H), 6.01 (d, 
3
J10,11 = 
11.0 Hz, 1H, 10-H), 5.67 (dd, 3J12,11 = 15.0, 
3
J12,13 = 7.7 Hz, 1H, 12-H), 5.27-5.21 (m, 
1H, 4-H), 3.7 (s, 3H, 21-H), 2.83-2.73 (m, 1H, 13-H), 2.41-2.27 (m, 2H, 14-H), 2.07 (s, 
3H, OCOCH3), 1.90 (s, 3H, 18-H), 1.79-1.58 (m, 2H, 3-H), 1.70 (s, 3H, 19-H), 1.47-
1.39 (m, 2H, 2-H), 1.1 (d, 3J20,13 = 6.8 Hz, 3H, 20-H), 1.03 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.7 (s, C-15), 171.0 (s, OCOCH3), 138.9 (d, C-8), 
138.7 (d, C-12), 136.2 (s, C-6), 135.7 (s, C-5), 132.6 (s, C-9), 130.6 (d, C-10), 126.7 (d, 
C-11), 126.1 (d, C-7), 72.5 (d, C-4), 51.4 (q, C-21), 41.2 (t, C-14), 34.6 (s, C-1), 34.3 (t, 
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C-2), 33.7 (d, C-13), 28.9 (q, C-16, C-17), 25.0 (t, C-3), 21.5 (q, OCOCH3), 20.5 (q, C-
20), 18.1 (q, C-18), 12.5 (q, C-19).  
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11-cis-97 
1
H NMR (400 MHz, CDCl3): δ = 6.34 (t, 3J11,10 = 3J11,12 = 11.5 Hz, 1H, 11-H), 6.31 (d, 
3
J10,11 = 11.5 Hz, 1H, 10-H), 6.13 (m, 2H, 7-H, 8-H), 5.31 (t, 
3
J12,11 = 
3
J12,13 = 9.7 Hz, 
1H, 12-H), 5.27-5.21 (m, 1H, 4-H), 3.64 (s, 3H, 21-H), 3.25-3.15 (m, 1H, 13-H), 2.41-
2.27 (m, 2H, 14-H), 2.07 (s, 3H, OCOCH3), 1.90 (s, 3H, 18-H), 1.79-1.58 (m, 2H, 3-H), 
1.70 (s, 3H, 19-H), 1.47-1.39 (m, 2H, 2-H), 1.09 (d, 3J20,13 = 6.8 Hz, 3H, 20-H), 1.03 (s, 
6H, 16-H, 17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.7 (s, C-15), 171.0 (s, OCOCH3), 139.2 (d, C-8), 
136.2 (s, C-6), 136.2 (d, C-12), 135.7 (s, C-5), 132.6 (s, C-9), 126.7 (d, C-7), 124.1 (d, 
C-11), 124.0 (d, C-10), 72.5 (d, C-4), 51.4 (q, C-21), 41.4 (t, C-14), 34.6 (s, C-1), 34.3 
(t, C-2), 28.9 (q, C-16, C-17), 28.5 (d, C-13), 25.0 (t, C-3), 21.5 (q, OCOCH3), 20.5 (q, 
C-20), 18.1 (q, C-18), 12.3 (q, C-19). 
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9-cis-97 
1
H NMR (400 MHz, CDCl3): δ = 6.61 (d, 3J8,7 = 14.0 Hz, 1H, 8-H), 6.50 (dd, 3J11,12 = 
14.7, 3J11,10 = 11.5 Hz, 1H, 11-H), 6.15 (d, 
3
J7,8 = 14.0 Hz, 1H, 7-H), 5.93 (d, 
3
J10,11 = 
11.1 Hz, 1H, 10-H), 5.59 (dd, 3J12,11 = 15.0, 
3
J12,13 = 7.7 Hz, 1H, 12-H), 5.27-5.21 (m, 
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1H, 4-H), 3.65 (s, 3H, 21-H), 2.83-2.73 (m, 1H, 13-H), 2.41-2.27 (m, 2H, 14-H), 2.07 
(s, 3H, OCOCH3), 1.90 (s, 3H, 19-H), 1.70 (s, 3H, 18-H), 1.79-1.58 (m, 2H, 3-H), 1.47-
1.39 (m, 2H, 2-H), 1.09 (d, 3J20,13 = 6.8 Hz, 3H, 20-H), 1.03 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.7 (s, C-15), 171.0 (s, OCOCH3), 137.8 (d, C-
12), 136.2 (s, C-6), 135.2 (s, C-5), 132.6 (s, C-9), 131.1 (d, C-8), 129.2 (d, C-10), 126.0 
(d, C-7), 124.8 (d, C-11), 72.5 (d, C-4), 51.4 (q, C-21), 41.2 (t, C-14), 34.6 (s, C-1), 34.3 
(t, C-2), 33.7 (d, C-13), 29 (q, C-16, C-17), 25 (t, C-3), 21.5 (q, OCOCH3), 21 (q, C-
20), 20.5 (q, C-19), 18.1(q, C-18). 
COOMe
OAc
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16 17
18
19
20
21
 
9,11-di-cis-97 
1
H NMR (400 MHz, CDCl3): δ = 6.65 (d, 3J8,7 = 16.0 Hz, 1H, 8-H), 6.43 (dd, 3J11,12 = 
15.1, 3J11,10 = 11.1 Hz, 1H, 11-H), 6.29 (d, 
3
J10,11 = 11.1 Hz, 1H, 10-H), 6.19 (d, 
3
J7,8 = 
16.0 Hz, 1H, 7-H), 5.27-5.21 (m, 2H, 4-H, 12-H), 3.65 (s, 3H, C-21), 3.25-3.15 (m, 1H, 
13-H), 2.41-2.27 (m, 2H, 14-H), 2.07 (s, 3H, OCOCH3), 1.90 (s, 3H, 19-H), 1.70 (s, 3H, 
18-H), 1.79-1.58 (m, 2H, 3-H), 1.47-1.39 (m, 2H, 2-H), 1.08 (d, 3J20,13 = 6.8 Hz, 3H, 20-
H), 1.03 (s, 6H, 16-H, 17-H). 
13
C NMR (100 MHz, CDCl3): δ = 172.7 (s, C-15), 171.0 (s, OCOCH3), 136.2 (s, C-6), 
135.2 (d, C-12), 135.2 (s, C-5), 132.6 (s, C-9), 130.9 (d, C-8), 127.0 (d, C-7), 124.0 (d, 
C-10), 123.1 (d, C-11), 72.5 (d, C-4), 51.4 (q, C-21), 41.2 (t, C-14), 34.6 (s, C-1), 34.3 
(t, C-2), 28.9 (q, C-16, C-17), 28.5 (d, C-13), 25.0 (t, C-3), 21.5 (q, OCOCH3), 21.0 (q, 
C-20), 20.5 (q, C-19), 18.1 (q, C-18). 
isomeric mixture: 
MS [EI, 70 eV]: m/z (%) = 374 (45) [M+], 332 (57), 314 (100), 299 (40), 292 (10), 283 
(10), 276 (20), 274 (22), 267 (20), 259 (20), 241 (30), 234 (35), 225 (63), 218 (30), 185 
(10), 157 (20), 119 (30), 105 (30), 91 (37), 77 (28), 55 (20), 43 (100). 
182 
IR (ATR): ν~ = 2959-2867 cm-1 (w), 1731 (s), 1438 (m), 1369 (m), 1236 (s), 1169 (m), 
1016 (m), 963 (m), 911 (m), 864 (m), 731 (s), 648 (w). 
UV (CHCl3): λmax (lg ε) = 229 nm (3.91), 289 (4.35). 
HRMS: C23H34O4 (374.52) calcd. 374.24573; found 374.24470 ± 1.15 ppm. 
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12 Abbreviations 
DMSO Dimethylsolfoxide 
RA Retinoic Acid 
LiHMDS Lithiumhexamethyldisilazide 
KOtBu Potassium tert-butoxide 
PCC  Pyridiniumchlorochromat 
RA Retinoic acid 
ROH Retinol 
CSP Chiral stationary phase 
CTA Cellulose triacetate 
CTB Cellulose tribenzoate 
MCPB meta-Chloroperbenzoic acid 
TESCl Triethylsilyl chloride 
HWE Horner-Wadsworth-Emmons 
dh-RA Dihydro-retinoic acid 
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